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ABSTRACT 
 
Ubiquitination is an extremely important post-translational modification, regulating 
a wide variety of cellular processes including proteasomal degradation, subcellular 
targeting, endocytosis and DNA repair. The HECT class of E3 ligases catalyse the 
final step of ubiquitin conjugation to the substrate; the Nedd4 family make up 9 
members of this class in humans, and are implicated in pathologies ranging from 
congenital ion channel misregulation to cancer, via the TGF-ß signalling pathway. The 
Nedd4-like proteins contain WW substrate recognition domains, which recognise and 
bind proline–rich PY motifs. This work focuses on the interaction between Nedd4 and 
PMEPA1, a membrane protein showing altered expression in prostate cancer and a 
known Nedd4 substrate. PMEPA1 is recognised as important in several cancers, 
although its detailed function is not yet known; it is upregulated in prostate cancer and 
has been postulated to decrease cellular androgen receptor (AR) via a negative 
feedback loop involving Nedd4 in a ubiquitin-proteasome dependent process. 
Misregulation of the AR response to testosterone is associated with a more advanced 
form of prostatic cancer and poor patient prognosis, for which there are currently few 
treatment options available. 
PMEPA1 contains two well-documented canonical (PPxY) PY motifs both required 
for interaction with Nedd4. This work details the identification and characterisation of 
a third motif with a variant PY (vPY) sequence, QPTY. Our findings indicate that the 
loss of this vPY motif leads to a significant reduction in Nedd4-dependent 
ubiquitination in vitro. In addition, the nature of the amino acid residues surrounding 
the vPY motif also appears to play a role in the functionality of the site. Alongside 
these experiments, immunodetection of protein levels in HeLa and LNCaP cell lysates 
was used in conjunction with confocal microscopy to shed light on the interactions 
between PMEPA1, Nedd4 and AR in vitro and in vivo. A possible non-proteasomal 
role for ubiquitination in the PMEPA1-AR interaction, as opposed to the simple 
ubiquitin-proteasome mediated degradation previously proposed, is discussed in the 
light of this new data. This work has expanded previous knowledge of the specificity 
of the PY-WW interaction, as well as providing a basis for further investigation, and 
possibly clinical targeting, of the role of PMEPA1 and AR in prostate cancer.
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1. INTRODUCTION   
 
 
1.1 Ubiquitin and ubiquitination 
 
1.1.1 Ubiquitination in the context of post-translational modifications 
  
Post-translational modification of proteins facilitates an extremely high level of 
variation and complexity in cellular proteins; from a genome containing a maximum of 
25,000 genes (International Human Genome Sequencing Consortium, 2004), a proteome 
consisting of over a million functional and structural protein variants (Jensen, 2004). 
Over 200 PTMs have been identified (Walsh, 2006), including some which are 
reversible, and an additional level of diversity is made possible by multiple sequential 
modifications, with widely varying effects. These are assisted by a diverse selection of 
enzymes and cofactors, as well as non-proteins such as lipids and small non-organic 
molecules, including phosphate ions, which can be covalently bonded to alter the nature 
of the protein. 
Ubiquitin, and an ever-increasing number of ubiquitin-like proteins (UBLs) such as 
SUMO and FAT10, are a family of structurally similar protein molecules which are 
covalently attached to proteins in an enzyme-mediated process. They serve diverse 
functional purposes which are summarised in figure 1.1, but are linked by a common 
secondary structure and a common multi-step cascade attachment mechanism. Ubiquitin 
and SUMO and the most relevant to this project and are covered in more detail below. 
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Figure 1.1. Ubiquitin-like proteins in humans. Overview of Eukaryotic proteins 
sharing a common domain structure with ubiquitin, their sizes, historical discovery 
dates and their diverse functions  
Name Size 
(kDa) 
First 
Discovered 
Functions 
Ubiquitin 8.5 1975 Proteasomal degradation, intracellular 
trafficking, endocytosis, regulation of 
inflammatory and stress response, DNA 
repair, viral budding, apoptosis, cell cycle 
control, neuronal morphogenesis and 
maintenance, transcription control via histone 
modification 
SUMO 11.5 1997 Intracellular trafficking, transcriptional 
regulation, DNA repair, regulation of 
inflammatory response 
NEDD8 9 1997 Regulation of cell cycle progression and 
cytoskeletal assembly, via regulation of 
ubiquitin conjugation machinery, 
embryogenesis and placental differentiation 
FAT10 18.5 1996 Proteasomal degradation, mediation of 
apoptosis, dendritic cell maturation and 
differentiation 
ISG15 17 1987 Innate immune response in higher 
Eukaryotes, tumorigenesis 
UFM1 9 2004 As yet undefined; associated with 
endoplasmic reticulum homeostasis and 
FUBI 9 1992 As yet undefined; associated with 
tumorigenesis 
GABARAP 14 1999 Intracellular transport of GABA receptors, 
regulation of autophagy and apoptosis 
GABARAPL1 14 2001 Intracellular trafficking of opioid receptors, 
formation and maturation of autophagosomal 
vesicles 
ATP7 78 1999 Caspase-induced autophagy, selective 
mitochondrial destruction, cell cycle 
regulation, axonal maintenance and 
homeostasis 
LC3 14 1994 Formation of autophagosomes 
URM1 11 2005 Oxidative stress response, regulation of 
tRNA stability 
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1.1.2 Ubiquitin discovery 
 
Ubiquitin was first identified as a free polypeptide involved in differentiation of 
immunocytes in 1975 and provisionally designated ubiquitous immunopoietic 
polypeptide (UBIP) due to its being highly conserved in numerous yeast and mammalian 
tissue extracts (Goldstein et al, 1975). Shortly after, the full sequence of the renamed 
ubiquitin was published as an adenylate cyclase stimulating peptide, and shown to be so 
highly conserved that, at the time, it was thought to be universal in living cells 
(Schlesinger et al, 1975). In 1977, covalent attachment of an unidentified non-histone 
protein to a lysine residue in the histone H2a was observed (Goldknopf & Busch, 1977); 
this was soon revealed through sequence comparison to be ubiquitin (Hunt & Dayhoff, 
1977). 
At the time, a role for ubiquitin in proteasomal degradation was not suspected. The 
early observation that intracellular proteolysis in eukaryotic cells uses ATP (Simpson, 
1953) was a biochemical curiosity that could not be explained by conventional ideas 
regarding protein turnover. In attempting to evaluate this phenomenon, reticulocyte 
extracts, lacking the lysosome which had been previously identified as having a 
proteolytic function (de Duve et al, 1953), was used. It was discovered that protein 
degradation in this extract required two fractions I and II; fraction I contained a small 
protein designated ATP-dependent proteolysis factor I (APF-1), and APF-1 formed 
covalently linked high molecular weight conjugates prior to degradation (Ciechanover et 
al, 1978). This was followed soon after by the observation that fraction II of the 
reticulocyte lysis contained as a high molecular weight species, APF-2, which was 
stabilised by ATP. Both fractions I and II were shown to be necessary for the proteolytic 
activity of the lysate (Hershko et al, 1980). It was rapidly established that the ATP-
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dependent incorporation of APF-1 into high molecular weight conjugates was the first 
step of this proteolysis pathway (Ciechanover et al, 1980), that APF-1 binds to many 
different cellular proteins, and that the free APF-1 it is regenerated from these conjugates 
by amidases (Hershko et al, 1980). It is now clear that APF-2 is the 26S proteasome 
(Waxman et al, 1987), a multi-subunit catalytic complex which assembles in the 
presence of ATP (Orino et al, 1991) and specifically degrades ubiquitinated proteins 
(Ugai et al, 1993), and APF-1 is ubiquitin. This was later confirmed by sequential and 
functional analyses showing that the two proteins were in fact the same (Wilkinson et al, 
1980). 
 
1.1.3 Ubiquitin structure 
 
 The first primary structure of ubiquitin to be published was the bovine protein in 
1975, using trypsin digestion and sequencing of the resulting peptides (Schlesinger et al, 
1975); this identified a 74 amino acid peptide with a single chain. Further analysis 
showed that the physiologically active form of ubiquitin is in fact 76 residues in length, 
and the truncated version was most likely an in vitro proteolytic artefact (Wilkinson & 
Audhya, 1981). Human (Schlesinger & Goldstein, 1975), fish (Watson et al, 1978), 
insect (Gavilanes et al, 1982) and mouse (Finch et al, 1990) ubiquitin sequences 
followed, and by the mid-1980s it was clear that the protein was almost universally 
conserved among Eukaryotes. As recently as this year, the ubiquitin sequence of the 
parasitic fluke Clonorchis sinensis was published and shown to be “extraordinarily 
conserved” when compared to other species (Huang et al, β01γ). Preliminary structural 
studies using circular dichroism and NMR predicted that ubiquitin is a globular protein 
with a tightly folded structure, mostly consisting of random coil with approximately 28% 
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helix and 1β% ȕ-sheet (Cary et al, 1980). More advanced structural resolution came in 
the mid-1980s, with a crystallographic analysis showing a much greater degree of 
ordered structure than previously indicated; one α-helix and four strands of ȕ-sheet, as 
well as a large rigid turn stabilised by hydrogen bonding, encompassing around 90% of 
the primary sequence (see figure 1.2). In addition, a buried ‘core’ consisting of 16 
hydrophobic residues, a hydrophobic ‘pocket’ on the surface of the molecule, and the 
protrusion, and mobile nature, of the carboxy-terminal Gly-Gly through which the 
molecule binds lysine residues, were identified (Vijay-Kumar et al, 1985). The specific 
pattern formed by four of the ȕ-strands surrounding the α-helix became recognised as a 
signature fold, the ȕ-grasp, common to ubiquitin-like proteins such as SUMO (Bayer et 
al, 1998), despite the lack of significant primary sequence similarity.  
 
1.1.4 Types of ubiquitination and their functions 
 
As well as the primary, secondary and tertiary structure of ubiquitin as a monomer, 
there is another aspect of its structure which plays a key role in ubiquitin-mediated 
signalling – its ability to form chains. Ubiquitin binds to proteins via an isopeptide bond 
linking the carboxyl group on its terminal glycine with the side chain amine on a lysine 
residue (Busch & Goldknopf, 1981) in a process known as ubiquitination, or 
ubiquitylation. The initial conjugation must necessarily be to a lysine on the substrate, 
but ubiquitin itself contains 7 lysine residues (K6, K11, K27, K29, K33, K48 and K63), 
as well as a terminal amine group, which can function as anchor points for additional 
isopeptide linkages. Proteins can be modified by a single ubiquitin molecule on a single  
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Figure 1.2. Crystallographic structures of ubiquitin at 1.8Ä resolution. The secondary 
structure is shown with ȕ-sheet represented as flat arrows and α-helix represented as 
spiral arrows. The overall structure is shown in panel (A), with the four strands of the 
characteristic ȕ-fold surrounding the single α-helix (foreground). The flexible Gly-Gly 
tail is visible as the end of the molecule on the bottom left. The positions of the 7 lysine 
residues are highlighted in panel (B). Images were rendered using Polyview-3D and 
JMol; RCSB PDB reference 1UBQ with original structure published by Vijay-Kumar et 
al, 2007.  
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lysine (monoubiquitination), single ubiquitin molecules on multiple lysines 
(multiubiquitination) or chain-linked ubiquitin molecules on one or more lysines 
(polyubiquitination) (see figure 1.3). 
 Monoubiquitination and multiubiquitination of proteins, along with the formation of 
very short 2- and 3-monomer ubiquitin chains, act as a signal for various non-
proteasomal cellular processes. The first of these to be identified was histone regulation 
(Busch & Goldknopf, 1981); this is a conserved role, as part of the DNA damage 
response, which has been shown to be crucial for sporulation and growth in yeast 
(Robzyk et al, 2000) as well as gene regulation in Drosophila (Pham & Sauer, 2000). 
Constitutive monoubiquitination of histones complexed with DNA represses 
transcription of the DNA (Zhou et al, 2008) and also serves to initiate the DNA damage 
repair cascade by recruiting kinases to the site of strand breaks (Pan et al, 2011). 
Monoubiquitination is also required for viral budding (Patnaik et al, 2000) and is the 
major form of ubiquitination involved in the complicated regulation of endocytosis 
(Terrell et al, 1998). Endocytosis is an important mechanism by which cell surface 
proteins, such as receptor tyrosine kinases and permeases, are regulated. In both yeast 
(Shih et al, 2000) and mammalian cells (Nakatsu et al, 2000), monoubiquitination and 
multiubiquitination (Haglund et al, 2003) of the cytoplasmic region of surface proteins is 
sufficient both to trigger internalisation and sort the proteins into lysosomal degradation 
pathways. The default cellular pathway for internalised proteins is recycling back to the 
cell surface (Mayor et al. 1993), so sorting of proteins from the endosome to the 
multivesicular body (MVB) pathway, which is essential for their correct delivery to the 
lysosome or vacuole, requires a positive signal. If the lysine residues on endocytosed 
proteins, such as the yeast hydrolytic enzyme Cps1p, are removed by mutagenesis, they 
cannot progress into the MVB and instead accumulate at the vacuolar membrane  
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Figure 1.3. Schematic illustration of different forms of ubiquitination. An example 
protein is presented with four lysine residues (K) with the attachment of a single 
ubiquitin (Ub) moiety on a single lysine (A) – monoubiquitination, single ubiquitin 
moieties on multiple lysines (B) – multiubiquitination, and a ubiquitin chain (C) – 
polyubiquitination.  
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(Reggiori & Pelham, 2001).  Another aspect of this sorting process is direct sorting from 
the trans-Golgi network to the lysosome, without diverting to the cell surface; this was 
first reported in yeast as a result of increased nitrogen availability, decreasing the amount 
of Gap1p amino acid permease at the plasma membrane (De Craene et al, 2001), and 
later found to be a result of GGA (Golgi-associated Ȗ-adaptin homologues, Arf-binding) 
proteins binding to ubiquitin on the surface of the target protein (Scott et al, 2004). The 
Golgi compartment marker TMD-23 was recently found to translocate to the vacuole 
when conjugated to ubiquitin (Scheuring et al, 2012) in plant cells, indicating that the 
ubiquitination signal alone is sufficient to trigger endosomal trafficking of Golgi 
proteins. These single-moiety and short chain modifications cannot be recognised by the 
ubiquitin receptors on the 26S proteasome, so this form is not directly involved in the 
targeting of proteins to the proteasome (Thrower et al, 2000) – there is, however, an 
example of one of the proteasomal ubiquitin receptor subunits in yeast, Rpn10, being 
regulated by monoubiquitination, blocking the ubiquitin interacting motif and indirectly 
regulating proteasomal degradation (Isasa et al, 2010). 
Polyubiquitination of substrate proteins can occur in various forms due to the multiple 
conjugation points on the ubiquitin chain described earlier. Each configuration has a 
specific structural character, with the different lysine linkages conferring varying degrees 
of flexibility and exposing different parts of the ubiquitin molecules. For example, linear 
chains, linked through K63 or the N-terminal methionine, adopt an open conformation, 
with no contact between ubiquitin monomers (apart from the single linkage point) and a 
high degree of flexibility (Komander et al, 2009). These linear chains are implicated in 
the NF-κB-mediated immune response pathway, via the ubiquitin-binding adapter 
NEMO; this binding is dependent on surface residues which are only exposed due to the 
stretched conformation of the ubiquitin, and hence is specific for the linear conformation 
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(Rahighi et al, 2009). In contrast, K48-linked chains, which are the principal signal for 
proteasomal targeting (Finley et al, 2004), adopt a more tightly packed, closed structure, 
with the hydrophobic surface residues sheltered in the space between the two moieties 
(Varadan et al, 2002). The less common K11-linked chains also adopt a close-packed 
conformation, but with the receptor-binding Ile44 residue exposed, and have, relatively 
recently, been identified as a cell cycle regulation signal (Bremm et al, 2010). The other 
lysine linkages have all been identified in vitro but their in vivo functions are less well 
defined; for example, K6-linked chains are tightly packed like K48 chains, but have an 
asymmetric structure unlike any other identified (Virdee et al, 2010). All non-linear types 
of chain play a role in protein degradation to some degree (Xu et al, 2009) and it may be 
that their roles are redundant, a reflection of the importance of the ubiquitin-mediated 
signalling in Eukaryotic cells. 
Instances of mixed-linkage chains, in which more than one lysine linkage is present 
on a single protein, are increasingly being reported (Ben-Saaden et al, 2006; Kim et al, 
2007; Goto et al, 2010). It is not currently clear what the role of these mixed linkages is; 
the RING ligase Ring1B autoubiquitinates, generating chains containing a mixture of 
K11, K48 and K63-linkages, and all three components are required to Ring1B to 
successfully ubiquitinate it’s substrate, the histone HβA (Ben-Saaden et al, 2006). 
However, receptors which selectively bind single linkage types, such as Rap80, which 
has specific affinity for K63-linked chains, show no difference in binding affinity 
between mixed- and single-linkage chains (Nakasone et al, 2013), indicating that the 
topology within a mixed-linkage chain is no different to one containing a single linkage 
type.  
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1.1.5 Enzymes involved in the ubiquitination reaction 
 
 The key to the formation of different ubiquitin chains lies in the multi-step process of 
ubiquitin conjugation; ubiquitinating a protein involves a sequential cascade of 3 
enzymes. This cascade is illustrated in figure 1.4; firstly, an E1 activating enzyme 
activates the ubiquitin, and then an E2 conjugating enzyme carries the activated ubiquitin 
via a thiol ester into position. Finally, an E3 ligase enzyme enables the transfer of the 
ubiquitin from the E2 to a lysine on the substrate (Scheffner et al, 1995). Each of these 
plays a fundamental role in the ubiquitination of proteins as well as substrate recognition 
and specificity of chain type. 
 Ubiquitin activating enzymes, referred to as E1 as they are the first enzyme involved 
in the conjugation reaction, are the least variable of the three. Originally thought to be a 
single protein (McGrath et al, 1991) designated Uba1, a small number of homologues 
have since been identified in yeast (Dohmen et al, 1995), wheat (Hatfield & Vierstra, 
1992) and humans (Pelzer et al, 2007). The chemistry of the E1-catalysed reaction was 
resolved over 30 years ago, and relies on the generation of a ubiquitin-adenylate 
intermediate, still tightly bound to an ATP-binding domain on the E1; this leaves the 
terminal carboxyl group on the ubiquitin moiety open to attack by the catalytic cysteine, 
to create a high-energy thioester bond which is then targeted by the next enzyme in the 
cascade (Haas & Rose, 1982). The structural events that accompany this activation are 
unknown, but solved crystal structures of the ubiquitin-like protein SUMO in complex 
with its E1 enzyme (Olsen et al, 2010) indicate that a major reconfiguration of the region 
containing the active site cysteine occurs between adenylation of the protein and 
formation of the thioester conjugate to allow the formation of the high-energy bond. 
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Figure 1.4. Schematic illustration of the stages of ubiquitin transfer. Free ubiquitin 
(black) binds to an activating enzyme E1 via a high-energy thioester bond. This activated 
ubiquitin is then transferred onto a ubiquitin conjugating enzyme, E2 (1). From there one 
of two routes to conjugation is followed; either a HECT type E3 ubiquitin ligase receives 
the ubiquitin onto itself (2a) and catalyses active transfer onto the substrate (3a), or a 
RING type E3  ubiquitin ligase binds both the ubiquitin-bound E2 and the substrate at 
separate sites (2b) and facilitates transfer from the E2 directly onto the substrate by 
acting as a scaffold (3b). 
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 Ubiquitin conjugating enzymes, referred to as E2s, have a conserved structure and 
catalytic cysteine similar to that found on E1s. While in humans there are only 2 E1s, 
there are around 30 E2s (van Wijk & Timmers, 2010) which conjugate ubiquitin, each of 
which is associated with a specific downstream function. While there is necessarily a 
high degree of conservation, in order to retain E1- and ubiquitin-binding capability and 
catalytic activity, there is sufficient variability to allow selectivity of interaction with 
E3s, and therefore of function (Martinez-Noel et al, 2001). The E1-E2 binding event is 
triggered by ubiquitin binding to E1; binding between free E1 and E2 is weak (Hershko 
et al, 1983). This is because the E2 binding surface actually consists of a combination of 
domains on the E1 and ubiquitin itself (Olsen & Lima, 2013); once this association has 
occurred, the high-energy ubiquitin thioester bond is rapidly transferred from the E1 to 
the E2 active site (Pickart, 2001).  
 The final step in the ubiquitination cascade, the transfer of ubiquitin onto the 
substrate, is achieved by one of a huge group of E3s referred to as ubiquitin ligases. 
These are the most complex and diverse of all the enzymes involved, with over 600 
distinct enzymes identified in humans alone (Li et al, 2008). There are two types of E3 
which are very different structurally and in their method of catalysis; this subject is 
covered in more depth in section 1.2. Broadly speaking, the HECT-type ligases actively 
catalyse the transfer of the ubiquitin from the E2 onto a catalytic cysteine within 
themselves before transferring it onto the substrate, while the RING-type ligases act as a 
molecular ‘scaffold’ to bring the substrate and the E2 into close enough proximity that 
the ubiquitin can be transferred directly from the E2 to the substrate. It is the wide 
variety of E3s that confer specificity to the ubiquitination reaction; each has a specific 
substrate recognition domain which enables binding to the ubiquitination target, either by 
the E3 alone or in complex with the correct E2.  
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1.2 HECT type ligases and the Nedd4 family 
 
1.2.1 Types of ubiquitin ligase enzymes 
 
 As mentioned above, there are two distinct classes of ubiquitin ligases, which have 
evolved completely distinct mechanisms to achieve the same goal; the transfer of 
ubiquitin from the E2 onto a substrate protein. First identified in the early 1990s as a 
cysteine-rich domain with similarities to zinc-binding proteins (Freemont et al, 1991), 
the RING finger ligases were named after initial database searches showed similarities to 
the newly identified Really Interesting New Gene 1 (RING1) and zinc finger domains 
(Stemberg, 1991). Their function as E3 ligases was only realised almost a decade later, 
as the role of the conserved zinc-coordinating residues in mediating ubiquitination and 
the E2-binding properties of the domains came to light (Kamura et al, 1999, Ohta et al, 
1999, Lorick et al, 1999). The conserved zinc-binding cysteine and histidine residues 
form part of a cleft in the surface of the proteins to which E2s directly when loaded with 
ubiquitin (Zhen et al, 2000). A separate, spatially distant substrate binding site associates 
with the protein to be ubiquitinated and holds it in the correct position for direct transfer 
of ubiquitin from the E2 (Orlicky et al, 2003); this is sometimes facilitated by a 
conformational change on the E3 which can in turn be initiated by binding of ubiquitin-
like proteins such as Nedd8 (Duda et al, 2008). The precise mechanism of ubiquitin 
transfer from the E2 to the substrate has not yet been elucidated, but the recently solved 
structure of the RING E3 RNF4 in complex with the E2 Ubc5Ha and ubiquitin showed 
that the RING domain acts to lock ubiquitin into the E2 active site and extend its 
conformation in such a way as to activate the thioester bond to attack a substrate lysine 
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(Plechanovova et al, 2012). Crucially, at no point is an E3-ubiquitin intermediate formed; 
the transfer occurs from the E2 directly onto the substrate.  
 This is in direct contrast to the other major type of E3 ligase, the HECT (Homologous 
to E6-AP Carboxyl Terminus) ligases, named for the first to be identified as functioning 
as a catalytic enzyme rather than a scaffold. These form a small minority of all the E3s in 
Eukaryotic systems; around 30 HECT ligases have been identified in mammals. Rather 
than acting as a scaffold to mediate a transfer of ubiquitin from the E2 onto the substrate, 
HECT family ligases have a conserved cysteine residue at the active site onto which the 
thioester ubiquitin bond is transferred from the E2, forming a stable  E3-ubiquitin 
thioester intermediate prior to the ubiquitin being transferred onto the substrate 
(Scheffner et al, 1995). The HECT domain itself has two major features; the C-terminal 
(“C lobe”) region, containing the catalytic cysteine, and the N-terminal lobe (“N lobe”), 
which binds the E2 (Huang et al, 1999). The residues in between the two lobes have been 
described as a “hinge” (Verdecia et al, β00γ), allowing rotational flexibility to bring the 
two lobes into closer contact and facilitate thioester transfer from the active site on the 
E2 to that on the E3. The importance of this hinge is emphasised by the fact that 
mutations in E6-AP which cause the genetic disorder Angelman syndrome are located in 
this region (Kishino et al, 1997). While the overall structure of the HECT domain and the 
catalytic cysteine are universally conserved among these ligases, the N lobe is much 
more variable, conferring specificity for certain E2s (Jentsch et al, 1992). As well as 
specificity for E2s, HECT E3s are associated with specific ubiqutin chain types, for 
example the yeast ligase Rsp5p is associated with K63 linkage (Galan and Haguenauer-
Tsapis, 1997), while the mammalian E3 KIAA0010 catalyses the formation of K29 and 
K48 chains (You & Pickart, 2001). The HECT domain is located at the C-terminus of the 
proteins, with the remainder of the protein determining subclassification into one of three 
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types; the HERC family, Nedd4 family, or other HECTs. The HERC family are 
distinguished by containing one or more RCC1-like domains (RLDs), multi-subunit 
protein binding domains, at their N-terminus. They have multiple functions which are 
still being elucidated, including regulation of intracellular membrane trafficking, but 
their ubiquitination substrates have not yet been identified (Garcia-Gonzalo & Rosa, 
2005), although there is evidence for a role in the regulation of the HECT ligase E6AP, 
and therefore a role in Angelman syndrome (Harlalka et al, 2013). There are 6 members 
of the HERC family in humans, along with 1γ that don’t appear to follow any pattern, 
having only the C-terminal HECT in common alongside assorted protein-binding 
domains such as zinc fingers and even RING motifs. However, the best characterised in 
terms of their ubiquitination activity, and the most relevant to this project, are the Nedd4 
family ligases, described in more detail in section 1.2.2.  
 There are some ligases which defy easy categorisation into either of the main 
designations; the IpaH proteins are secreted by some bacterial pathogens to modulate the 
host immune response (Aishida et al, 2007). When the structure of IpaH from the 
bacterium Shigella flexneri was solved in 2008, it was found to be an entirely novel class 
of E3 ubiquitin ligase, with a catalytic cysteine reminiscent of a HECT ligase but with 
different secondary structure around the catalytic site and no conservation of the C-
terminal region of the HECT domain, working in the context of a mechanistically unique 
cascade involving non-covalent binding of the E2 to ubiquitin (Singer et al, 2008; Zhu et 
al, 2008). These are still relatively poorly studied, especially compared to the two major 
ligase groups, but recent work has revealed that IpaH0722 blocks the host immune 
response by promoting proteasomal degradation of the NF-κB pathway signalling 
molecule TRAF2 (Ashida et al, 2013). Finally, a hybrid class of ligases with aspects of 
both RING and HECT type enzymes has recently emerged as separate, having been 
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previously classified as a subtype of RING ligases. These are known as “RING-between-
RING” (RBR) type, and include the ligase associated with familial Parkinson’s disease, 
Parkin (Wendel et al, β011). These RBR’s bind Eβ though a conventional RING domain, 
but have a conserved in-between RING (IBR) and second, noncanonical RING (RING2) 
domain, and form a thioester bond directly between a conserved cysteine on this RING2 
and the ubiquitin, in a manner reminiscent of HECT-type ligases (Wendel et al, 2011). 
Once again, insights into this novel hybrid class are just starting to be presented, and at 
present little is known about them beyond the basics of their mechanism of transfer. 
 
1.2.2 Structure of the Nedd4 family ligases 
 
 Nedd4 family ligases are linked by a common domain structure that includes a HECT 
domain at the C-terminus, a lipid-binding C2 domain at the N-terminus, and a number of 
substrate recognition ‘WW’ domains in between. The family are named for the first 
member to be identified, Neural precursor cell Expressed Developmentally Down-
regulated protein 4 (Kumar et al, 1992), and are conserved across Eukaryotes, from a 
single member in yeast to 9 in humans (see figure 1.5). The C2 domain mediates plasma 
membrane binding via phospholipids, including endosomes, in a calcium-dependent 
manner (Dunn et al, 2004), and also plays an auto-inhibitory role, stabilising both the 
enzymes themselves and their substrates by interacting both intra- and intermolecularly 
with the C-terminal HECT domain (Wiesner et al, 2007).   
The number and arrangement of WW domains is what distinguishes the Nedd4 family 
members from each other. These small, approximately 38-residue regions are defined by 
four conserved aromatic residues, including two conserved tryptophans which give them 
their name (Bork & Sudol, 1995). Their primary sequence homology is quite low, even  
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Figure 1.5. Comparative illustration of the domain structure of the Eukaryotic Nedd4 
ubiquitin ligase family. The topmost diagram shows the single yeast Nedd4 family 
member, Rsp5p, in the context of the nine human Nedd4 ligases listed below. The C2 
and HECT domains are conserved, with the number and arrangement of the WW 
domains (dark grey) providing variation in substrate specificity and function. 
f  
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between WW domains on the same protein; WW2 on the oncogenic transcription factor 
YAP, for example, has a primary sequence closer to that of a WW domain on the yeast 
Nedd4 ligase Rsp5p than WW1 on YAP itself (Sudol et al, 1995). Early structural studies 
showed that specific WW domain resides, including the conserved tryptophans, form a 
hydrophobic surface that binds strongly to the sequence proline-proline-X-tyrosine 
(PPxY) (Macias et al, 1996). An example of a WW domain from Drosphila Nedd4 
bound to a PY motif is shown in figure 1.6. However, not all WW domains have these 
“PY motifs” as their preferred targets, instead targeting phosphorylated serine side chains 
alongside proline residues (Verdecia et al, 2000), glycine- and methionine-rich motifs 
(Bedford et al, 1998) or longer proline-rich sequences (Bedford et al, 1997). Not all WW 
domains within a protein are equal; for example, WW3 of the canonical human Nedd4 
protein binds the epithelial sodium channel ENaC, a well-studied Nedd4 substrate, 20-30 
times more strongly than either WW2 or WW4, while WW1 shows no affinity for ENaC 
at all (Lott et al, 2002). The variation between the primary sequences of WW domains, 
and the different arrangements in different Nedd4 family members, allows each to retain 
distinct substrate specificity and functionality (Peng et al, 2007). 
 
1.2.3 Members of the Nedd4 family and their functions 
 
1.2.3.1 In the genus Saccharomyces 
 The Nedd4 ligases are highly conserved through Eukaryotic systems, varying in 
number from just a single member, Rsp5p, in yeast, to nine in humans. Rsp5 is an 
essential gene in yeast (Hein et al, 1995), and has many functions, including regulation 
of transcription via RNA polymerase binding (Huibregtse et al, 1997), glucose-mediated 
activation of the plasma membrane H+ ATPase (de la Fuente et al, 1997) and regulation  
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 Figure 1.6. Structures of conserved domains of the Nedd4 ubiquitin ligase family. Crystallographic structure of the HECT domain from 
human Nedd4 at 2.5Ä resolution in grey with the conserved catalytic cysteine highlighted in red (A); RCSB PDB reference 2XBF with 
original structure published by Maspero et al, 2011. Lowest energy consensus solution NMR structure of the WW3 domain of 
Drosophila Nedd4 in complex with the LPXY motif of Commisureless (B), with the WW domain chain shown in purple with the ligand 
shown in green. The two conserved tryptophan residues of the WW domain are highlighted in red; RCSB PDB reference 2EZ5 with 
original structure published by Kanelis et al, 2006. Images were rendered using Polyview-3D and JMol.  
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of mitochondrial inheritance (Fisk & Yaffe, 1999). The best-studied role of Rsp5p is in 
the yeast endocytic pathway, mediating the regulation of plasma membrane proteins by 
internalisation and passage into the vacuolar degradation (which has a similar function to 
the mammalian lysosome). This is an extremely important pathway as yeast need to react 
quickly to changes in the environment to maintain internal homeostasis. There are many 
examples in the literature, including the amino acid permeases Fur4p (Galan et al, 1996) 
and Gap1p (Springael & André, 1998), the galactose transporter Gal2p (Horak & Wolf, 
1996) and the ATP-binding cassette drug transporter Pdr5p (Egner et al, 1995) of 
membrane proteins which are ubiquitinated by Rsp5p, and subsequently internalised, in a 
process which is halted by inhibition of vacuolar proteases, but not of the proteasome. 
The ability of Rsp5p, as a single ligase, to recognise multiple targets is mediated by 
adaptor proteins, which act to mediate between the ligase and its substrate, especially if 
that substrate does not contain a direct recognition motif. The Rsp5p adaptor Bsd2 is an 
example of such a protein; it contains WW domain recognition motifs (PY motifs) which 
act as binding motifs for Rsp5p, and in turn binds transmembrane domain-containing 
proteins such as the metal ion transporter Smf1p (Liu & Culotta, 1999), and the ATPase 
Pma1p (Luo & Chang, 1997). This is an example of an adaptor with homologues in 
mammalian systems, the mouse proteins Ndfip1 & Ndfip2, which are essential for the 
interaction of the mammalian ligase WWP2 with the iron transporter DMT1 (Foot et al, 
2008), as well as several other Nedd4 family ligase pathways (Mund & Pelham, 2010). 
However adaptors seem to be less prevalent in higher organisms, which was postulated 
by Novoselova et al (2012) to be because they have instead developed a wider range of 
more specific ligases. 
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1.2.3.2 In the genus Drosophila 
 The number of Nedd4 family ligases increases with increasing organism complexity, 
from the single yeast Rsp5p through three in Drosophila; dNedd4, which indirectly 
regulates axonal formation via Commisureless (Myat et al, 2002), Su(dx), which 
downregulates several genes associated with the Notch signalling pathway (Mazaleyrat 
et al, 2003) and dSmurf, which regulates embryonic organogenesis (Podos et al, 2001).  
 
1.2.3.3. In mammals 
Mammals have a total of nine Nedd4 ligases, with additional regulation and further 
complexity arising from alternative splicing arrangements (Flasza et al, 2002). The main 
functions are summarised in figure 1.7; the canonical member Nedd4, now also known 
as Nedd4-1, has been shown in vivo to regulate growth & development via the insulin 
response pathway (Cao et al, 2008), as well as to promote tumorigenesis by 
ubiquitinating & destabilising the tumour suppressor PTEN (Wang et al, 2007). In 
addition, Nedd4-1 is associated with neuronal development and differentiation (Persaud 
et al, 2011), ubiquitin-mediated sorting of newly synthesised proteins to the plasma 
membrane (Rougier et al, 2011) and clathrin-mediated endocytosis of cell surface 
receptors (Katz et al, 2002; Vina-Vilaseca et al, 2011). Nedd4-2 (previously known as 
Nedd4-like, NEDD4L) shares a high degree of homology with Nedd4-1, but has distinct 
substrate specificity (Persaud et al, 2009), and is particularly associated with the 
ubiquitination and regulation of the epithelial Na+ channel ENaC, which is disrupted in 
the hereditary hypertensive disorder Liddle syndrome (Zhou et al, 2007). The Smad 
ubiquitin regulatory factors, Smurf1 and Smurf2, have a similarly high degree of 
sequence similarity, and were originally thought to be functionally redundant (Narimatsu 
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Figure 1.7. Mammalian members of the Nedd4 ubiquitin ligase family. Summary of 
the nine members of the Nedd4 ligase family in mammals, their canonical 
designation, alternative names and their functions. 
 
  
Protein 
name 
Alternative designations Primary functions 
Nedd4 Nedd4-1 Regulation of growth & development, tumorigenesis, 
neuronal development & differentiation, protein 
sorting & endocytosis. 
Nedd4-2 NEDD4L Some overlap with Nedd4; regulation of ENaC in 
Liddle syndrome 
Smurf1 SMAD-specific E3 
ubiquitin-protein ligase 1 
Cell growth and differentiation, protein kinase 
regulation, autophagy. 
Smurf2 SMAD-specific E3 
ubiquitin-protein ligase 2 
Some overlap with Smurf1; cell cycle progression 
regulation, tumour suppression & senescence. 
AIP4 Itch Cytokine regulation, tumour suppression, regulation of 
NFκB & notch signalling pathways, regulation of 
inflammatory immune response. 
WWP1 Tiul1, AIP5 Cell proliferation, highly expressed in prostate and 
breast cancer, virus proliferation. 
WWP2 AIP2 Some overlap with WWP1; tumour prevention via 
stabilisation of TGF-ȕ pathway components, metal 
transporter regulation 
NEDL1 HECW-1 Associated with cytotoxic aggregates in familial 
neurodegenerative disease, p53-mediated apoptotic 
cell death 
NEDL2  Some overlap with NEDL1; stabilization of p73-
dependent transcriptional activation 
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et al, 2009). However, they do have some distinct roles, for example Smurf1 lacks the C2 
domain-mediated auto-inhibition observed in Smurf2, resulting in selective affinity for 
the GTPase RhoA (Lu et al, 2011), while Smurf2 depletion results in cell cycle 
irregularities that Smurf1 cannot compensate for (Osmundson et al, 2008). In the case of 
tissue separation during embryonic development, the two work antagonistically, with 
Smurf2 targeting the receptor ephrinB1 and Smurf1 acting as an inhibitor, binding to 
ephrinB1 in place of Smurf2 but not catalysing ubiquitination or degradation (Hwang et 
al, 2013). Atrophin-1 interacting protein 4 (AIP4), also known as Itch due to the multiple 
immunological phenotypes of knockout mice (Perry et al, 1998), is associated with 
lysosomal degradation of the melanosomal protein Melan-A (Lévy et al, 2005) and 
negative regulation of tumorigenic cytokines (Ahmed et al, 2011), as well as acting as 
part of a complex of proteins to regulate NFκB signalling (Shembade et al, β008). WW 
domain-containing protein 1 (WWP1), also known as Tiul1 and AIP5, is highly 
expressed in androgen-independent prostate cancer (Gu et al, 2005) and promotes cell 
proliferation in prostate cancer tissues (Chen et al, 2007). WWP1 is also amplified in 
breast cancer (Chen et al, 2007), implying steroid hormone regulation. WWP2 shares 
some functional characteristics with WWP1; for example, both promote virion release in 
an ubiquitination-dependent process (Martin-Serrano et al, 2005), but retains its own 
distinct functionality, for example in the Ndfip-dependent regulation of the iron 
transporter DMT1 (Foot et al, 2008). The final two members of the family, the Nedd4-
like ubiquitin ligases (NEDL) 1 & 2, are less well characterised. Both NEDL1, aka 
HECW-1, and NEDL2 are associated with p53-mediated apoptosis (Li et al, 2008; 
Miyazaki et al, 2003) and NEDL1 is also linked to innate behavioural characteristics in 
C. elegans (Chang et al, 2011) 
Introduction 
 
Page 39 of 229 
 
While each member of the Nedd4 family has its own functions and substrates, there is 
sometimes a degree of redundancy and overlap between them; for example, both Itch and 
Nedd4-2 are associated with increased survival of neuronal tissue following transient 
ischaemia, but only in the case of Nedd4-2 is this mediated by the adaptor/activator 
Ndfip1 (Lackovic et al, 2012). However, Ndfip1 and Itch have been shown to interact in 
different tissue types (Oliver et al, 2006), indicating that this is not an exclusive 
mechanism.  
 
1.3 PY motifs and PMEPA1 
 
1.3.1 PY motifs as WW-domain interacting motifs  
 
 The term ‘PY motif’ was coined by Chen & Sudol (1995) with reference to the 
putative YAP ligands WBP (WW-domain binding proteins) -1 & 2. At that point, the 
WW domain was newly characterised as a 38 residue conserved region found in several 
unrelated proteins, including Rsp5p and Nedd4, which was postulated as being a protein-
binding domain due to its similarity to protein-binding SH3 domains (Yu et al, 1994). 
Chen & Sudol isolated the shared sequence PPxY and reported that they bound the WW 
domain of YAP with high affinity & specificity (Chen & Sudol, 1995). Schild et al 
(1996) again referred to the ‘PY motif’, this time with the sequence PPPxY, with 
reference to such a conserved consensus sequence in the alpha, beta and gamma subunits 
of the epithelial sodium channel ENaC. While it had been previously observed that 
deletion of the C-terminus of any of the subunits resulted in Liddle syndrome, a 
hereditary hypertension (Shimkets et al, 1994; Schild et al, 1995), this was the first time 
the residues responsible for the disease had been isolated. Taking into account that 
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Nedd4 was known to bind ENaC via WW domains (Staub et al, 1996), this was the first 
link between Nedd4 family ligases and PY motifs (Schild et al, 1996). By 1999, WW 
domains had been delineated into three groups according to their binding affinity 
(Espanel & Sudol, 1999), with group I WW domains, including those of YAP and the 
Nedd4 family, being defined as those with the core interaction sequence PPxY, as 
opposed to separate groups which were associated with either proline-rich regions 
punctuated with lysines (Chan et al, 1996), or proline-glycine-methionine motifs 
(Bedford et al, 1998). While the structures of the different WW domain classes are 
broadly conserved, mutation of a single conserved leucine in a canonical group 1 WW 
domain from YAP was shown to be sufficient to induce a switch from PPxY to 
polyproline substrate specificity (Espanel & Sudol, 1999). The conformationally rigid, 
cyclic structure of the proline backbone means that proline-rich sequences form a left-
handed helical structure known as a polyproline II (PPII) helix (Creamer, 1998), forming 
a very distinct recognition motif which require a unique ‘groove’ in the binding surface 
to accommodate it. Different classes of WW domains differ according to the number of 
these ‘grooves’ their surfaces form, which in turn is dictated by the number and position 
of the conserved aromatic residues (Zarrinpar & Lim, 2000). This groove, dubbed the 
‘X-P’ binding groove, in group 1 WW domains such as those of Nedd4, is formed from 
the second conserved tryptophan, Trp487, and a second conserved aromatic residue, 
Phe476 (Kanelis et al, β001). Between the ȕ-strands that form this X-P groove are two 
linking loops which essentially enclose both ends of the groove, and therefore determine 
the substrate specificity. Especially important and conserved in group I WW domains is 
loop II, which forms a hydrophobic ‘pocket’ that the tyrosine residue of the PY motif 
binds to. Loop I shows more variation between individual WW domains, for example in 
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having conserved proline and alanine residues in WW3 of Nedd4 which are not present 
in other WW domains (Henry et al, 2003), thereby contributing to substrate specificity.  
 
1.3.2 Different permutations of PY motifs & the roles of multiple PY motifs 
 
Following the initial reporting of PY motifs as PPxY and PPPxY, as described above, 
in the mid-nineties, several PY-containing proteins, particular cell surface receptors and 
ion channels, were identified and used in turn to identify novel WW-domain containing 
proteins (Pirozzi et al, 1997). The first indication that PY motifs may be more variable 
than previously thought came with a screen of bacteriophage M13, which identified the 
alternative consensus LxLPxY (Kasanov et al, 2001) as a specific Nedd4 family 
recognition sequence, and by 2004 this had been refined to LPxY (Fotia et al, 2004). 
Leucine and other large, branched residues had been identified previously as being 
acceptable substitutes for proline with regards to SH3-binding domains, which share an 
X-P groove structure with WW domains (Yu et al, 1994). The LPxY form of PY motif 
was recognised as common and classed as a canonical motif by 2008 (Bruce et al, 2008), 
having been identified in a variety of substrates including tight junction kinases, and the 
HECT domain of Nedd4 ligases themselves (Patrie, 2005; Bruce et al, 2008). It was later 
established that some WW domains, such as WW3 of Nedd4, bind LPxY motifs more 
efficiently than others, such as the WW domain of YAP (Kanelis et al, 2006). While 
occasional reports of Nedd4 WW domains binding to non-PY sequences, such as 
phosphorylated serine (Edwin et al, 2010) and extended motifs (Chong et al, 2006), the 
L/PPxY motif is still the most common and generally accepted Nedd4 WW domain 
binding motif. 
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The same paper that reported differences in binding affinity of WW domains to 
L/PPxY motifs also noted that the two motifs LPSY and PPCY, of the Drosophila 
protein Commisureless bound different WW domains of Nedd4, WW3 and WW4 
respectively (Kanelis et al, 2006). The two motifs are only five residues apart on the 
substrate protein, making it spatially unlikely that simultaneous binding is occurring. The 
authors do not present any alternative hypothesis for the role of the two motifs. While 
there are many examples of a single PY motif being necessary and sufficient for Nedd4-
mediated binding, for example the inositol phosphatise MTMR4 (Plant et al, 2009) and 
the kinase SGK1 (Wiemuth et al, 2010), other published interactions require more than 
one such sequence, for example the interaction of the Ndfip adaptors with Itch (Mund & 
Pelham, 2009). In addition, not all PY motifs in a protein may behave equally; Ndfip 2 
contains three PY motifs, all of the PPxY type, but removing either PY2 or PY3 has a 
greater effect on its ability to bind to and activate Itch than PY1 (Mund & Pelham, 2009).  
In 2007, a variant APSY motif was identified on the yeast Rsp5p adaptor Bsd2p, 
which was shown to be just as important for its activity as a second, canonical PY motif 
(Sullivan et al, 2007). This was important not only because it was the first time that a 
residue other than leucine or proline had been identified at position 1 of a functional PY 
motif, but because it revealed several interesting points about the interaction of Nedd4 
ligases and their substrates. The variant PY motif was shown to have an indispensible 
role in Bsd2p-mediated ubiquitination of Cps1p in vivo, despite demonstrating only weak 
binding to Rsp5p WW domains in vitro. In addition, substituting the variant alanine for a 
proline eliminated the binding to Rsp5p, as did switching the positions of the two motifs, 
suggesting that multiple PY motifs binding to specific WW domains is important for 
activity. Finally, and importantly, this paper posited a model for the role of multiple PY 
motifs; one may bind transiently to the ligase to ensure correct orientation of the ligase 
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with respect to the adaptor, before being displaced, in this case by another adaptor with a 
stronger affinity for the WW domain. To date, this is the only published example of such 
a variant motif and the best-described model of multiple PY motif roles in the same 
protein. 
 
1.3.3 Identification of PMEPA1 as a Nedd4 substrate, and the PY motifs in PMEPA1 
 
PMEPA1 (prostate transmembrane protein, androgen induced 1) was first identified as 
one of a number of androgen-induced genes present in the LNCaP prostate cancer cell 
line and called TMEPA1 (transmembrane, prostate androgen induced RNA 1) (Xu et al, 
2000). It was put forward at the time as a potential biomarker for androgen signalling 
activity as a measure of prostatic disease, and at the time very little was known about it 
apart from the observation that it was localised to glandular epithelial cells in the 
prostate, and it was strongly up-regulated in response to synthetic androgen treatment, as 
well as in 75% of prostatic tumours (Xu et al, 2000). A type Ib transmembrane domain 
was identified between residues 9 and 25 at the N-terminus of the protein, and its size 
was determined as 252 residues. This would be predictive of subcellular targeting to the 
secretory pathway, and this was corroborated by the observation that a fluorescent-
tagged PMEPA1 construct transiently expressed in LNCaP cells broadly co-localises 
with the cis-Golgi marker GM130 (Xu et al, 2003). Around the same time, an Australian 
group had used a similar screening method to identify binding partners of Nedd4 in 
mouse embryos (Jolliffe et al, 2000), one of which was called N4wbp4 and contained 
two PPxY PY motifs. PMEPA1 was found to share 83% sequence homology with 
N4wbp4, including the two PY motifs, and was later shown to interact with Nedd4 
through those PY motifs (Xu et al, 2003). In the mean time, another Australian group had 
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independently identified PMEPA1 as being upregulated in renal,  stomach and rectal 
cancers, and dubbed it STAG1 (solid tumour associated gene 1) before acknowledging 
that the sequence overlapped with that of PMEPA1 (Rae et al, 2001). This group also 
identified several proline-rich regions as potential SH3 and WW domain interaction 
motifs, but did not suggest specific interactions with Nedd4 or any other WW-domains 
containing proteins.  
PMEPA1 was definitively identified as a Nedd4 substrate in vitro and in vivo in 2003, 
in a paper which also identified that it showed perinuclear localisation with approximate 
colocalisation with cis-Golgi markers, and demonstrated that a growth inhibitory effect 
in prostate cancer cell lines was abrogated by mutating the PY motifs, and therefore was 
Nedd4-mediated (Xu et al, 2003). The apparent conflict in subcellular localisation is 
common to other Nedd4-interacting proteins such as Ndfip2, which has 3 transmembrane 
domains and is Golgi- and late endosome-associated (Shearwin-Whyatt et al, 2004), so 
evidently is no barrier to binding in vivo. In fact it has been proposed that Ndfip2 
sequesters Nedd4 and Nedd4-2 in the secretory pathway, specifically vesicular bodies, as 
a form of activity regulation (Konstas et al, 2005).  
The two motifs, designated PY1 and PY2 according to their position in the primary 
sequence of PMEPA1, had the sequences PPPY126 and PPTY197 respectively. The 
functional loss of either of these two motifs resulted in significant loss of binding to 
Nedd4 WW domains, as measured using in vivo immunoprecipitation studies on prostate 
cancer lines (Xu et al, 2003), with this paper reporting PY2 as having a larger role in 
binding that PY1. However, it was simultaneously observed that the loss of PY1 had a 
greater impact on the growth inhibitory effects of PMEPA1, as measured by in vivo 
colony formation. Later studies confirmed the importance of the PY motifs in PMEPA1-
androgen receptor interaction (see section 1.4.5) but did not expand on these initial 
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observations that the two may not be equal in terms of binding affinity and function (Li 
et al, 2008).  
 
1.4 Androgen receptor function, regulation and interplay with PMEPA1 
 
1.4.1 Function and structure of the androgen receptor 
 
 The androgen receptor (AR) is one of a family of nuclear hormone receptors which 
bind to steroids and act as ligand-regulated transcription factors. The activation cycle of 
AR is shown in figure 1.8; the natural ligands of AR are the male hormone testosterone 
and its metabolite dihydrotestosterone (DHT). Of the two, DHT binds more strongly to 
AR (Wilson & French, 1976), as well as dissociating more slowly and stabilising the 
receptor more effectively than testosterone (Zhou et al, 1995), and therefore acts as a 
more potent activator of the receptor. The development and maintenance of male sexual 
characteristics commonly associated with testosterone, including embryonic sexual 
differentiation, pubertal secondary sexual development, and spermatogenesis (George & 
Wilson, 1994), are all mediated by the androgen receptor. Its importance is demonstrated 
by the fact that androgen insensitivity syndrome (AIS) caused by mutations on the AR 
gene is associated with normal, indeed often elevated, levels of testosterone, but varying 
degrees of androgeny ranging from a completely female appearance at birth to infertility 
(Gottlieb et al, 1999). In addition to being expressed at high levels in prostatic and 
testicular tissues, AR has also been detected immunohistochemically in breast and 
vaginal tissue, as well as in cardiac muscle, hepatocytes and certain skin tissues in both 
males and females (Ruizeveld de Winter et al, 1991); that AR plays a role in breast 
cancer is widely accepted and the focus of intense research at present, as it has been  
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Figure 1.8. Schematic representation of the androgen receptor cycle. Testosterone is 
converted to DHT (black squares in top left) by the cytosolic enzyme 5α-reductase. 
AR (red) is maintained in a stable, inactive state in the cytoplasm by chaperones such 
as heat shock protein (white). Upon binding to DHT (1), a conformational change 
occurs and the HSPs dissociate (2), facilitating binding of coactivators (blue) such as 
importin α, which enable AR to move into the nucleus (γ). Dimerisation occurs, and 
the AR dimer moves into the nucleus (3) and binds to androgen receptor elements on 
DNA, with concurrent dissocation of DHT (4). Once transcription is complete, the 
unliganded AR dissociates from the DNA and from the coactivators, and moves back 
into the cytoplasm (5), where it is free to bind stabilising HSPs (6a) or be degraded by 
the ubiquitin-proteasome system (6b). 
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found that a higher proportion of tumours show elevated AR (70-90%) than elevated 
oestrogen (70-80%) or progesterone (50-70%) receptors, the female steroid hormone 
receptors, yet AR levels correlate strongly with patient survival in non-metastatic cases 
(Gonzalez et al, 2008). In skin, AR is associated with slight inhibition of wound healing 
(Ashcroft & Mills, 2002), as well as with hormonally-induced conditions such as 
pubertal acne, for which anti-androgen have been used as a treatment for over 20 years 
(Greenwood et al, 1983; Muhlemann et al, 1986), and male pattern baldness, as part of 
its role as a mediator of the effects of circulating testosterone and DHT. AR has been 
detected in both male and female cardiac muscle, but the higher levels of circulating 
androgens in males is the likely cause of the relative hypertrophy of the cardiac muscle 
in males of several species (Marsh et al, 1998) as well as the basis of myocardial 
infarction as a consequence of anabolic steroid abuse (Melchert & Welder, 1995). 
 Structurally, AR is 110kDa in size and shares a common domain structure, and a high 
degree of sequence homology, with other steroid hormone receptors (Maclean et al, 
1997). The N-terminal region consists of a polyglutamine repeat tract, a repeating 
sequence of glutamine residues with polymorphic repeat number which is associated 
with endocrinological and neurological disorders (Palazzolo et al, 2008), and an AF-1 
domain, less well conserved compared to the other steroid hormone receptors, containing 
two overlapping transcriptional activation signals, both of which are required to initiate 
transcription, dubbed TAU1 and TAU5 (Jenster et al, 1995). The DNA-binding domain, 
which mediates transcriptional activation, is conserved throughout the steroid hormone 
receptor superfamily and contains 2 zinc finger motifs with a 66-residue core sequence 
(Luisi et al, 1991). It is located in the central region of the protein and mediates 
dimerization as well as DNA binding; the question of how such a well-conserved domain 
can mediate such different responses to the different steroids is ongoing, but there is a 
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large number of coactivators and a complex network of regulation involved, covered in 
more detail in section 1.4.3. The hinge region downstream from the DNA-binding 
domain is less well-studied, but plays a role in ligand-mediated nuclear translocation and 
DNA binding; there is conflicting evidence as to how this occurs as mutations in this 
region result in lower translocation efficiency but a stronger androgen response (Haelens 
et al, 2007). Finally the ligand-binding domain is at the C-terminus, unique among the 
steroid hormone receptors in that it is solely a ligand-binding region with no role in 
nuclear translocation. While the sequence homology between hormone receptors in this 
region is relatively low, they share a common folding pattern, known as an α-helical 
sandwich, consisting of a small section of ȕ-sheet surrounded by a variable number of α 
helices (Matias et al, 2000), shown in figure 1.9. This fold is the basis of the structural 
change that occurs when a ligand is bound; one of the helices moves from being in an 
‘open’ conformation to adopting a more compact, closed conformation that encloses the 
binding pocket. The specific residues within this binding pocket determine the ligand 
specificity of the receptor, for example this is the location of the T877A mutation found 
in the AR of the LNCaP prostate carcinoma cell line, resulting in a much greater binding 
affinity, and lower specificity, for steroids including progesterone (Matias et al, 2000) 
 
1.4.2 Role in prostate cancer 
 
 There are over 10,000 known androgen receptor binding sites on the human genome, 
identified through chromatin immunoprecipitation (ChIP) sequencing (Sharma et al, 
2013; Lamb et al, 2014), and several recent papers have reported the discovery of a 
significantly altered transcriptional profile in both early and late-stage prostatic tumours 
compared to normal tissue, both in cell lines in vitro and in tissue samples in vivo; these  
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Figure 1.9. Schematic of the domain structure of androgen receptor (A), showing the 
N-terminal transactivation domain, containing the polyglutamine tract (PolyGln) and 
the two transcriptional activation regions TAU1 and TAU5, the two DNA-binding 
zinc finger motifs (Zn), the hinge region and the C-terminal ligand binding domain 
(LBD). Also shown is a crystallographic structure of the LBD of human AR at 1.9Ä 
resolution, bound to DHT (B). AR is shown with secondary structures in light grey, 
while DHT is shown as dark grey spheres. The small section of ȕ-sheet characteristic 
of the α-helical sandwich is shown in the bottom left, surrounded by 1β α-helices. The 
threonine residue which is mutated in the LNCaP cell line is highlighted in red. RCSB 
PDB reference 2AMA with original structure published by Pereira de Jesus-Tran et al, 
2006. 
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are presented in more detail in figure 1.10. The most immediately striking characteristic 
of this selection of transcriptional targets is the widely ranging functionality, from 
MUC6, which encodes gastric mucin, to CHRM1, an acetylcholine-binding G-protein 
coupled receptor. However, patterns have emerged; Perets et al (2012) identified seven 
ontology categories that were significantly over-represented in early stage prostatic 
tumour cells in the presence and absence of an agonist, including transcriptional 
regulators and ligand-gated ion channels. While the correct functioning of AR is 
essential for normal prostate development and function (Yeh et al, 2002), there are over 
50 identified functional mutations in the AR gene which are associated with prostatic 
cancer (Heinlein & Chang, 2004). A high level of AR expression is predictive of 
progession to less treatable forms of the disease, as well as lower long-term survival 
(Lee, 2003).  In normal prostate tissue, cells are turned over at a slow but balanced rate, 
keeping the overall organ size constant, but during early stages of cancerous 
development the rate of proliferation increases while the rate of death remains the same, 
allowing a slow but significant increase in size. As the disease progresses, the rate of 
death increases to balance the increased proliferation rate, meaning that although the 
growth is slowed, the number of splitting cycles each cell undergoes increases along with 
the chance of accumulating further mutations (Berges et al, 1995). The primary course of 
treatment for prostate cancer is androgen ablation therapy, which has been in use for over 
70 years (Huggins et al, 1941) – today, this consists of a combination of chemical or 
surgical castration and AR antagonists, blocking the production of testosterone and DHT 
and simultaneously preventing them binding to AR. This treatment is effective in 80% of 
cases, but sometimes ceases to work after a period of 12-18 months, after which the 
disease is said to be androgen-independent, hormone-refractory or castration-resistant 
(the preferred term, as this form of the disease is still dependent on steroid hormones),   
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Figure 1.10. Venn diagram showing transcriptional targets of AR associated with 
prostatic cancer in vitro and in vivo. There are over 2,500 identified transcriptional 
targets of AR which have been identified as up-regulated, compared to normal tissue, 
in either cell line models of prostate cancer or tissue samples from prostatic tumours. 
This diagram represents a sample of identified genes from three publications (Lamb et 
al, 2013; Jariwala et al, 2007; Decker et al, 2012) which used ChIP sequencing and 
microarray techniques to pinpoint specifically novel genes which were significantly 
up-regulated in cell lines and/or prostatic tumours. Gene targets identified in vitro are 
bounded by the blue line and have refer to those found in the LNCaP and/or its 
derivative, C4-2B cell lines. Gene targets identified in vitro are bounded by the red 
line and refer to those found in human prostatic tissue samples. Those which overlap 
are highlighted in bold text.  
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(Heinlein & Chang, 2004). Paradoxically, withdrawal of anti-androgen therapy can result 
in a period of rapid symptomatic improvement and tumour regression (Scher et al, 1996), 
however this is temporary, and the mean survival time once the disease has progressed to 
that stage is 40-68 months (Oefelein et al, 2004). Second line therapy for castration-
resistant prostate cancer is also dependent on anti-androgens, especially less commonly 
used treatments such as nilutamide, as well as adrenal suppressants and oestrogens 
(Chang, 2007). 
 The two transcriptional elements of the N-terminal AF-1 domain of AR both show 
several polymorphic variants associated with altered transcriptional activation (Gao et al, 
1996) and variable rate of prostate growth (Zitzmann et al, 2003); while these seem to be 
common polymorphisms within the male population, the penetrance of associated cancer 
is relatively low (Nwosu et al, 2001). In terms of androgen-dependent, early stage 
cancers, AR has been shown to mediate androgen-dependent cell cycle progression, 
particularly during the transition from G1-S stage (Knudsen et al, 1998) via activation of 
cyclin-dependent kinases and subsequent phosphorylation & inactivation of repressors 
(Sherr, 1996), so androgen ablation therapy halts cell cycle progression. However, AR 
may also have a context-dependent protective role; it has been reported that mice lacking 
AR in the prostatic endothelium developed more aggressive prostate cancers and did not 
live as long as wild type mice (Niu et al, 2008). Similarly, AR can act indirectly to 
promote cell survival by upregulating cytoprotective proteins and downregulating others, 
such as the clusterin isoforms (Cochrane et al, 2007). 
Rather than the initial development of prostate cancer however, the most striking 
association is between AR and the progression to the more advanced and less treatable 
castration-resistant form of the disease. AR levels in androgen-independent tumours are 
an average of six times higher than in early stage or benign tumours (Linja et al, 2001), 
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and amplification of the AR gene has been reported in patients who have developed 
hormone refractory prostate cancer after androgen ablation, but not before (Koivisto et 
al, 1997), suggesting that progression is at least partly caused by selection for increased 
AR copy number during low androgen therapy. In addition, there is a high frequency of 
AR mutations in advanced metastatic prostate cancer compared to early stages of the 
disease (Marcelli et al, 2000), again possibly due to selection pressure during treatment. 
These mutations may cause the AR to respond improperly to steroids other than 
testosterone and DHT (“promiscuous receptor pathway”) such as the CaP T877A 
mutation, found in the LNCaP cell line and approximately 25% of androgen independent 
tumours (Gaddipati et al, 1994), or to become activated in the absence of steroids 
(“outlaw receptor pathway”). The tyrosine kinase HER-2/neu is strongly associated with 
breast and ovarian cancers (Slamon et al, 1989), both linked to the oestrogen receptor 
(ER) which is very closely related to AR. The drug Herceptin acts to bind HER-2/neu 
and blocks binding to the ER, and HER-2/neu has been shown to activate AR-dependent 
genes in the absence of steroid binding via the MAP kinase pathway (Yeh et al, 1999), 
emphasising again the varied roles of AR and the many potential pathways for its 
involvement in prostatic cancers. Which of these pathways is dominant, or even 
significant, in the development of castration-resistant cancer is not known and probably 
varies from case to case, but it is certain that AR plays an important role not only in the 
transformation of prostate tumours from androgen-dependent to androgen-independent, 
but in maintaining androgen-independent growth through an entirely different 
transcriptional program to that found in normal tissue and androgen-dependent tumours 
(Wang et al, 2009), including higher levels of histone methylation and upregulation of 
cell cycle progression.  
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1.4.3 Regulatory mechanisms 
 
 The regulation of androgen receptor activity is hugely complex, involving many 
pathways and other signalling molecules as well as steroids and intramolecular 
interaction of AR itself. Figure 1.11 illustrates the interplay and complementary nature of 
the intra- and selected intermolecular regulatory processes and their effect on ligand 
binding stability and AR activity. The intramolecular interaction, called the N/C 
interaction, involves an FQNLF motif on the N-terminal domain (Dubbink et al, 2004) 
and AF-2 region on the C-terminal ligand binding domain. On other steroid hormone 
receptors, the AF-2 region strongly binds coactivator complexes through the same motif, 
but AR is unique in that this is a much weaker binding compared to the binding to itself 
(He et al, 1999). This N/C interaction stabilises bound testosterone and potentiates the 
action of the receptor, but is abolished on translocation to the nucleus and binding to 
DNA, opening up the C-terminal binding site to coregulators (van Royen et al, 2007). In 
addition, it was recently reported that the DNA-binding and ligand-binding domains 
interact directly with each other when AR dimerizes, and that the loss of this interaction 
negatively impacts the ability of AR to bind ligands and to transactivate target DNA 
(Helsen et al, 2012). This novel interface is the site of several mutations associated with 
androgen insensitivity syndrome and highlights the holistic nature of the receptor 
activity, with the function of each domain being dependent on allosteric interactions with 
the rest of the protein. 
One of the most important ways in which AR, in common with other steroid hormone 
receptors, is regulated is through over 130 identified coregulators which can both 
negatively and positively affect AR function (Chmelar et al, 2006). Of these, the 
canonical example is the p160 family, which consists of three large 160 kDa proteins  
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Figure 1.11. Schematic illustration of inter- and intra-molecular regulatory mechanisms of AR. The domain structure of AR is shown 
with the three main domains colour coded (A); the N-terminal domain (NTD) is shown bounded in red, the DNA binding domain (DBD) 
is shown bounded in blue, the hinge region is shown in black and the ligand binding domain (LBD) is shown bounded in green. These 
colours are retained throughout the figure to illustrate which parts of the protein are involved in the various interactions. The 
intramolecular N/C interaction is shown in (B) by the black broken line; this binding is maintained during ligand binding (C) but lost 
during dimerisation and DNA binding (D), during which the NTD and LDB domains of the two AR monomers interact, again shown by 
black broken lines. Two examples of intermolecular regulatory interactions, the binding of a p160 family co-activator to the TAU5 region 
of the NTD via the LXXLL motif (E) and the binding of the nuclear receptor co-repressor (NCoR) to the DBD (F), are also shown. 
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named SRC (steroid receptor coactivator) 1, 2 (aka TIF2 or GRIP1) and 3 (alternatively 
RAC3/AIB1). The SRCs are recruited mainly through the transcription activation 
domain TAU5 in the N-terminal region of AR (Callewaert et al, 2006), but the precise 
nature of the DNA promoter region being targeted and the internal regulation of the N/C 
interaction seem to play a part (Christiaens et al, 2002). These p160s bind AR via 
LXXLL motifs which compete for the AF-2 binding with the internal N-terminal site 
described above (Ding et al, 1998) and act as co-activators, stabilising the ligand-AR 
complex and enhancing the duration and efficiency of transcription. Other AR-associated 
coactivators are numerous and diverse, with no structural similarity, and for simplicity 
are named for their molecular weight e.g. ARA267, which mediates apoptosis (Wang et 
al, 2004). There are also a number of AR co-repressors, such as the nuclear receptor 
corepressor (NCoR), which interacts with the ligand-binding domain of AR, specifically 
the α helix which encloses the ligand when bound, and suppresses transcriptional activity 
(Cheng et al, 2002). Figure 1.11 illustrates several examples of intra- and intermolecular 
regulatory mechanisms for clarity. Many AR corepressors also have histone deacetylase 
(HDAC) activity, meaning that they inhibit transcription by preventing RNA 
polymerases from accessing promoter regions (Mathis et al, 1978). 
The other major system of AR regulation is through post-translational modification 
(PTM), with a summary of the known modifications and their functions presented in 
figure 1.12. AR has been demonstrated to undergo ubiquitination mediated by the RING 
ligase Mdm2 (Gaughan et al, 2005), in a process which also requires the deacetylase 
HDAC1, resulting in decreased activity and increased AR turnover. Ubiquitination of 
AR is also associated with response environmental toxins such as dioxins, during which 
the dioxin receptor acts as a component of an E3 ligase complex to mediate enhanced 
degradation of sex hormone receptors (Ohtake et al, 2011). As well as regulating histone  
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Modification Catalysed by Modification site(s) Net effect(s) on AR activity 
Phosphorylation Multiple kinases 
including PKC, 
MAPK, p38 and 
Src 
At least 17 serine 
residues, 3 tyrosine 
residues, 1 threonine 
residue 
Either increased or decreased; 
associated with increased 
translocation when carried out 
in the cytoplasm and both up- 
and down-regulation in the 
nucleus 
Acetylation Acetylases 
including p300, 
PCAF 
Lysines within 
KLKK/ motif 
Increased activation and 
recruitment to AREs; reported 
oncogenic effects 
Ubiquitination Ubiquitin E3s 
including Mdm2, 
CHIP and RNF6 
K845, K847 Decreased activity due to 
increased proteasomal 
degradation 
SUMOylation Several SUMO 
E3s including 
PIAS1, RanBP2 
and Pc2 
Lysines within the 
consensus sequence 
ψKxE 
Reduction of transcriptional 
activity, possibly by interfering 
with intramolecular stabilisation 
Methylation Methyltransferase 
Set9; possibly 
others 
Lysines within the 
hinge region 
Enhanced transcriptional 
activation 
 
Figure 1.12. Table summarising post-translational modification (PTM) of AR. The 
type of PTM is shown as well as the enzyme that catalyses the reaction, the target 
residue(s) in human AR and the reported effect on AR activity. 
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acetylation status, HAT enzymes also modify AR directly, for example the coactivators 
p300 and P/CAF, which selectively modify specific lysine residues at the C-terminal end 
of the DNA-binding domain (Fu et al, 2000); this mutation of these lysines resulted in a 
loss of DHT-dependent transactivation of AR. Phosphorylation is a particularly well-
studied and important PTM, and AR undergoes multiple phosphorylation events which 
serve several purposes. It is constitutively phosphorylated very soon after synthesis, and 
impairment of this process results in loss of effective ligand binding and a drop in 
transcriptional activity (Blok et al, 1998). Ligand binding in turn induces a further 
increase in phosphorylation to almost twice the initial extent, which is linked to increased 
nuclear translocation (van Laar et al, 1991) and is linked to ligand-induced 
conformational change increasing the availability of AR to kinases (Yang et al, 2007), 
and phosphorylation of AR alone has been shown to make the difference between 
ligands acting as agonists or antagonists (Wang et al, 1999). There are at least 17 
conserved serine residues in AR which act as targets for phosphorylation (Coffey & 
Robson, 2012), which are preferentially modified depending on the subcellular location 
of AR in a further level of regulation (Kesler et al, 2007). There is a high degree of 
interplay between PTMs and other forms of regulation, for example overexpression of 
the activating kinase HER-2/neu mentioned earlier enhances phosphorylation of AR in 
vivo, while inhibition of HER-2/neu reduces phosphorylation of AR and curtails its 
transactivation (Sugita et al, 2004), as well as between different forms of PTMs. 
Phosphorylation of AR has been shown to be crucial for recruitment of the ubiquitin 
ligase Mdm2 to AR bound to DNA, and mutation of the conserved modified serine 
results in the preferential recruitment of a different ligase, CHIP, and the accumulation of 
AR at the PSA promoter (Chymkowitch et al, 2011). The final major PTM on AR is 
SUMOylation, which is discussed in more detail as a modification in section 1.5. SUMO 
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is an ubiquitin-like molecule which is conjugated to substrates via an enzymic cascade in 
much the same way, but has its own specific E1-E3 enzymes. SUMOylation is associated 
with functional repression of transcription factors in a process that depends on chromatin 
association (Stielow et al, 2008), and AR contains two SUMOylation motifs which, 
when mutated, result in enhanced transcriptional activity of AR and are clinically 
associated with testicular cancer, AIS and prostate cancer (Mukherjee et al, 2011). This 
is a dynamic process, triggered by ligand binding, during which extant AR is constantly 
cycling through SUMOylation and deSUMOylation in order to facilitate rapid response 
to stress signals such as heat (Rytinki et al, 2012). 
 
1.4.4 A published feedback loop between AR and PMEPA1  
 
 In 2008, an American group published a report in which they laid out a potential 
negative feedback loop between AR and PMEPA1 (Li et al, 2008). PMEPA1 is now 
well-established as a transcriptional target of AR alongside PSA and others (Xu et al, 
2012), and was previously shown to exhibit a negative effect on prostate cancer cell 
growth, both in vitro in laboratory cells lines and in vivo through a correlation between 
lower PMEPA1 expression and more advanced tumours (Xu et al, 2003). The new paper 
confirmed that this was mediated by ligand activation of AR, as well as showing a 
physical interaction between PMEPA1 and AR via co-immunoprecipitation. The most 
significant finding in terms of the feedback loop hypothesis was that induction of 
PMEPA1 expression in LNCaP prostate cancer cells, which express high levels of 
endogenous AR, caused a complete loss of detectable AR. Similarly, when PMEPA1 
expression was silenced, detectable AR levels, as well as transcriptional activity as 
measured by PSA expression, increased slightly, as did S-phase cell cycle progression, 
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inferring that cell growth rate had also risen. Inhibition of the ubiquitin-proteasome 
system using the 26S proteasome inhibitor MG132 reinstated normal endogenous AR, as 
did another proteasome-specific inhibitor LLnL and, to a much lesser extent, lactacystin, 
although the non-proteasomal cysteine protease inhibitor E64 did not demonstrate this 
ability. Co-transfection of AR with HA-tagged ubiquitin and PMEPA1 resulted in a 
larger high molecular weight smear of ubiquitinated AR compared to AR and HA-Ub 
alone, and the downregulation of AR was shown to be attenuated when a PMEPA1 
construct with both PY motifs mutated out was used in place of wild type, and Mdm2 
knockout cells showed a reduced PMEPA1-mediated effect on AR levels.  
Based on these findings, the group put forward a model for PMEPA1 acting to recruit 
Nedd4 to promote ubiquitin-mediated degradation of AR as a negative feedback loop, in 
which ligand binding initiates AR translocation to the nucleus and initiates PMEPA1 
transcription. PMEPA1 in turn recruits Nedd4 and triggers degradation of AR, abolishing 
its effects. An additional layer of complexity is added by more recent findings by the 
same group; not only does Nedd4 down-regulation result in an increase of AR levels, but 
overexpression of AR results in a drop in Nedd4 levels (Li et al, 2012). However, there 
are several holes in this theory that the 2007  paper does not address; firstly, they do not 
make any suggestions as to how PMEPA1, which has been shown to associate strongly 
with the Golgi apparatus (Xu et al, 2003) but is absent from the nucleus and cystoplasm, 
makes physical contact with AR, which is cytoplasmic until testosterone binding triggers 
nuclear shuttling (Saporita et al, 2003). Secondly, they interpret the inhibition of the 26S 
proteasome and the subsequent restoration of cellular AR levels as showing that the 
effect of PMEPA1 on AR is proteasome-mediated i.e. is a degradation effect. While this 
is certainly a feasible explanation, inhibiting the proteasome does not result in lower 
levels of ubiquitination, rather it causes a build-up of ubiquitinated products which 
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would usually be broken down by the proteasome and their ubiquitin conjugates recycled 
into the cell’s free ubiquitin pool. This in turn means that the pool of free ubiquitin is 
depleted, and other ubiquitin-dependent processes, such as trafficking and endocytosis, 
are also halted. There is some evidence in the paper itself that this is the reason for the 
observations; one of the experiments detailed was a transient transfection of HEK 293 
kidney cells with a tagged form of ubiquitin and exogenous AR, with and without 
PMEPA1. It was observed that on addition of PMEPA1, increased high molecular weight 
conjugates of AR were seen on Western blots compared to AR and ubiquitin alone. 
However, this result clearly does not replicate their reported loss of AR in the presence 
of PMEPA1. If the result were due to increased proteasomal turnover of AR mediated by 
PMEPA1/Nedd4, the addition of exogenous ubiquitin should not make any difference to 
AR levels, however if it were due to another function of ubiquitin signalling, the 
additional ubiquitin would compensate for the depletion of the ubiquitin pool caused by 
the inhibition of the proteasome, and AR levels would remain stable, at least for a longer 
period of time. The ubiquitin experiment seems to suggest the latter. Finally, it is not 
clear from the paper whether PMEPA1 acts as an adaptor to mediate Nedd4 
ubiquitination of AR, or whether PMEPA1 itself is ubiquitinated, and possibly trafficked 
to a location in which it can interact with AR as a result; the paper does not address 
physical interactions of either protein with Nedd4, only infers its involvement by the 
importance of the PY motifs in PMEPA1. 
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1.5 Summary and outstanding questions 
 
 This work focuses on clarifying the interaction between the ubiquitin ligase Nedd4 
and its known substrate PMEPA1, a membrane protein showing altered expression in 
prostate cancer. PMEPA1 contains two well-documented canonical PY motifs, both 
required for interaction with Nedd4, and recent work has identified a third motif with a 
variant PY (vPY) sequence, QPTY. The roles of the multiple PY motifs in PMEPA1, as 
well as the importance of the precise nature of the amino acid residues within and 
surrounding the vPY motif, are not yet clear.  
PMEPA1 is involved in regulating the cellular response to testosterone via the 
androgen receptor (AR) and has been shown to decrease cellular AR via a negative 
feedback loop involving Nedd4. This process is attenuated in PMEPA1 mutants that 
cannot interact with Nedd4, implying that receptor regulation is dependent on 
ubiquitination. However AR and PMEPA1 are reported to be located in different 
subcellular compartments, raising questions about the mechanism of interaction between 
them; this leads back to the indeterminate precision of the PMEPA1 localization reported 
in the original paper, discussed previously. While the individual interactions between 
PMEPA1 and Nedd4, as well as between PMEPA1 and AR, have been confirmed and 
studied, the interplay between the mechanisms involved, including how the ubiquitin-
proteasome system might underpin the PMEPA1-mediated androgen receptor regulation 
cycle, remains unresolved. 
 
 
 
 
Introduction 
 
Page 63 of 229 
 
The specific questions that this project aimed to answer were: 
 What is the difference, if any, in functionality between the vPY motif and the two 
canonical PY motifs in PMEPA1? 
 How flexible is the vPY motif, in terms of its precise sequence? 
 Does altering the residues immediately flanking all three PY motifs have any 
impact on their function? 
 What is the in vivo significance of each of the three PY motifs in PMEPA1? 
 Does altering the Nedd4 binding ability of PMEPA1 affect in vivo cellular protein 
levels and subcellular localisation? 
 What are the precise roles of PMEPA1, Nedd4 and ubiquitin in the AR/PMEPA1 
feedback cycle? 
 
1.6  Hypotheses 
1 The vPY motif will, in a similar way to that identified in Bsd2p (Sullivan et al, 
2007), be involved in ubiquitination of PMEPA1, and that this unique role will be 
related to differential binding to WW domains through this motif compared to the 
two canonical motifs. 
2 A soluble variant of PMEPA1, lacking the N-terminal transmembrane domain, 
will be free to colocalise with the cytosolic proteins AR and Nedd4 
3 The in vitro significance of the PY motifs in PMEPA1 reflect a prominent in vivo 
role in mediating Nedd4 ubiquitination, and this interaction is implicated in 
regulation of AR. 
4 The proposed feedback loop between AR and PMEPA1 is dependent on a direct 
interaction as described above, and this is triggered by a ubiquitin-mediated 
trafficking process rather than ubiquitin acting as a degradation signal.
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2. MATERIALS AND METHODS 
 
2.1 Cloning 
 
2.1.1 Plasmids 
For the in vitro ubiquitination assays, a construct of PMEPA1 lacking the N-terminal 
hydrophobic domain (first 23 amino acids), with an N-terminal S-tag and 6xHis tag, 
cloned previously by Dr. Jim Sullivan into a pET30a vector (Novagen) was used. Each 
alteration was made as a single point mutation, first in the wild type construct, and then 
on the resulting plasmids as necessary to make double and triple mutants. N-terminal 
GST-tagged Nedd4 and Uba1 were both previously cloned by Dr Aipo Diao and Dr. Jim 
Sullivan, respectively, into pGEX-6P2 (GE Healthcare). The circular dichroism 
experiments, which required an ultraviolet-invisible tag, necessitated cloning an 
additional Nedd4 construct with a 6xHis-tag for bacterial expression. This was done by 
ligating the Nedd4 ORF from the GST-tagged construct into pET30a via BamHI and SalI 
restriction sites. 
For the microscopy, full length PMEPA1 with C-terminal green fluorescent protein 
(GFP) or mCherry tags, in a pGRIP vector (obtained from Alison Gillingham, MRC-
LMB, Cambridge), was used. This plasmid has a CMV promoter for mammalian 
expression, along with a polyadenylated terminator sequence and an ampicillin resistance 
gene. The wild-type Nedd4 constructs with N-terminal GFP and mCherry tags used were 
similarly cloned into the same plasmid. The PMEPA1 triple ΔPY mutant was made in 
the same way as the bacterial expression plasmid described above, using the same SDM 
primers to sequentially introduce the mutations. The ΔNT truncated mutant was made 
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using PCR as detailed below to produce a DNA fragment coding for PMEPA1 without 
the first 23 amino acids, using the full length ORF in the pGRIP vector as a template, 
with sticky ends to ligate directly into the same pGRIP17 plasmid via existing AfeI and 
ClaI restriction sites. The AR-GFP plasmid was made by first cloning human AR from 
the IMAGE clone (number 40146997) into a pGRIP intermediate vector using BamHI & 
XhoI restriction enzymes to introduce additional cloning sites, and then inserting the 
ORF into the pGRIP mammalian expression plasmid downstream of the GFP tag via 
BamHI and XbaI restriction sites. To introduce the CaP (T877A) mutation into the 
androgen receptor, oligonucleotides were designed as described below, and SDM was 
performed as previously. A GFP-only plasmid was cloned previously into the pGRIP 
vector for mammalian expression, and an mCherry-only plasmid was cloned by inserting 
the mCherry sequence from a previously cloned mCherry-SUMO (Giulia Bená, 
unpublished) plasmid into pCMV (Addgene) via SacI & BamHI restriction sites. 
 For the epitope tagged mammalian expression constructs, firstly PCR was used (see 
2.1.2) to introduce additional restriction sites at either end of the PMEPA1 ORF. This 
fragment was then digested & inserted into a variant of the pGRIP17 plasmid (cloned 
previously by Dr. J. Sullivan) via BamHI and XhoI restriction sites, to give a single ORF 
with a C-terminal tag (2x Myc + IgG binding domain of Protein A) fused to full-length 
PMEPA1. This new plasmid was then used to clone a ΔNT truncated PMEPA1 construct 
using a similar method to that used for the fluorescent protein tagged ΔNT PMEPA1 
plasmid; PCR was used to amplify out a fragment containing the entire PMEPA1-Myc-
IgG ORF, without the N-terminal transmembrane domain and with the addition of extra 
restriction sites at both ends, which was then ligated into a p3HA plasmid (provided by 
Thomas Mund, MRC-LMB, Cambridge) via BamHI and SalI restriction sites. AR was 
cloned directly from the GFP plasmid into pGRIP in place of PMEPA1 using BamHI and 
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XhoI restriction sites, and an untagged construct, created by ligating the IMAGE clone 
into pGRIP-HA cut using BamHI and XhoI restriction enzymes, was also made. In 
addition, TAP-Nedd4 was cloned into pGRIP17 previously by Nasra Diriye (QMUL, 
undergraduate project student), and 8xHis-FLAG-ubiquitin was cloned into p3HA 
previously by Arfa Jalil (QMUL, undergraduate project student). 
 
2.1.2 Primer Design 
 
For site directed mutagenesis (SDM), oligonucleotides were designed using the 
Primer X online program available at http://www.bioinformatics.org to ensure the 
melting temperatures and GC content were suitable for use in SDM, and purchased from 
Eurofins MWG. KOD Hot Start 2x Master Mix (Novagen) and Phusion Hot Start Flex 
2x Master Mix (New England Biolabs) were used as described in 2.1.3 below, and 
success was confirmed using the Eurofins MWG DNA sequencing service. 
See figure 2.1 for a complete list of all the primers used for PCR. 
 
 
2.1.3 Polymerase Chain Reaction (PCR) 
 
  For all PCR reactions a PeqStar 96 thermocycler (Peqlab) was used.  Primers were 
supplied as lypophilised powder and reconstituted using an appropriate volume of sterile 
distilled water to a stock concentration of 100 µM. 
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Target Mutation Foƌǁaƌd pƌiŵeƌ seƋueŶce ;5’-3’Ϳ Reǀeƌse pƌiŵeƌ seƋueŶce ;5’-3’Ϳ 
PMEPA1 Y102A (PY1) CCG CTT CCA GCC CAC CGC TCC GTA CCT GCA G CTG CAG GTA CGG AGC GGT GGG CTG GAA GCG G 
PMEPA1 Y126A (PY2) GAC GAG CCC CCA CCC GCC CAG GGC CCC TG CAG GGG CCC TGG GCG GGT GGG GGC TCC TC 
PMEPA1 Y197A (PY2) GGC CGC CGC CCA CCG CCA GCG AGG TCA TCG CGA TGA CCT CGC TGG CGG TGG GCG GCG GCC 
PMEPA1 Q99A CGC TTC CAC CGC TTC AAT CCC ACC TAT CCG TAC GTA CGG ATA GGT GGG ATT GAA GCG GTG GAA GCG 
PMEPA1 Q99D CGC TTC CAC CGC TTC GAT CCC ACC TAT CCG TAC GTA CGG ATA GGT GGG ATC GAA GCG GTG GAA GCG 
PMEPA1 Q99A CTT CCA CCG CTT CGC GCC CAC CTA TCC G CGG ATA GGT GGG CGC GAA GCG GTG GAA G 
 
PMEPA1 T101S CGC TTC CAG CCC AGC TAT CCG TAC CTG CAG GTA CGG ATA GCT GGG CTG GAA GCG 
PMEPA1 T101E CAC CGC TTC CAG CCC GAA TAT CCG TAC CTG CAG CTG CAG GTA CGG ATA TTC GGG CTG GAA GCG GTG 
 
PMEPA1 T101A CGC TTC CAG CCC GCG TAT CCG TAC CTG CAG GTA CGG ATA CGC GGG CTG GAA GCG 
 
PMEPA1 T101P CAC CGC TTC CAG CCC CCG TAT CCG TAC CTG CAG CTG CAG GTA CGG ATA CGG GGG CTG GAA GCG GTG 
PMEPA1 Q99P CTT CCA CCG CTT CCC GCC CAC CTA TCC G CGG ATA GGT GGG CGG GAA GCG GTG GAA G 
PMEPA1 F98A CGC TTC CAC CGC GCG CAG CCC ACC TAT C GAT AGG TGG GCT GCG CGC GGT GGA AGC G 
PMEPA1 F98E GCG CTT CCA CCG CGA ACA GCC CAC CTA TC GAT AGG TGG GCT GTT CGC GGT GGA AGC GC 
PMEPA1 P103A CAG CCC ACC TAT GCG TAC CTG CAG C GCT GCA GGT ACG CAT AGG TGG GCT G 
PMEPA1 P103E CTT CCA GCC CAC CTA TGA ATA CCT GCA GCA CGA G CTC GTG CTG CAG GTA TTC ATA GGT GGG CTG GAA G 
AR IŶtroductioŶ of NheI site at 3’ 
end of ORF 
GAC AAG GCC ATG GCT GAT ATC GGA TCC ATG GTG GTG GTG GTG GTG GTG CTC GAG TCA CTG 
PMEPA1 IŶtroductioŶ of SalI site at 5’ 
aŶd BglII site at 3’ eŶd of ORF 
CTA CTC ACT ATA GGG AGA CCG GAA GCT TAT G CAT CTC CCG GGG ATC TCT AGA TTA CGC 
PMEPA1 Introduction of BamHI and SalI 
sites at 5’ aŶd XhoI site at 3’ 
end of ORF 
CGA CTC ACT ATA GGG GAT CCG GGT CGA CAT GGC 
GGA GCT GG 
ATT TTT TTC TCC ATC TCG AGG AGA GGG TGT CC 
AR IŶtroductioŶ of NdeI site aŶd 5’ 
and BaŵHI site at 3’ eŶd of ORF 
GCC AGA GAT CAA CAT ATG AAA AGG CAG TCA GGT GGG TGG GGA AAT AGG GGA TCC AAT GCT TCA CTG 
AR T877A GAG AGC TGC ATC AGT TCG CGT TTG ACC TGC TAA TCA 
AG 
CTT GAT TAG CAG GTC AAA CGC GAA CTG ATG CAG 
CTC TC 
PMEPA1 Removal of first 23 residues 
with iŶsertioŶ of SacI site at 5’ 
aŶd BaŵHI site at 3’ eŶd of ORF 
TGA TGG TGA TGG AGC TCG GAT CCA CGA TGC TGC 
TGA GCC AC 
AGT TAG CCT CCG TCG ACT CCC GGG GAT C 
 
Figure 2.1.  Table of all primers used in PCR for SDM and cloning. Includes the name of the gene to be altered, forward and reverse 
primer sequences and a brief explanation of the residue(s) to be altered. Single letter abbreviations are used for amino acid sequence 
changes. Complete DNA and amino acid sequences of PMEPA1 are included for reference in chapter 1.
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2.1.3.1 Kod Hot Start Master Mix 
 
 The Kod Hot Start Master Mix (Novagen) was provided at 2x concentration, and 25 
µL was used in a reaction mixture containing 1 µL plasmid DNA (approx. 10-20 pg), 2 
µL forward primer & 2 µL reverse primer (both at 10 µM working concentration), with 
sterile distilled water to make up the volume to 50 µL.  
 The Kod PCR conditions were an initial incubation of 2 min at 95 oC, followed by 20-
30 cycles of 1 min at 95 oC, 1 min at 54-55 oC and 20 sec/kb at 70 oC, and a final 
incubation of 5 min at 70 oC. 
 
2.1.3.2 Phusion Hot Start Flex Master Mix 
 
 The Phusion Hot Start Flex Master Mix (New England Biolabs) was also provided at 
2x concentration, and 25 µL was used in a 50 µL volume containing 1 µL plasmid DNA 
(10-20 pg), 2 µL forward primer and 2 µL reverse primer (at 10 µM), with the volume 
made up with sterile distilled water. 
 The Phusion PCR conditions were an initial incubation of 2 min at 98 oC, followed 
by 25-30 cycles of 10 sec at 98 oC, 20 sec at 75-92 oC and 30 sec/kb at 72 oC, and a final 
incubation of 5 min at 72 oC.  The annealing temperature was adjusted for each primer 
pair with reference to the Thermo Scientific melting temperature calculator available at 
http://www.thermoscientificbio.com/webtools/tmc/.  
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2.1.3.3 DNA digestion and cleanup for SDM 
 
 Following the PCR reaction, methylated template DNA was removed by the addition 
of 10 units DpnI (New England Biolabs) per 50 µL reaction, which was then incubated 
overnight at 37 oC. The digested PCR product was cleaned up using a commercial kit 
according to manufacturer’s protocol (Bioneer or Fermentas), by adding 500 µL binding 
buffer (5.5 M guanidine thiocyanate, 20 mM Tris-HCl pH 6.6), 20µL 3 M sodium 
acetate pH 5.2,  and 100 µL isopropanol to the PCR reaction. This mixture was added to 
a DNA binding column in a 2 ml tube and centrifuged for 1 minute at 14,000 rpm, then 
the flow-through was loaded back onto the column and the centrifugation repeated. The 
column was washed by centrifuging for 1 minute at 14,000 rpm with 700 µL of a buffer 
containing 80% v/v ethanol with 20 mM sodium chloride and 2 mM Tris-HCl pH 7.5, 
then dried by removing the flow-through and centrifuging at 14,000 rpm for 2 minutes. 
The DNA was eluted by incubation with 55 µL autoclaved, ultrapure water at room 
temperature for 5 minutes, then centrifuging at 14,000 rpm for 1 minute. 5 µL of the 
eluted PCR product was run on a 1% w/v agarose gel in order to assess the purity and 
yield, before being used in downstream applications. 
 
2.1.3.4 Agarose gel electrophoresis 
 
 An appropriate weight (0.8-2 g) of powdered agarose (Web Scientific) was dissolved 
in 100 ml TAE buffer (40 mM Tris acetate with 1 mM EDTA) and heated in the 
microwave until the agarose was completely dissolved. Once the liquid agarose had 
cooled sufficiently, but not started to set, ethidium bromide (Sigma Aldrich) was added 
to a final concentration of 0.5 µg/ml and the mixture was poured into a Submarine 
horizontal electrophoresis unit (Hoefer) with one or more combs in place to form wells. 
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Once the gel had set, the unit containing the gel was submerged in TAE buffer and the 
comb removed. A 6x DNA loading buffer (New England Biolabs) was added to the 
sample(s) and they were run at 100-120 V for 20-60 min alongside a 2-log 0.1-10 kb size 
comparison ladder (New England Biolabs). Gels were visualised using the Syngene 
G:BOX gel imaging system with GeneSnap software. 
 
2.1.3.5   Gel slice extraction 
 
 A gel slice containing the appropriate DNA fragment was cut out of the agarose using 
a scalpel blade; this was done using a standard UV transilluminator (UVP). The DNA 
was purified from the gel slice using a commercial kit according to manufacturer’s 
protocol (Bioneer/Fermentas) by dissolving the gel slice in an equal volume (400-600 
µL) of DNA binding buffer (5.5 M guanidine thiocyanate, 20 mM Tris-HCl pH 6.6) at 
60 oC, then adding 100 µL isopropanol and 20 µL 3M sodium acetate pH 5.2. This 
mixture was added to a DNA binding column in a 2 ml tube and centrifuged for 1 min at 
14,000 rpm, then the flow-through was loaded back onto the column and the 
centrifugation repeated. The column was washed by centrifuging for 1 min at 14,000 rpm 
with 700 µL of a buffer containing 80% v/v ethanol with 20 mM sodium chloride and 2 
mM Tris-HCl pH 7.5, then dried by removing the flow-through and centrifuging at 
14,000 rpm for 2 min. The DNA was eluted by incubation with 55 µL autoclaved, 
ultrapure water at room temperature for 5 min, then centrifuging at 14,000 rpm for 1 
minute. 
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2.1.4  Restriction digestion and ligation 
 
 Endonuclease enzymes were supplied by New England Biolabs, Promega and Thermo 
Scientific. Digests were performed in a 20 µL volume containing 100-500 ng DNA (5-10 
µL), 2 µL appropriate reaction buffer as supplied by the manufacturer of the enzyme(s) 
at 10x concentration, 2 µL 10 mg/ml bovine serum albumin (BSA), and 5 units each 
enzyme, and the volume was made up with autoclaved distilled water. The reaction 
mixture was incubated at 37 oC for 1-3 hours, and then 4 µL 6x loading buffer (New 
England Biolabs) was added before the mixture was run on an appropriate percentage 
agarose gel as described previously.  
 The digested, cleaned up DNA fragments were ligated using T4 DNA ligase (New 
England Biolabs). The ligation mixture contained varying ratios of vector to insert DNA 
depending on their relative sizes, between 1:2 and 1:30, for a total volume of 10-15 µL 
DNA, as well as 2 µL buffer provided by the manufacturer at 10x concentration, and 400 
units of ligase. The volume was made up to 20 µL with sterile, double-distilled water and 
the reaction was incubated at 16 oC overnight or at 4 oC for 72 h. The ligation mixture 
was transformed directly into chemically competent E. coli as described below. 
 
2.1.5  Bacterial transformation 
 
 Four strains of E. coli were used; Rosetta-Gami 2 (Novagen) and BL21-CodonPlus 
(DEγ) (New England Biolabs), for overexpression of recombinant proteins, DH5α (New 
England Biolabs) and XL1-Blue (Stratagene) for DNA production and cloning. 
To make chemically competent bacteria for transformation, we used a modified 
version of the standard protocol published by Inoue et al (1990). Individual colonies of 
E. coli were isolated by streaking a liquid culture out onto a plate containing 2XYT broth 
Materials and Methods 
 
Page 72 of 229 
 
(Melford) containing 16 g/L digest peptone, 10 g/L yeast extract and 5 g/L sodium 
chloride with 100 g/L high gel strength agar (Melford) under sterile conditions, and 
incubating overnight at 37 oC. A single colony was grown up in 5 ml liquid 2XYT broth 
overnight at 37 oC on an orbital shaker at 180 rpm, then 1 ml of this culture was 
inoculated into 100 ml 2XYT broth and incubated at 37 oC on an orbital shaker at 180 
rpm for 2 h. The cells were cooled on ice for 15 min, then centrifuged at 4000 rpm for 7 
min at 4 oC. The resulting pellet was resuspended in 50 ml ice cold buffer containing 30 
µM potassium acetate, 50 µM manganese (II) chloride tetrahydrate, 100 µM potassium 
chloride, 10 µM calcium chloride dihydrate and 15% v/v glycerol, incubated on ice for 
15 min then spun again at 7000 rpm for 7 min. Finally the pellet was resuspended again 
in 4 ml ice cold buffer containing 10 µM MOPS, 75 mM calcium chloride dihydrate, 10 
µM potassium chloride and 15% v/v glycerol, aliquotted into 100 µL volumes and flash-
frozen in liquid nitrogen before being stored at -80oC. 
For transformation, a 100 µL aliquot of competent cells was combined gently with 50-
300 ng plasmid DNA, or 10 µL of ligation reaction, and incubated on ice for 30 min. The 
mixture was heat shocked at 42 oC for 45 sec, then incubated on ice for a further 2 min. 
900 µL of 2XYT broth, without any antibiotic selection, was added and the tube was 
incubated at 37 oC for 1 h. The tube was spun in a microcentrifuge for 1 min at 14,000 
rpm, then 900 µL of supernatant was removed and the pellet resuspended in the 
remaining 100 µL. The resuspended cells were streaked or spread over a 2XYT-agar 
plate, with appropriate antibiotic selection under sterile conditions (see figure 2.2), then 
incubated at 37 oC overnight. 
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Name of antibiotic Stock concentration Working concentration 
Chloramphenicol 50mg/ml in ethanol 50µg/ml 
 
Kanamycin 50mg/ml in distilled water 
 
50µg/ml 
Ampicillin 100mg/ml in distilled water 
 
200µg/ml 
 
 
Figure 2.2. Antibiotics used to maintain selection in E. coli.. The stock concentrations 
as well as the solvent used are given; these stocks were aliquotted and frozen at -20oC. 
The working concentrations are the final concentrations of the stocks diluted in 2XYT 
media, with or without agar. Kanamycin was obtained from Melford which ampicillin 
and chloramphenicol were obtained from Sigma Aldrich. 
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2.1.6  Plasmid DNA preparation 
 
 Small-scale plasmid DNA extraction (“Minipreps”) was either performed using a 
commercial kit or using a variation of the alkaline lysis method (Birnboim & Doly, 
1979). DNA concentration was determined using a Nanovue (GE Healthcare) 
microspectrophotometer. Typical yield was 100 ng/µL for the column-based method and 
2000 ng/µL for the alkaline lysis protocol. 
 
2.1.6.1 Small (mini) scale extraction via kit 
 
One of two commercial columns based kits (Bioneer/Thermo Scientific) was used; the 
names of the buffers varied but the protocol for both was the same. The buffers for each 
are given in figure 2.3 but are referred to here as 1, 2, 3 and 4. 3 ml of an overnight 
bacterial culture transformed with the plasmid of interest was centrifuged at 14,000 rpm 
for 1 min and the pellet resuspended in 250 µL of buffer 1. Then 250 µL buffer 2 was 
added, followed by 350 µL of buffer 3 and gently mixed by inversion. The tube was then 
centrifuged at 14,000 rpm for 10 min, and the supernatant was added to a DNA-binding 
column and centrifuged for 1 min at 14,000 rpm. The flow-through was discarded, 700 
µL buffer 4 was added to the column and centrifuged for 1 min at 14,000 rpm, then the 
flow-through was discarded and the column was dried by centrifugation at 14,000 rpm 
for 2 min. The DNA was eluted by placing the column into a clean tube and incubating 
with 55 µL sterile distilled water for 5 min at room temperature, followed by 
centrifuging at 14,000 rpm for 1 min. 
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Figure 2.3. Names of buffers in commercial kits used for plasmid minipreps. The first 
column indicates how each buffer is designated in the text, which the specific 
manufacturer names for each solution are given in the second and third columns. The 
formulae for all buffers are equivalent in both kits. 
 
 
 
 
 
 
 
 
 
  
Notation in text Bioneer Accuprep notation Thermo Scientific GeneJET notation 
1 1 Resuspension Solution 
2 2 Lysis Solution 
3 3 Neutralisation Solution 
4 4 Wash Solution 
Materials and Methods 
 
Page 76 of 229 
 
2.1.6.2 Alkaline lysis 
 
3 ml of overnight bacterial culture transformed with the plasmid of interest was 
centrifuged at 14,000 rpm for 1 min. The supernatant was discarded and the pellet 
resuspended in 150 µL resuspension buffer (50 mM Tris-HCl, 10 mM EDTA and 100 
µg/ml RNAse A, at pH 8). Then 250 µL lysis buffer (200 mM sodium hydroxide and 1% 
w/v SDS) was added to the mixture, followed by 350 µL neutralisation buffer (3M 
potassium acetate pH 5.5). The tube was gently inverted to mix and centrifuged at 14,000 
rpm for 10 min. The supernatant was transferred to a clean tube, then 400 µL 
phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma Aldrich) was added, and centrifuged 
for 3 min at 14,000 rpm. The top aqueous layer, containing the DNA, was removed and 
transferred to a clean tube. 880 µL ethanol and 40 µL 3 M sodium acetate (pH 5.2) was 
added and the mixture was incubated on ice for 30 min to precipitate the DNA, which 
was pelleted by centrifugation at 14,000 rpm for 15 min. The pellet was resuspended in 
200 µL 70 % v/v ethanol, then the tube was spun again for 2 min at 14,000 rpm, the 
ethanol was removed and the pellet was allowed to air dry at 37 oC for 5 minutes. Finally 
the DNA pellet was resuspended in 55 µL sterile double-distilled water.  
 
2.1.6.3 Larger (midi) scale extraction via kit 
 
 For larger scale production of plasmid DNA, a peqGOLD XChange midi-prep kit 
(PEQlab) was used, providing a typical total yield of 100-400 µg DNA. This method is 
based on a technique described by Prazeres et al (1998). 100 ml of overnight bacterial 
culture transformed with the plasmid of interest was pelleted by centrifugation at 4000 
rpm for 20 min. The pellet was resuspended in 8 ml of Buffer I, then 8 ml of Buffer II 
was added, followed by 8 ml Buffer III. The resulting mixture was incubated on ice for 5 
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min before being cleared by centrifugation at 10,000 rpm for 25 min at 4 oC, and 
additionally filtered through a wad of Miracloth (Millipore) before being added onto the 
column (which was pre-equilibrated with 2.5 ml EQ buffer) and allowed to drip through 
completely by gravity flow. The column was then washed using 12 ml DNA Wash 
Buffer and the DNA eluted using 5 ml Elution Buffer by gravity flow. Excess salt was 
removed by precipitating the DNA in 3.5 ml room temperature isopropanol and 
centrifuging at 13,500 rpm for 30 min at 4 oC. The resultant DNA pellet was resuspended 
in 2 ml 70% v/v ethanol and spun again at 20-25 oC for 10 min. The supernatant was 
carefully removed and any remaining ethanol allowed to evaporate by air drying at room 
temperature for 5-10 min. Finally the pellet was redissolved in 100 µL sterile distilled 
water. 
 
2.2  Recombinant protein production 
 
2.2.1  Small scale 
 
500 µL of a 5 ml bacterial culture, grown overnight and expressing the construct of 
interest, was seeded into 11 ml 2XYT broth with appropriate antibiotic selection 
(chloramphenicol to select for the codon plus plasmid, as well as ampicillin or 
kanamycin to select for the transfected plasmid) and grown at 37 oC on an orbital shaker 
at 180 rpm for 2 h. 1.5 ml was harvested, centrifuged at 14,000 rpm for 1 min and the 
pellet resuspended in 1 ml SDS sample buffer (4% w/v SDS, 20% v/v glycerol, 5% v/v 
-mercaptoethanol and 0.05% w/v bromophenol blue) as a pre-induction sample. Protein 
expression was induced in the remaining 10 ml using 1 mM IPTG (Melford). The 
induced bacteria were grown for an additional 4 h at 30 oC, then another 1.5 ml was 
harvested as an induced sample. The induced sample was sonicated using a Sonics 
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Vibra-Cell VCX130 at 80% amplitude for 90 sec (30 sec on, 30 sec off) to break the cell 
membranes, and the debris pelleted by centrifugation at 14,000 rpm for 10 min. The 
supernatant was removed and had an equal volume of SDS sample buffer added to it; this 
was the soluble fraction. The pellet was resuspended in 1 ml SDS sample buffer as the 
insoluble fraction. The samples were run out on an appropriate percentage SDS-PAGE 
gel and stained with Coomassie as described in 2.3.1.  
 
2.2.2  Large scale 
 
5 ml bacterial culture, grown overnight and expressing the construct of interest, was 
seeded into 1 L 2XYT broth with appropriate antibiotics and incubated for 4-5 h at 37 oC 
with shaking at 180 rpm. Protein expression was induced with 1 mM IPTG, following 
which the cultures were incubated overnight with shaking at 16 oC. The cells were 
harvested by centrifugation at 6,000 rpm for 5 min and resuspended in 50 ml lysis buffer, 
the composition of which varied according to the affinity tag on the protein as described 
below. The resuspended cells were lysed by homogenisation using an EmulsiFlex-C2 
(Avestin) at 15,000 kPa, and the cell debris pelleted by centrifugation at 20,000 rpm for 
10 min. The pellet was discarded and an appropriate binding resin was added to the 
cleared lysate.  
For 6xHis-tagged proteins the lysis buffer contained 50 mM sodium dihydrogen 
phosphate, 300 mM sodium chloride, 10 mM imidazole, 1 mM PMSF and protease 
inhibitor cocktail (Roche) at pH 8.0. For 1 L of bacterial culture, 400 µL HisSelect nickel 
affinity gel (Sigma Aldrich) was used; this was centrifuged at 14,000 rpm for 30 sec, the 
storage buffer removed and the resin resuspended in 400 µL His lysis buffer. The 
centrifugation was repeated, the supernatant was discarded and the pellet resuspended 
again in 400 µL His lysis buffer; this washed resin was added directly to the 50 ml 
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cleared lysate, and incubated at 4 oC for 1-2 h with rotation. The bound resin was washed 
using 2 column volumes of a His wash buffer (50 mM sodium dihydrogen phosphate, 
300 mM sodium chloride and 20 mM imidazole at pH 8.0), and the protein was eluted in 
a total volume of 2.5 ml His elution buffer, added in 0.5 ml aliquots, containing 50 mM 
sodium dihydrogen phosphate,  300 mM sodium chloride and 500 mM imidazole, also at 
pH 8.0.  
For GST-tagged proteins, Super-Glu glutathione fast flow resin (Generon) was used, 
with 800 µL resin slurry, washed in the same way as the HisSelect resin, but using GST 
wash buffer (50 mM Tris base and 150 mM sodium chloride at pH 7.4). The resin was 
added to 50 ml cleared lysate, and incubated at room temperature for 1-2 h with rotation. 
The GST lysis buffer contained 50 mM Tris base, 150 mM sodium chloride, 5 mM DTT, 
1 mM PMSF and protease inhibitors at pH 7.4. The bound resin was washed using 2 
column volumes of GST wash buffer and the protein was eluted by capping the column 
and adding 0.5 ml elution buffer (50 mM Tris and 10 mM reduced glutathione at pH 8.0) 
incubating for 5 min at room temperature then allowing the eluant to drip through, and 
repeating 5 times to give a total volume of 2.5 ml. For Nedd4, adding 1% Triton X-100 
(Sigma Aldrich) to the GST lysis buffer and increasing the DTT concentration to 5 mM 
improved stability and yield. 
 
2.2.3  Buffer exchange and FPLC 
 
 Purified proteins were desalted using PD10 columns (GE Healthcare), by 
equilibrating with 25 ml storage buffer containing 50 mM Tris pH 8.0 with 10% 
glycerol, adding 2.5 ml of protein solution and eluting with 3.5 ml storage buffer. If 
necessary, the resulting protein solution was concentrated using Generon Vivaspin 
concentrating spin columns with an appropriate molecular weight cut off (100 kDa for 
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Nedd4 [~120kDa], 30 kDa for PMEPA1 [~36kDa]). ÄKTA FPLC (detector model UPC-
900, pump model P-920) was used with a Superdex 200 10/300 GL column (GE 
Healthcare). The column was equilibrated using a buffer containing 20 mM phosphate 
pH 7.4 and 10% v/v glycerol. The sample was run at a flow rate of 0.5 ml/min, and 
eluted into 0.5 ml fractions. 20 µL of each fraction containing protein was run out on an 
SDS-PAGE gel and stained with Coomassie to confirm the size (see 2.3.1); fractions 
containing the correct protein were combined into a single sample and concentrated 
again if necessary. 
 
2.3 Protein analysis 
 
2.3.1  Protein separation and visualisation 
 
2.3.1.1  Polyacrylamide gel electrophoresis (PAGE) 
 
 For most applications, we used denaturing SDS-PAGE for separation of proteins 
based on the Laemmli method (Laemmli, 1970). This involved the use of the 
OmniPAGE mini vertical electrophoresis system (Cleaver Scientific) to pour and run 
10x10cm gels. A solution of 40% acrylamide:bisacrylamide 37.5:1 (Melford) was diluted 
to the appropriate percentage based on the size of the protein to be resolved. The 
acrylamide was mixed with 5 ml buffer containing 0.75 M Tris base and 7 mM SDS at 
pH 8.8, 100 µL 10% w/v AMPS (Sigma Aldrich) in distilled water and 5 µL undiluted 
TEMED (Melford), with the volume made up to 10 ml with distilled water. This mixture 
was pipetted between 2 glass plates and allowed to polymerise at room temperature for 
10-30 minutes. A 5 % acrylamide stacking gel was mixed by adding 625 µL 40 % 
acrylamide:bisacrylamide 37.5:1 to 2.5 ml buffer containing 0.25 M Tris base and 7 mM 
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SDS at pH 6.8, along with 50 µL 10 % w/v AMPS and 5 µL undiluted TEMED, with the 
volume made up to 5 ml with distilled water. This stacker was pipetted on top of the 
resolving gel around a plastic comb to form 8-12 wells and allowed to polymerise at 
room temperature for 10 min. 
 Once the gel was prepared, the samples were added to an equal volume of SDS 
sample buffer, and heated at 95 oC for 10 min in a hot block. The electrophoresis tank 
was filled with running buffer containing 25 mM Tris base, 200 mM glycine and 3.5 mM 
SDS, and 20-50 µL of the samples were loaded. A marker containing pre-stained 
proteins of known sizes from 10-230 kDa (New England Biolabs) was loaded alongside 
the samples for reference. The gel was run at a constant voltage (180-220 V) for 
approximately 1 h, until the dye front ran almost to the bottom of the gel.  
 For native PAGE, the resolving gel consisted of an appropriate volume of 
acrylamide:bisacrylamide 37.5:1 in a final concentration of 0.375 M Tris-HCl pH 8.8, 
0.05 % w/v AMPS and 0.05 % v/v TEMED, with the volume made up to 10 ml with 
distilled water. The stacking gel consisted of 3 % acrylamide:bisacrylamide 37.5:1 in 
0.125 M Tris-HCl pH 6.8 with 0.1 % w/v AMPS and 0.1 % v/v TEMED, and the volume 
made up to 4 ml with distilled water. The gel was poured and the wells formed in the 
way described above, but the sample was added to an equal volume of sample buffer 
containing 100 mM Tris pH 6.8, β0 % v/v glycerol, 5 % v/v ȕ-mercaptoethanol and 0.05 
% bromophenol blue, and was heated at 37 oC for 30 min. The samples were loaded in 
the same way as a denaturing gel, with the same marker, but the running buffer used 
consisted only of 25 mM Tris base and 200 mM glycine, and the gel was run at a much 
lower voltage (100 V) for longer, up to 2 h, to avoid overheating. 
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2.3.1.2  Coomassie Brilliant Blue staining 
 
Gels were stained using a solution of 25 % v/v isopropanol, 10 % v/v glacial acetic 
acid, and 0.05 % Coomassie Brilliant Blue R-250, according to Meyer & Lambert 
(1965), for about 30 min with gentle shaking, then the nonspecific polyacrylamide 
staining was removed by gentle shaking in 30 % methanol and 10 % glacial acetic acid 
for 1-12 h, adding fresh destaining solution 2-3 times.  
 
2.3.2  Western blotting 
 
Proteins were transferred from a polyacrylamide gel using a 200x200 mm semi-dry 
blotting system (Jencons) onto a 7.5x8 cm piece of low background fluorescence 
Immobilon PVDF membrane (Millipore), which was soaked in methanol to activate it 
and then washed for 5 min in transfer buffer (50 mM Tris base, 380 mM glycine, 20 % 
v/v methanol, 0.1 % w/v SDS) before being stacked in a ‘sandwich’ with the gel on top 
(i.e. closer to the cathode) and three 8x8 cm pieces of 0.8 mm blotting paper (Whatman) 
soaked in transfer buffer on top and underneath to stop the membrane drying out. The 
blotting apparatus was secured and the transfer was run at a constant current of 400 mA 
for 1-2 h, depending on the size of the protein of interest. 
Once the transfer was complete the membrane was blocked using a solution of 5 % 
w/v skimmed milk powder in TBS for one hour at room temperature with gentle shaking, 
then the membrane was transferred to a 1.5 % w/v solution of milk in TBS containing the 
primary antibody at an appropriate concentration, and incubated overnight at 4 oC with 
gentle shaking (a complete list of all primary antibodies used during this project is shown 
in figure 2.4). After washing 3 times for 1 min with TBS, the membrane was then 
incubated with gentle shaking in a 1.5% w/v solution of milk in TBS containing an  
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Epitope recognition 
sequence 
Clonality Supplier Working 
dilution 
α S-tag 
(KETAAAKFERQHMDS) 
Monoclonal Novagen 1:5000 
α GST Polyclonal Sigma Aldrich 1:1000 
α Nedd4 (WW2 domain) Polyclonal Abcam 1:2000 
α GFP Monoclonal Roche 1:2000 
α AR (441) Monoclonal Santa Cruz 1:200 
α Actin Polyclonal UCL 1:3000 
α Tubulin Polyclonal Abcam 1:1000 
α GAPDH Monoclonal UCL 1:5000 
α HA Monoclonal Thermo Scientific 1:5000 
α FLAG clone M2 Monoclonal Sigma Aldrich 1:1000 
α Myc clone 9E10 Monoclonal Sigma Aldrich 1:5000 
α CBP clone C167 Monoclonal Millipore 1:5000 
 
Figure 2.4. Epitope recognition sites, clonality, suppliers and working concentrations 
of all primary antibodies used for detection of proteins via Western blotting. Where 
supplier is given as ‘UCL’, these antibodies were provided by Sergei Novoselov at 
University College, London. 
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appropriate concentration of secondary antibody for 60 min at room temperature. Finally, 
the membrane was washed for at least 30 min in TBS, with 5 changes of buffer. The 
washed blot could then be analysed by one of the two methods described below. 
 
2.3.3 Odyssey detection 
 
For detection of most immunoblotted proteins, we used the Licor Odyssey infrared 
scanning system. A combination of goat anti-rabbit IRDye 680LT (Licor), goat anti-
mouse IRDye 680LT (Licor) and CF680 goat anti-mouse (Biotium) was used to image in 
the 700nm (red) channel, and goat anti-rabbit IRDye 800CW (Licor), goat anti-mouse 
IRDye 800CW (Licor) and CF770 goat anti-mouse (Biotium) to image in the 800nm 
(green) channel. The Licor 680LT dyes were used at a 1:20000 dilution, while the Licor 
800CW dyes were used at a 1:3000 dilution and the Biotium CF dyes were used at a 
1:30000 dilution. The Licor software accompanying the Odyssey scanner was used to 
image the blots at 89 µm resolution and obtain relative quantification data by using the 
integrated intensity calculation function. Adobe Photoshop C4 was used for limited 
image manipulation such as brightness adjustments. 
 
2.3.4  Enhanced chemiluminescence (ECL) detection 
 
 After incubation with an appropriate primary antibody, the blot to be imaged was 
incubated in an HRP-conjugated secondary antibody raised in goat, either anti-mouse or 
anti-rabbit (Sigma Aldrich), at a concentration of 1:10000 in a 1.25% w/v solution of 
skimmed milk in TBS for 1 h. Alternatively, proteins fused to the TAP tag were detected 
using a single step by incubating in peroxidase-anti-peroxidase (Sigma Aldrich) at 
1:10000. After being thoroughly washed in TBS, the blot was incubated in a 1:1 mixture 
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of each of the 2 components of the Immobilon Western HRP substrate (Millipore) for 5 
min, then the excess was drained and the blot placed into a cassette and held in place 
with clear plastic wrap.  
 To image the blot, a piece of 13x18 cm X-ray film (Kodak) was placed over the 
plastic wrap in a dark room, and the cassette was closed and locked to prevent external 
light from entering. After a suitable exposure period, varying from 30 sec to 1 h 
depending on the level of signal, the film was removed and immersed in photographic 
developer and fixer (Champion Photochemistry). 
 
2.4 Mammalian cell culture and transfections 
 
2.4.1 Cell culture 
 
2.4.1.1 Maintenance and passage 
 
 HeLa cervical cancer cells, as described by Scherer et al (1953) were maintained in 
modified Eagle media with Earle’s salts (PAA Laboratories) containing β mM glutamine, 
1 % v/v penicillin-streptomycin and 10 % v/v foetal bovine serum (FBS, PAA). LNCaP 
prostate cancer cells, as described by Horoszewicz et al (1983), (provided by Yong-Jie 
Lu, Barts & the London, School of Medicine & Dentistry) were maintained in the same 
media with the addition of 1 % v/v supplementary non-essential amino acids (PAA) 
containing 890 mg/L alanine, 1500 mg/L asparagine, 1330 mg/L aspartic acid, 1470 
mg/L glutamic acid, 750 mg/L glycine, 1150 mg/L proline and 1050 mg/L serine. Both 
cell lines were maintained at 37 oC and a 5 % CO2 atmosphere, in 25 cm2 and 75 cm2 
flasks with plasma treated surfaces to optimise adherence and caps containing a 22 µM 
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filter to allow gas exchange (PAA). Sterile conditions were maintained by working in a 
Jencons Microflow biological safety cabinet. 
 Cells were grown to 80-90 % confluency then, to subculture, the media was removed 
and the cells washed with Dulbecco’s PBS (PAA). A sterile solution of 0.05 % trypsin 
and 0.02 % EDTA (PAA) was added to the adhered cells and the flask was incubated at 
37 oC for 5 min to allow the cells to detach from the plasticware. An equal volume of 
media with 10 % FBS (containing protease inhibitors) was then added to deactivate the 
trypsin and a fraction of the trypsinised cells were added to fresh media in a new flask. 
The time between passages depended on the rate of growth of the cells, for example 
HeLa cells divided more quickly and adhered better than LNCaP cells, and how densely 
the cells were seeded into the culture vessel, but was usually 3-4 days. 
 
2.4.1.2 Freezing & thawing cell cultures 
 
 Cells with low passage numbers were routinely frozen to maintain a stock of healthy 
cell lines. The cells were trypsinised as described above, and then pelleted by 
centrifugation at 1000 rpm for 5 min at 4 oC. The pellet was resuspended in complete 
medium containing 10 % v/v DMSO and aliquoted into 1 ml volumes in 2 ml, internal-
thread cryogenic vials. The aliquots were frozen slowly, at a rate of 1 oC/minute, to -80 
oC using a Mr. Frosty freezing container (Nalgene), then transferred to liquid nitrogen for 
long term storage. To reanimate the cells, an aliquot was first warmed quickly to 37 oC, 
then added to a fresh flask containing a large volume (10-20 ml) complete media.  
To maximise the number of healthy cells, particularly of the LNCaP line, surviving 
this practice, plasticware was pre-coated with an autoclaved 0.1 % w/v solution of 
porcine gelatine (Sigma Aldrich) in distilled water and incubated at 37 oC for 60 min. 
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The gelatine was then aspirated and fresh medium added to the flask before the defrosted 
cells were added as described above.  
 
2.4.2  Transfection of mammalian cells 
 
2.4.2.1  FuGene 
 
For the majority of this project, FuGene HD (Promega), a multi-component lipid-
based reagent, was used for mammalian cell transfection. The cells to be transfected 
were seeded into a 10 cm2 dish and grown to 80 % confluency in complete media, then 
washed with Dulbecco’s PBS. 1 ml serum-free growth medium, containing glutamine, 
pen/strep and amino acids as described previously but no FBS, was added to the cells, 
then 6 µL FuGene HD reagent and 2 µg DNA was added and mixed by gentle rocking. 
The mixture was incubated at 37 oC for 4 h, then aspirated off and 2 ml complete 
medium added to the cells. The dish was returned to the incubator and allowed to express 
the protein of interest for 24-72 h; the optimal time of incubation was determined by the 
expression construct and the cell line, with LNCaP cells requiring longer incubation 
times than HeLa. An apparent transfection efficiency of 40-80  % was observed in both 
cell lines using FuGene HD. This was calculated by counting the number of cells 
exhibiting fluorescence in the spectral range expected from the transfected gene of 
interest in a sample of transfected cells compared to a control sample of untransfected 
cells of the same line. 
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2.4.2.2   JetPRIME 
 
 JetPRIME (PolyPlus), a cationic polymer-based reagent, was used alongside FuGene 
HD. The cells were grown to 80 % confluency in a 10 cm2 in complete media and 
washed with PBS as for the FuGene protocol, but instead of using serum-free media, 2 
ml of complete growth media was added to the cells. 2 µg DNA and 4 µL JetPRIME 
reagent were added to 200 µL JetPRIME buffer, mixed and incubated at room 
temperature for 10 min. The mixture was added drop-wise to the cells and incubated for 
4-16 h at 37 oC, and the media was aspirated and replaced with 2 ml fresh complete 
media. The dish was then incubated at 37 oC for 24-72 h, once again with the time 
between transfection and harvesting being dependent on the cell line and protein being 
expressed. An apparent transfection efficiency of 70-90 % was observed in both cell 
lines using JetPRIME. This was calculated by counting the number of cells exhibiting 
fluorescence in the spectral range expected from the transfected gene of interest in a 
sample of transfected cells compared to a control sample of untransfected cells of the 
same line. 
 
2.4.2.3 Calcium chloride 
 
 For applications such as pull-downs, a transfection protocol based on a technique first 
described by Graham & van der Eb (1973) and refined by Wigler et al (1977) and Lewis 
et al (1980) using calcium chloride and HEPES, was used 
Cells to be transfected were trypsinised and seeded into a 35 mm dish, then 
transfected after 4 h. A transfection mixture was prepared containing 400 µL HEPES-
buffered saline (20 mM HEPES, 140 mM sodium chloride, 5 mM D-glucose, 50 mM 
potassium chloride and 0.1 mM disodium hydrogen phosphate heptahydrate, pH 7.1), 8 
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µg plasmid DNA and 16 µL 2.5 M calcium chloride, incubated at room temperature for 
25 min, then added drop-wise to the cells in complete growth media. The dish was 
incubated at 37 oC overnight, then the media aspirated, the cells washed twice with PBS, 
and fresh complete media added. The protein of interest was harvested after a further 12-
24 h. A lower apparent transfection efficiency of approximately 20-40% was observed 
using this transfection method. This was calculated by counting the number of cells 
exhibiting fluorescence in the spectral range expected from the transfected gene of 
interest in a sample of transfected cells compared to a control sample of untransfected 
cells of the same line. 
 
2.4.3     Harvesting mammalian cells for Western blotting 
 
 Two methods were used for harvesting total cell lysates from mammalian cells; TCA 
precipitation as described by Schwert (1973) and detergent lysis method as described by 
described by Li et al (2008). 
 
2.4.3.1 TCA precipitation 
 
The cells were grown in 6-well plate wells and, at a suitable time following 
transfection, the media was aspirated and the cells were washed with PBS. 1 ml of lysis 
buffer (0.β M NaOH with 0.β % ȕ-mercaptoethanol) was added to the cells and the plate 
was incubated on ice for 30 min, then a pipette tip was used to manually scrape any 
remaining cells off the bottom of the well. 160 µL 30 % w/v TCA in distilled water was 
added to the supernatant, then the mixture was incubated on ice for 10 min, and the 
precipitated proteins were pelleted by centrifugation at 14,000 rpm for 10 min. The 
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resulting pellet of protein was resuspended in 20 µL Tris base before 80 µL SDS sample 
buffer was added and the sample was run on SDS-PAGE as described previously. 
 
2.4.3.2   Detergent lysis 
 
 The cells were transfected & grown as described, then the media was aspirated and 
the cells washed with PBS. 100 µL lysis buffer containing 50 mM Tris-HCl pH 8, 1 mM 
EDTA, 1 % v/v Triton X-100, 150 mM sodium chloride and 10 % v/v glycerol, with 0.1 
% v/v protease inhibitor cocktail in DMSO (Sigma Aldrich), was added to the cells and 
the plate was incubated on ice for 30 min. Cell debris and insoluble cell fractions were 
pelleted by centrifugation at 14,000 rpm for 5 min, then the pellet was discarded and 100 
µL SDS sample buffer was added to the supernatant. These samples were then run on 
SDS-PAGE as described, except that they were heated at 37 oC, instead of 95 oC, for 20-
30 min in a heat block. 
 
2.5 Immunoprecipitation 
 
2.5.1   IgG sepharose 
 
 Cells were transfected and grown as described previously in 6-well plate wells; 
usually 3-5 wells of transfected cells, in addition to an equal number of untransfected 
cells as a control. 2.5 mM NEM was added to the growth medium and incubated at room 
temperature for 30 min, then the media was aspirated and the cells washed twice with 
4mM NEM in PBS (NEM-PBS). The cells were trypsinised as described previously, but 
without the addition of media to inactivate the trypsin. Instead, the detached cells were 
placed into a Falcon tube and the cells washed with an equal volume of NEM-PBS, then 
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this was aspirated and added to the same tube. The cells were pelleted by centrifugation 
at 1,000 rpm for 5 min at 4 oC, then washed with NEM-PBS and spun again. 1 ml IP 
buffer (50 mM Tris-HCl pH 8, 250 mM sodium chloride, 2 % v/v Triton X-100, 20 % 
v/v glycerol, 3 mM magnesium chloride
 
and 0.1 %  protease inhibitor cocktail in DMSO 
[Sigma Aldrich]) was added to the pellet and incubated on ice for 10 minutes, then the 
pellet was resuspended and sonicated at 20 % amplitude for 30 sec (10 sec on, 30 sec). 
Cell debris was pelleted at 14,000 rpm for 1 min, then the pellet was discarded and 50 µL 
supernatant placed aside, with 50 µL SDS sample buffer added, as the “Input” i.e. pre-
pulldown sample.  
 0.5 ml of IgG Sepharose 6 Fast Flow (GE Healthcare) resin was washed by 
centrifuging at 1000 rpm for 1 min, removing the supernatant, resuspending the pellet in 
1 ml 100 mM glycine pH 3 and centrifuging again. The pellet was resuspended in 1 ml 
IP buffer, and centrifuged again. This was repeated with 1 more wash in glycine pH 3, 
then 2 more washes in IP buffer, before the washed pellet was resuspended in 800 µL IP 
buffer. 50 µL of this washed resin was added to the remaining lysate and incubated with 
rotation at 4 oC for 16 h. The bound resin was pelleted by centrifugation at 1000 rpm for 
1 min and the supernatant was removed without disturbing the pellet. The bound resin 
was washed 5 times by resuspending in 1 ml IP buffer, resuspending, then pelleting at 
1000 rpm for 1 min and removing the supernatant. After the last wash, 50 µL glycine pH 
3 was added to elute the bound protein; the pellet was resuspended in the glycine 
solution and incubated for 2 min at room temperature, then the tube was centrifuged at 
5000 rpm for 1 min, the supernatant was retained and the elution was repeated on the 
pellet 4 times, giving 200 µL total eluate volume.  
A 10 µL aliquot of the eluate was set aside for analysis and 19 µL 20 % w/v sodium 
deoxycholate (Melford) was added to the remaining 190 µL of sample followed by 209 
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µL 30 % w/v TCA. This mixture was incubated on ice for 30 min then centrifuged for 15 
min at 14,000 rpm. The supernatant was discarded and the pellet neutralised by the 
addition of 20 µL 1 M Tris base, followed by 30 µL SDS sample buffer to produce the 
final pull-down sample. Both the input and pull down samples were run on an 
appropriate percentage SDS-PAGE gel and a Western blot performed as described 
previously. 
 
2.5.2  Protein A sepharose 
 
 Protein A coupled to sepharose resin (Amersham Biosciences) was used to bind an 
appropriate primary antibody to interact with a tagged protein expressed in mammalian 
systems. 
 The first part of the process is as described in 2.5.1; the cells were washed in PBS-
NEM and trypsinised, then pelleted, washed and pelleted again. The pellet was 
resuspended in 1.05 ml A-IP buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 
mM EGTA, 1 % sodium deoxycholate and 1 % Triton X-100) and incubated on ice for 
10 min, then lysed by sonication and centrifuged to remove cell debris. 50 µL of the 
supernatant was set aside with 50 µL SDS sample buffer as the input sample, and the 
remaining 1 ml was split into two 500 µL aliquots (referred to here as A and B). Primary 
antibody was added into tube A only at an appropriate dilution, and both tubes were 
incubated at 4 oC with rotation for 16 h. The protein A resin was reconstituted in TBS at 
a concentration of 1 mg/ml and 50 µL was added to each tube A and B, then both tubes 
were incubated at 4 °C with rotation for a further 4-12 h.  
The bound beads were pelleted by centrifugation at 1000 rpm for 1 min and the 
supernatant removed. 1 ml cold A-IP buffer was added to each tube and the pellets were 
resuspended then centrifuged again. This process was repeated for a total of 4 washes in 
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A-IP buffer, then the washed pellets were each resuspended in 50 µL 100 mM glycine at 
pH 3.0 and incubated for 2 min at room temperature. The tubes were centrifuged at 5000 
rpm for 1 min and the supernatant transferred to clean tubes (also designated A & B 
here); this process was repeated 3 times to yield a total volume of 200 µL from each 
sample. 20 µL 20 % w/v sodium deoxycholate and 220 µL TCA was added to each tube 
and incubated on ice for 30 min. The tubes were centrifuged for 15 min at 14,000 rpm, 
the supernatant was discarded and the pellets were resuspended in 20 µL 1 M Tris base 
and 30 µL SDS sample buffer to give the eluted samples; tube B is a control, with only 
the protein A and no primary antibody present, while tube A is the experimental sample.  
 
2.5.3   HisSelect resin 
 
 Transfected cells were incubated in media containing 4 mM NEM for 30 min then 
washed with PBS. One well of a 6-well plate was harvested using TCA precipitation as 
described in 2.4.5 and set aside as the input sample. Each of the pull-down samples 
consisted of 3 wells of a 6-well plate; the cells from all 3 wells were lysed by the 
addition of a total of 5 ml denaturing lysis buffer (DLB) containing 6 M guanidine 
hydrochloride (Melford), 100 mM monosodium phosphate, 10 mM Tris, 1 % v/v Triton 
X-100 and 4 mM NEM at pH 8.0. The lysate was centrifuged at 4,000 rpm for 15 min at 
4 oC and 100 µL HisSelect resin (Sigma Aldrich), washed twice and resuspended in 
DLB, was added to the cleared lysate and incubated at room temperature with rotation 
for 2-4 h.  
 The bound resin was pelleted by centrifugation at 1,000 rpm for 1 min and the buffer 
removed. The pellet was washed in 1 ml DLB twice, then once in a 50:50 mixture of 
DLB and His wash buffer, then twice more in the wash buffer alone. After the final 
wash, the sample was centrifuged at 4,000 rpm and the supernatant removed. 100 µL 
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SDS sample buffer was added directly to the resin and heated at 95 oC for 10 min to elute 
the protein and form the pull-down sample.  
 
2.6  Recombinant protein analyses 
 
2.6.1 In vitro assays 
 
2.6.1.1 Ubiquitination assays 
 
The purified proteins to be assayed were first run out on a Western blot with Odyssey 
detection as described above, and the relative protein levels calculated using Odyssey 
intensity values. The loading volumes were equalised accordingly. Based on the relative 
loading volumes, an appropriate volume of each protein was then added to a mixture 
containing (final concentrations) 5 mM Tris pH 7.4, 0.01 M magnesium chloride, 0.01 M 
ATP, along with 100 ng recombinant human Uba1 (Boston Biochem), 100 ng 
recombinant yeast Ubc1 (cloned & produced in house) and 1 µg methylated human 
ubiquitin (Boston Biochem). 100-500 µg recombinant human Nedd4 or yeast Rsp5 was 
added to initiate the reaction and samples were incubated at 30 oC for 45 min. For 
autoubiquitination assays where the E3 enzyme is also the substrate, a negative control 
consisting of all the above with no ubiquitin was incubated and run alongside. For 
ubiquitination assays where the activity of the E3 on a substrate was being assessed, the 
negative control instead lacked the E3. The reaction was stopped by heating to 95 oC 
with an equal volume of SDS sample buffer and the samples were analysed by running 
on an appropriate percentage SDS-PAGE gel and Western blotting.  
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2.6.1.2 SUMOylation assays 
 
 As with the ubiquitination assays, the E3 proteins to be assayed were approximately 
equalised by running them out on an SDS-PAGE gel and performing a Western blot with 
Odyssey detection to assess the relative protein levels. An appropriate relative volume 
based on these results was used in the assays. The E3, acting as both ligase and substrate, 
was added to a reaction volume containing (final concentrations) 0.05 M Tris pH 7.4, 
0.01 M magnesium chloride
 
and 0.01 M ATP, along with 150 ng E1 conjugating 
complex (Uba2/Aos1, cloned & produced in house), 150 ng E2 activating enzyme Ubc9 
(cloned and produced by Dr. Jim Sullivan) and 1 µg Smt3 (cloned and produced by Dr. 
Jim Sullivan). The reaction volume was made up to 30 µL with ddH2O and the E3 added 
last to initiate the reaction. The mixture was incubated at 30 oC for 2 h then stopped by 
the addition of an equal volume of SDS sample buffer, then run on a 7.5 % SDS-PAGE 
gel alongside a negative control containing the reaction mixture with no SUMO present, 
followed by a Western blot as described previously. 
 
2.6.2  Microscale thermophoresis 
 
 Recombinant proteins to be assayed were produced and run through FPLC as 
described previously. C-terminal GST-tagged full length Nedd4 was concentrated to 80 
µM (using spin columns as described in section 2.2.3) and 16 serial dilutions were 
prepared, ranging from 80 µM to 2 nm. Each of the N-terminal 6xHis-tagged ∆NT 
PMEPA1 constructs used was either concentrated or diluted with a buffer containing 
20mM phosphate as 10% v/v glycerol to 5-20 µM, then mixed with an equal volume of 
30 µM NT-red dye (Nanotemper Technologies) and incubated on ice for half an hour. 
The labelled protein was then passed through a desalting column and eluted with 600 µL 
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phosphate buffer, and 10 µL was added to an equal volume of each Nedd4 dilution, 
resulting in a total 20 µL reaction volume. The mixture was allowed to incubate at room 
temperature for 10-15 minutes, and then each reaction was taken up into a glass capillary 
and loaded into a Monolith NT.115 (Nanotemper Technologies) for analysis by Dr. 
James Wilkinson of Nanotemper Technologies. By titrating Nedd4 and PMEPA1 
solutions of known concentration, it is possible to estimate the binding affinity (KD) by 
plotting the change in fluorescence of the labelled PMEPA1 (when exposed to the high 
temperature of the laser beam) against the concentration of Nedd4. This produces a 
sigmoid curve which can be fitted against the equilibrium solution given by the Law of 
Mass Action, given that the magnitude of the ‘reaction’ produced by the interaction of 
the two proteins, and the concentrations are already known and leaving the affinity 
constant KD as the calculated unknown. 
 
2.7 Cell imaging 
 
2.7.1   Fixing and mounting 
 
 Cells were seeded into 6-well plate wells each containing a single, circular 16 mm 
diameter, 1 mm sterile coverslip (Scientific Laboratory Supplies), grown and transfected 
as described in section 2.4. After 24-48 h, growth media was removed and the cells were 
washed with PBS. The cells were fixed on the coverslip by immersion in 4 % w/v PFA 
(Sigma Aldrich) in PBS at pH 7.0 for 15 minutes, then washed three times in PBS. The 
fixed, washed cells on the coverslip were mounted on a microscope slide using 3 µL 
Fluoromount-G (Southern Biotechnology Associates) and sealed with nail varnish, then 
stored at 4 oC in a low light environment, if necessary, until imaging. 
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2.7.2  Immunostaining 
 
 Cells were fixed following transfection in 4 % PFA as described above, then washed 
three times in PBS containing 100 mM glycine (Melford) and permeabilized by 
immersion in PBS containing 0.1 % v/v Triton X-100 for 4 min. Nonspecific protein 
binding sites were blocked by immersion in PBS containing 1 % v/v FBS for 1 h at room 
temperature and the cells were incubated in an primary antibody diluted in the blocking 
buffer for 16 h at room temperature, or for 48 h at 4 oC. 
 The primary antibody was removed with three 5-min washes with PBS and the cells 
incubated in an appropriate dilution of Alexa Fluor (Life Technologies) secondary 
antibody, conjugated to either a green-fluorescent or red-fluorescent dye, in the blocking 
buffer for 1 hour at room temperature. The fixed cells were washed five times for 10 
min, then mounted and sealed on microscope slides as described previously. 
 
2.7.3 Confocal microscopy 
 
 We used confocal microscopy to directly visualise fluorescent-tagged proteins, cloned 
as described in 2.1, as well as untagged, endogenous proteins detected via 
immunofluorescence as described previously. For brevity, the notation ‘green channel’ is 
used to refer to both green-fluorescent-protein-tagged transfected proteins and to 
endogenous proteins detected using Alexa Fluor 488-congugated secondary antibodies. 
The notation ‘red channel’ is used to refer to both mCherry-tagged transfected proteins 
and to endogenous proteins detected using Alexa Fluor 594-conjugated secondary 
antibodies. 
 Confocal images were captured and processed using a Leica TCS SP5 type DMI6000 
microscope with Leica LAS AF software. The pinhole was set to 95 µm diameter and the 
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objective used was a 63x oil immersion lens with Immersol microscopy immersion oil 
(Zeiss). Green channel fluorophores were excited, using an argon laser at 25% power, at 
488 nm and emission was collected across the region 500-570 nm. Red channel 
fluorophores were excited at 633 nm using a HeNe laser and emission was collected 
across the region 660-750 nm.  For fluorescence resonance electron transfer (FRET) 
analysis, green channel fluorophores were excited using an argon laser at 25% power, at 
488 nm and emission was collected across the region 660-750 nm. Non-overlap of the 
green and red emission spectra was confirmed by calibrating the spectral range with 
single-channel images before gathering FRET data. 
 Captured images were taken in 2048x2048 pixel format at 200 Hz, and subjected to 
two line averages and two frame averages.  These images were saved in .TIFF format 
and subsequently adjusted using Adobe Photoshop CS4 to convert to monochrome as 
necessary and ensure that images were directly comparable. 
 
2.8 Statistical & in silico analysis 
 
2.8.1 Relative ubiquitination 
 
The ubiquitination assay results were quantified by assessing the relative intensity of 
the bands corresponding to the unmodified protein compared to those corresponding to 
the ubiquitinated products. The combined value of the modified and unmodified protein 
was taken to represent the total protein in that assay, and the value of the ubiquitinated 
products was calculated as a percentage of the total protein in each column to give values 
for percentage ubiquitination. For each PMEPA1 assay, these values were then adjusted 
so that the wild type construct was always given an arbitrary value of 1.0, and the degree 
of modification of the mutant constructs were represented as a proportion of that value. 
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These adjusted values were used to find the mean and standard deviation of the data. The 
statistical significance was calculated using a 2-tailed t-test, assuming unequal variance, 
on all repeats of the assays.  
 
2.8.2 Localization of cellular proteins 
 
 The localisation of GFP-AR in HeLa and LNCaP cells was visualised using confocal 
microscopy and categorised as cytoplasmic, nuclear or a combination of the two. The 
number of cells showing each localisation distribution was counted in three treatments; 
expressing wild type AR with no hormonal treatment, expressing wild type AR 
following treatment for 24 h with 10 µM DHT, and expressing AR with the CaP 
mutation (T877A). Cell counts for each treatment were repeated a minimum of 5 times. 
To determine whether observed differences between treatments were statistically 
significant, several statistical analyses were carried out using the statistical computing 
programme R (Strubig et al, 2012). For each cell line (HeLa and LNCaP), an analysis of 
variance (ANOVA) was carried out on the variance of the experiments to see if any 
differences in cellular localisation between treatments were significant. An F-test 
compared the variance within treatments to variance between treatments and returned a 
calculated F value, which was compared to a table of critical values to determine 
whether the difference between treatments was significant (P<0.05). Tukey’s post-hoc 
test was applied to the means of the cell numbers in each experiment to compare 
treatments pairwise, generating a q value which was compared to a table of critical 
values to determine whether differences are statistically significant (P<0.05).  
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2.8.3  In silico prediction of PMEPA1 localisations 
  
Protein localisation was predicted using five online programs; the University of 
Queensland’s PProwler (http://bioinf.scmb.uq.edu.au/pprowler_webapp_1-2/), National 
Chaio Tung University’s CELLO (http://cello.life.nctu.edu.tw/), University of 
Tübingen’s MultiLoc (http://abi.inf.uni-tuebingen.de/Services/MultiLoc/), Technical 
Univeristy of Denmark’s TargetP (http://www.cbs.dtu.dk/services/TargetP/) and Japan’s 
National Institute of Advanced Industrial Science & Technology’s WoLF PSORT 
(http://wolfpsort.org/). Full length wild type PMEPA1, a truncated form with the N-
terminal βγ amino acids absent (∆NT) and a full length form with all three PY motifs 
mutated at the tyrosine residues (Y10βA/Y1β6A/Y197A; ∆PY) were all run through the 
prediction software with and without a GFP tag at the C-terminus (full sequences 
available for reference in the appendices). 
 
2.8.4  In silico production of 3D molecular images 
 
 3D images were produced using Polyview-3D 
(http://polyview.cchmc.org/polyview3d.html) with source information from entries 
included in the RCSB Protein Data Bank (http://www.rscb.org). Image orientation was 
set using the Jmol application for Windows (http://jmol.sourceforge.net/) and images 
were resized & made equivalent using Adobe Photoshop CS4.  
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3. RESULTS 
 
 
3.1 Investigating the interaction between Nedd4 and PMEPA1 in vitro 
 
3.1.1 Introduction 
 
3.1.1.1 WW domains and PY motifs 
 
 The tryptophan-containing substrate recognition (WW) domains of Nedd4 and related 
proteins have long been reported as binding to proline-rich (PY) motifs (Staub et al, 
1996). The recognition sequence required for WW-PY interaction varies from protein to 
protein and dictates how the WW domain is classified (Chong et al, 2006); in the case of 
the Nedd4 family of E3 ligases, the core consensus motif required for substrate 
recognition and binding is generally accepted as Pro-Pro-x-Tyr (PPxY, sometimes 
represented as xPPxY), where X can represent any amino acid (Staub et al, 1996). 
Occasionally variant motifs with the sequence LPxY (Bruce et al, 2008; Kanelis et al, 
2006) have been reported, but the canonical PPxY consensus sequence remains the most 
frequently cited (Aragón et al, 2011; Kotorashvili et al, 2009; Lu et al, 2007). 
 The human prostatic androgen-induced protein PMEPA1 has been known and studied 
as a PY motif-mediated binding partner for Nedd4 for a decade (Xu et al, 2003). With 
respect to the interaction between Nedd4 and PMEPA1 two PY motifs were originally 
identified (Xu et al, 2003) and are accepted as the only WW-domain binding motifs 
present in PMEPA1 (Shi et al, 2010). Previous studies looking at the relationship 
between Nedd4 and PMEPA1 have assumed that eliminating the binding capacity of 
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these two motifs equates to a functional loss of interaction between the two proteins (Li 
et al, 2008).  
 
3.1.1.2 The role of vPY motifs and multiple PY motifs 
 
 A variant PY (vPY) motif, with sequence APSY, has been reported in the yeast 
protein Bsd2p an adaptor for the yeast Nedd4 ligase Rsp5p (Sullivan et al, 2007). This 
vPY motif was shown to be absolutely required for Bsd2p to function as an adaptor in 
vivo and when absent, Rsp5p was unable to ubiquitinate and thereby regulate the 
manganese transporter Smf1p. It was postulated that, given the observation that between 
the adaptors Tre1p and Bsd2, there are 3 PY motifs required for Smf1p modification, but 
only 2 of the 3 WW domains on Rsp5p are involved, there is a sequential binding event 
occurring. The vPY motif may bind transiently to Rsp5p to ensure correct orientation of 
the ligase with respect to the adaptor, therefore enhancing the ubiquitination of the 
substrate. The Drosophila protein Commissureless has a similar binding site LPSY that 
specifically binds a different WW domain to the stronger PPxY sequence (Kanelis et al, 
2006), adding further weight to the theory that the vPY motifs are conserved in order to 
preserve an orientation function.   
 
3.1.1.3 Additional factors that may affect the Nedd4/PMEPA1 interaction 
 
3.1.1.3.1 Phosphorylation 
 
 Phosphorylation is being increasingly implicated in regulation of Nedd4-family 
dependant ubiquitination; the ability of the family member Itch to bind to the PY motif-
containing substrate p63 was shown to be affected by the absence of a conserved 
threonine/serine residue just downstream from the PY motif (Bellomaria et al, 2010), 
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suggesting a phosphorylation event at that position. In addition, phosphorylation by 
protein kinases can act to regulate the activity of some Nedd4-family adaptors; a proline-
rich region of Itch is phosphorylated on a specific serine and threonine residues by the 
MAPK family kinase JNK1, activating it and greatly enhancing its activity (Gallagher et 
al, 2006). The ability of specific residues of PMEPA1 to be phosphorylated must 
therefore be considered, as this may impact the ability of Nedd4 to interact with some or 
all of the PY motifs present.     
 
3.1.1.3.2 SUMOylation  
 
 SUMO consensus motifs have the consensus sequence ΨKxD/E, where Ψ represents a 
large, hydrophobic amino acid and x can be any residue (Rodriguez et al, 2001).  A 
variant SUMO interacting motif with sequence Ψ(I)x(S)KE was identified in the HECT 
domain of Nedd4, and preliminary investigations seemed to show that, when the lysine 
in this variant motif was mutated, a reduction in modification of Nedd4 mediated by the 
SUMO E2 protein Ubc9 was observed, indicating that this variant motif might play a 
role in SUMOylation of Nedd4 (Sullivan, personal communication). 
SUMOylation can alter ubiquitin ligase activity both up and down depending on the 
particular ligase involved; when the RING-type E3 BRCA1 is SUMOylated by the PIAS 
family of SUMO E3 enzymes, it results in an increase in the ubiquitination activity of 
BRCA1 (Morris et al, 2009). However, in contrast it has been shown that SUMOylation 
of the yeast Nedd4-family protein Rsp5p, by the PIAS homologues Siz1p and Siz2p, 
reduces Rsp5p activity (Novoselova et al, 2013).  
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3.1.2   Results 
 
3.1.2.1 PMEPA1 mutagenesis 
 
3.1.2.1.1 Identification and confirmation of a variant PY motif ‘PY1’ 
 
Through a process of analysis of the human proteome, searching specifically for 
proteins containing at least one canonical (PPxY) motif in addition to a motif with 
sequence xPxY (where the first residue was not proline), PMEPA1 was identified as 
containing a third putative PY motif, QPTY, upstream from the two canonical motifs 
(Cotton & Sullivan, personal communication). This PY motif has not been previously 
identified or studied due to its variant nature, and so presented an ideal model for 
investigating the binding of WW domains to PY motifs, particularly with regards to the 
environment surrounding the interaction site, as well as the potential role of multiple PY 
motifs. The vPY motif was designated PY1 due to its location at the N-terminus of the 
protein, and the two canonical motifs PPPY126 and PPTY197 were designated PY2 and 
PY3 respectively. 
To investigate whether the newly identified vPY motif in PMEPA1 was necessary for 
ubiquitination of PMEPA1 by Nedd4 in vitro, ubiquitination assays were performed. 
Given the difficulties of working with recombinant integral membrane proteins, an N-
terminally truncated form of PMEPA1 was expressed and purified in E. coli containing 
only the soluble cytoplasmic domain. Mutated versions of this protein were produced in 
which the putative vPY and the 2 previously identified PY motifs were functionally 
eliminated by mutating the tyrosine at the fourth position in the motif (Y102, Y126 and 
Y197) to alanine, which is known to prevent the site from being able to interact with 
WW domains (Goulet et al, 1998). Recombinant PMEPA1 and versions lacking each of 
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the three PY motifs alone, in double and triple combinations, were prepared and the 
ability of these proteins to be ubiquitinated by recombinant Nedd4 was assessed in vitro.  
Figure 3.1.1 shows a workflow diagram of the process behind each experiment 
 
3.1.2.1.2  Initial investigation of PY1 vs. PY2 and PY3 
 
The initial mutagenesis, the results of which are shown in figure 3.1.2, indicated that 
the loss of the canonical PY motifs PY2 or PY3, results in a reduction in Nedd4-
dependent ubiquitination of 55.2% and 43.9% respectively, as compared to the wild-type 
protein. Similarly, the loss of PY1 results in a reduction in ubiquitination of 26.9%, 
which is much less than either of the canonical motifs, but still a statistically significant 
(P = 0.014) deviation from the wild type. In addition, although there was no significant 
difference between the PY3 mutant (Y197A) when PY1 was functionally removed or left 
intact (P = 0.230), leaving PY1 intact actually decreases the ubiquitination of the PY2 
mutant (Y126A) by 19 % compared to the double mutant where both are functionally 
removed (Y102A/Y126A, P = 0.090). However, there was no significant difference in 
the amount of ubiquitination between the triple mutant (with all three PY motifs 
functionally removed), and the mutant with only PY1 motif present (Y126A/Y197A) (P 
= 0.104), indicating that the vPY motif alone is not sufficient to facilitate ubiquitination 
of PMEPA1 by Nedd4 in the absence of the two canonical sites. In summary, while the 
newly identified vPY motif contributes significantly to the efficiency of Nedd4-mediated 
ubiquitination of PMEPA1 in vitro, this motif alone cannot enable a significant degree of 
ubiquitination to occur, in contrast to either of the two previously identified canonical 
motifs. 
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Figure 3.1.1. Workflow schematic to show the process behind each ubiquitination 
assay blot and histogram. Each protein used was individually cloned via site-directed 
mutagenesis, produced in E. coli using 2-3 L of culture per protein, and purified using 
HisSelect resin. The resulting recombinant protein was used in ubiquitination assays 
and analysed using SDS-PAGE and Western blotting using Odyssey detection. The 
relative extent of ubiquitination was assessed using the Odyssey software and a 
student’s t-test was carried out to assess significance, where applicable. All methods 
are explained fully in section 2.  
  
Designing & ordering primers 
Performing SDM and confirming 
success by sequencing 
Large scale protein production 
and purification from E. coli 
In vitro ubiquitination assays 
SDS-PAGE and Western blotting 
Quantification and statistical 
analysis 
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3.1.2.1.3  Altering the variant residues in PY1 
 
The differences in the ability of the motifs to mediate ubiquitination by Nedd4 must 
be dependent on the two residues that are variable in the newly identified PY1 motif of 
PMEPA1, i.e. first and third (Q99, T101).  In order to investigate this, an initial 
mutagenesis trial was performed. Each iteration was only a single mutation, with the 
whole designed to see if these small alterations had any impact on subsequent 
ubiquitination of PMEPA1. Each single mutation, as well as those described later on, 
were carried out in a construct of PMEPA1 lacking a functional PY2 motif (Y126A) as 
initial experimental data produced by a previous member of the group initially indicated 
that any effect on PY1 would be more pronounced in absence of PY2. While the data 
presented in figure 3.1.2 shows that this is not in fact the case, these constructs had 
already been made, and experimental work begun, when this was realised. 
Figure 3.1.3 shows the results of the in vitro ubiquitination assays from this round of 
mutagenesis. Interestingly, none of the mutations had a significant effect on PMEPA1 
ubiquitination, with the exception of the T102S mutant, which showed an increase in 
ubiquitination of 14.3 % (P = 0.017). However it should be noted that the presence of a 
phosphomimic (Androutsellis-Theotokis et al, 2006), glutamic acid, at this position did 
not increase ubiquitination. It can also be seen in figure 3.1.3 that in the case of the 
T101S mutant, both the modified and unmodified protein signal shows a double band 
characteristic, possibly indicating a post-translational modification event occurring in E. 
coli independent of ubiquitination. 
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Figure. 3.1.2. Schematic showing the position of the residues motifs being modified 
within the broad structure of PMEPA1 (A). The designated nomenclature, with the 
vPY motif being labelled PY1, is shown alongside the residue number for clarity. 
Representative western blot, showing the results of an in vitro ubiquitination assay on 
soluble PMEPA1 constructs lacking the transmembrane domain but with an N-
terminal S-tag, with the tyrosine residues in each PY motif mutated to alanine singly 
and in combination (B). Recombinant PMEPA1 was detected using α S-tag primary 
antibody followed by IR-labelled α mouse secondary antibody and imaged using the 
Odyssey IR laser scanning system. The relative ubiquitination was calculated by 
measuring the proportion of unmodified protein (indicated by the arrow) vs. modified 
protein (indicated by the vertical line). Combined data from 5 replicates with the data 
normalised to that of the wild-type (WT) sample given an arbitrary value of 1.0 (C). 
Error bars indicate one standard deviation. A 2-tailed students’ t-test was carried out 
to determine the statistical significance of major pairs of data sets as indicated by the 
horizontal lines. P values indicate the probability that the resulting difference is due to 
chance, with relative significance of the differences between means indicated by zero 
(P>0.1), one (0.1>P>0.05), two (0.05>P>0.025) or three (P<0.025) asterisks.  
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Figure 3.1.3. Schematic showing the broad structure of Y126A PMEPA1 and the 
mutations made within PY1 (A). Representative western blot, showing the results of an 
in vitro ubiquitination assay on soluble S-tagged PMEPA1 constructs, with first and third 
residues of the vPY motif mutated as indicated in a Y126A construct. (B) PMEPA1 was 
detected using α S-tag primary followed by IR-labelled α mouse secondary antibody and 
imaged using the Odyssey IR laser scanning system. The relative modification by Nedd4 
was calculated by the proportion of unmodified (indicated by the arrow) vs. modified 
(indicated by the vertical line) protein and shown in the histogram (C) as normalised to 
show Y126A as 1.0. Data are based on four replicates of the experiment, with error bars 
showing one standard deviation. A 2-tailed students’ t-test was carried out to determine 
the statistical significance of major pairs of data sets as indicated by the horizontal lines. 
The P values indicate the probability that the resulting difference is due to chance,  with 
relative significance of the differences between the means indicated by zero (P>0.1), or 
three (P<0.025) asterisks.  
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3.1.2.1.4 Altering the residues immediately flanking PY1 
 
 As well as the core four residues, PY motifs are sometimes reported as extending 
further e.g. PPPxY (Furuhashi et al, 2005); although this feature is not considered 
canonical it is commonly found in PY motifs (including the flanking region of PY3 in 
PMEPA) and it is possible that the nature of the residues flanking the core motif might 
be important for function. To address the importance of the phenylalanine
 
and proline 
residues flanking PY1 these residues were altered to an alanine (F98A, P103A), as well 
as to a glutamic acid (F98E, P103E), in a construct lacking a functional PY2 motif. In 
addition, T101 was also mutated to proline (T101P) in order to assess the effect, if any, 
of specifically having a proline in this position as in the canonical motif PY3.   
Figure 3.1.4 shows that although altering F98 to a glutamic acid had no significant 
impact on the level of modification, altering this residue to an alanine resulted in a 53% 
drop in ubiquitination (P=0.005). The mutation P103A resulted in a significant reduction 
in ubiquitination of 45% (P=0.035), while the effect of P103E was a less pronounced 
reduction of 38% (P=0.015. Interestingly, the double mutant P103E/F98E had no 
significant effect on the ubiquitination of the protein, which may suggest that any 
structural characteristic that is disrupted by the mutation of one of these residues is 
compensated for by the mutation of the other, possibly by facilitating access to the PY 
motif which was previously blocked. In addition, the T101P mutation that alters PY1 to a 
canonical PY motif did not have any significant impact on the level of ubiquitination 
(figure 3.1.4).  
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Figure 3.1.4. Schematic showing the broad structure of Y126A PMEPA1 and the 
mutations made within and around PY1 (A). Representative western blot, showing the 
results of an in vitro ubiquitination assay on soluble S-tagged PMEPA1 constructs, 
with the residues within and flanking the vPY motif mutated as indicated in a Y126A 
construct (B). PMEPA1 was detected using α S-tag primary followed by IR-labelled α 
mouse secondary antibody and imaged using the Odyssey IR laser scanning system. 
The relative modification by Nedd4 was calculated by the proportion of unmodified 
(indicated by the arrow) vs. modified (indicated by the vertical line) protein and 
shown in the histogram (C) as normalised to show Y126A as 1.0. Data are based on 
three replicates of the experiment, with error bars showing one standard deviation. A 
2-tailed students’ t-test was carried out to determine the statistical significance of 
major pairs of data sets as indicated by the horizontal lines. The relative significance 
of the differences between the means is indicated by zero (P>0.1), two 
(0.05>P>0.025) or three (P<0.025) asterisks. 
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3.1.2.1.5 Altering PY1 to resemble the canonical motifs  
 
The final stage of the mutagenesis programme investigated the two variant residues in 
the vPY motif, altering the character of this motif to make it more similar to the sequence 
of PY2 (PPTY) and then PY3 (PPPY). This was achieved by introducing the mutation 
Q99P, alone and in combination with T101P, in both Y126A and Y126A/Y197A 
constructs to see if making the vPY site more canonical can compensate for the loss of 
ubiquitination associated with the functional loss of the canonical motifs. The results 
from the in vitro ubiquitination assays are shown in figure 3.1.5. The Q99P mutation 
alone had no significant impact on the extent of ubiquitination in the Y126A background, 
but the double mutation Q99P/T101P resulted in a small decrease in ubiquitination of 
31% (P=0.012) in the same construct. This supports the hypothesis that the presence of a 
vPY motif with a non-canonical sequence is important for effective interaction between 
Nedd4 and PMEPA1. However, the same double mutation in the Y126A/Y197A 
background did not result in a statistically significant change in ubiquitination.   
 
3.1.2.2  Ubiquitination and SUMOylation assays on Nedd4  
 
 To investigate whether the variant SUMO motif on Nedd4 has a significant role in the 
ability of Nedd4 to autoSUMOylate, SUMOylation assays were carried out (as detailed 
in section 2) on recombinant wild type Nedd4 and Nedd4 with the lysine of the variant 
site mutated out (K598R). Rsp5p, the yeast homologue of Nedd4, was assayed alongside 
as a control as it has no ability to autoSUMOylate under the same conditions as Nedd4, 
but shows a similar, if not stronger, ability to autoubiquitinate. In addition, a 
ubiquitination assay was carried out on the same proteins to check whether any effects 
seen were specific to the SUMOylation pathway and not related to any loss of general 
catalytic activity. From the ubiquitination assay (figure 3.1.6) it appears that the mutation  
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Figure 3.1.5. Schematic showing the broad structure of PMEPA1 and the mutations 
made within PY1 and PY3 in a Y126A construct (A). Representative western blot, 
showing the results of an in vitro ubiquitination assay on soluble, S-tagged PMEPA1 
with the residues within and flanking the vPY motif mutated as indicated in a Y126A 
or Y126A/Y197A construct (B). PMEPA1 was detected using α S-tag primary 
followed by IR-labelled α mouse secondary antibody and imaged using the Odyssey 
IR laser scanning system. The relative modification by Nedd4 was calculated by the 
proportion of unmodified (indicated by the arrow) vs. modified (indicated by the 
vertical line) protein and shown in the histogram (C) as normalised to show Y126A 
protein as 1.0. Data are based on three replicates of the experiment, with error bars 
showing one standard deviation. A 2-tailed students’ t-test was carried out to 
determine the statistical significance of major pairs of data sets as indicated by the 
horizontal lines. The relative significance of the differences between the means 
indicated by zero (P>0.1) or three (P<0.025) asterisks. 
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Figure 3.1.6. The results of in vitro ubiquitination (A) and SUMOylation (B) assays on GST-tagged Nedd4 and Rsp5 protein. The ligase 
being assayed is indicated at the bottom of the blot as WT (wild type Nedd4), ∆K (Nedd4 K598R) or R (Rsp5). The presence or absence 
of the modifying protein (ubiquitin is represented by Ub) is indicated by the -/+ at the bottom of the blot. Proteins were detected using 
αNedd4 primary antibody followed by IR-labelled α rabbit secondary antibody and imaged using the Odyssey IR laser scanning system. 
The unmodified proteins are indicated by the arrows to the right of the blots and the modified forms are the higher molecular weight 
bands indicated by the vertical line. 
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K598A has little or no impact on the ability of the Nedd4 to catalyse autoubiquitination, 
indicating that any effect seen could legitimately be considered the result of the mutated 
SUMO motif being rendered unavailable. However, there was a small observable 
decrease in SUMOylated products of K598R compared to the wild type (figure. 3.1.6B). 
This is particularly obvious when looking at the very high molecular weight products 
which manifest as a smear towards the top of the blot; however this is possibly an 
artefact of the lower total protein concentration in the K598R sample compared to the 
wild type. This would seem to indicate that the variant SUMO motif ISKE does play a 
role in the autoSUMOylation of Nedd4 in vitro. 
   
3.1.2.3 Microscale thermophoresis as a tool for investigating the PMEPA1/Nedd4   
       interaction 
 
 While the results of the PMEPA1 mutant assays provide important information about 
the functional role of PY motifs in Nedd4-mediated ubiquitination and SUMOylation, 
they do not give any information about the binding between Nedd4 and PMEPA1. To 
analyse the binding affinity of recombinant Nedd4 to PMEAPA1 a microthermophoresis 
experiment was performed (Wienken et al, 2010). The movement of a labelled protein, in 
this case PMEPA1, inside a narrow capillary is measured. An IR laser is used to heat a 
very small area of the capillary to a temperature 1000-6000 times higher than the rest of 
the solution, resulting in a temperature gradient which the labelled molecules move down 
by diffusion. The time taken for this movement to result in equilibrium depends on the 
hydration shell, charge or size of a solution, which in turn is dependent on the extent to 
which the labelled molecule is associating with an unlabelled binding partner. By 
titrating in increasing amounts of this unlabelled partner (in this case Nedd4), a binding 
curve is produced, from which the binding affinity can be inferred. 
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 Three PMEPA1 constructs were used – wild type, a triple PY mutant (∆PY 1,β,γ) and 
the double PY mutant ∆PY β,γ, all with the N-terminal transmembrane domain removed 
and a C-terminal 6xHis tag, alongside GST-tagged Nedd4, at concentrations of 9.5-14 
µM (see figure 3.1.7). A KD of 40 nM for binding of Nedd4 to wild type PMEPA1 (i.e. at 
a Nedd4 concentration of 40 nM, half the total Nedd4 in the solution is bound to 
PMEPA1) was obtained, and a much higher KD of 16.5µM for binding of Nedd4 to the 
triple mutant Y102A/Y126A/Y197A. However the result for the double mutant 
Y126A/Y197A was inconclusive. 
 
3.1.3 Discussion 
 
PY motifs have, until now, been considered well-defined in the literature, with PPxY 
being commonly cited as the minimal recognition motif for the WW domains of Nedd4 
ligases (Chen & Sudol, 1995; Gautam et al, 2013). The data presented in figure 3.1.2 
show that in PMEPA1 the variant PY motif QPTY, while not as indispensible as the two 
downstream canonical motifs, still contributes to Nedd4-dependent ubiquitination in 
vitro. This is consistent with previously published work, which showed that removing a  
vPY motif from the Rsp5p adaptor Bsd2p eliminated the ability of Bsd2p to function in 
vivo even when another, canonical PY motif was intact (Sullivan et al, 2007). The fact 
that the reduction in ubiquitination seen when the vPY site is eliminated is relatively 
small, compared to eliminating either of the two canonical motifs, might indicate weaker 
binding to the site. However, if this were the case we might expect that making the vPY 
motif more canonical in nature would result in an increase in Nedd4-dependent 
ubiquitination. The decrease in modification seen in the Q99P/T101P/Y126A mutant, 
which makes the vPY1 motif similar to PY3 in character, supports the hypothesis that the  
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Figure 3.1.7. Microscale thermophoresis data showing PMEPA1 WT (A), ∆PY 1,β,γ 
(B) and ∆PY β,γ (C) with titration of increasing concentrations of Nedd4. The x-axis 
shows the concentration of Nedd4 in nM and the y axis shows the ratio of 
fluorescence detected under hot and cold conditions, which is used to infer the 
fraction of molecules bound. While a single binding event is seen in both the WT and 
∆PY 1,β,γ spectra, no clear corresponding event is seen in the ∆PY β,γ data. 
Experiments were carried out by Dr. James Wilkinson of Nanotemper Technologies 
(Germany).  
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‘strengthening’ of the vPY site is not conducive to efficient ubiquitination, and that the 
function of this and other variant PY motifs is to bind the ligase transiently in order to 
bring the canonical PY motifs into contact with the correct WW domains for efficient 
modification.  In fact, the data presented in figure 3.1.5 show that this is not the case, as 
altering the vPY motif to recreate the canonical sequence has little effect on modification 
of PMEPA1. This does not fit with the findings of Sullivan et al (2007), which found that 
mutating the APSY motif to mimic the canonical PY2 site (PPTY) resulted in an increase 
in ubiquitination, however this was only assessed with the canonical site functionally 
lost, a scenario in which a proposed orientation function for the vPY motif would be 
redundant. 
One possible explanation for this is that the interaction of Nedd4 with PMEPA1 
involves a transient binding event, involving the vPY motif, which precedes the 
interaction with PY2 and/or PY3. This transient binding may serve to orient PMEPA1 
correctly with respect to one of the four Nedd4 WW domains and/or HECT domain in 
order to facilitate efficient ubiquitination. Ubiquitination targets lysine residues, and four 
of the five lysines in PMEPA1 are clustered at the very end of the primary sequence (see 
appendix iii), so it is logical that the PMEPA1 has to be oriented specifically against the 
ligase in order to avoid restricting access to these residues. If this were the case, we 
would not expect to see a complete loss of ubiquitination, because the correct orientation 
could still be achieved, albeit with less efficiency. This fits well with the results as 
presented in figure 3.1.2. One odd observation is that the level of ubiquitination in the 
double mutant Y102A/Y126A is higher than the level in the single mutant Y126A, i.e. 
loss of the vPY motif appears to slightly enhance ubiquitination when only PY3 remains 
functional. This effect is not seen on the PY3 (Y197A) mutant, or the double PY2/3 
mutant (Y126A/Y197A), indicating that the vPY motif seems to have a negative impact 
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on specifically PY3-mediated interaction (figure 3.1.2). This may be due to the PY2 
motif being the ‘stronger’ binding site; the loss of this site has by far the largest effect on 
ubiquitination of PMEPA1. It is feasible that the transient binding of the vPY site to 
Nedd4 has developed to bring the PY2 site in contact with Nedd4 at the optimal position, 
with the resultant PY3/WW interaction being less productive but still contributing to the 
overall level of ubiquitination. In the absence of PY2 but the presence of the vPY, this 
orientation effect would still take place, but with only the ‘weaker’ PYγ site intact, the 
ubiquitination reaction would be less efficient. In the absence of both the orienting vPY 
and PY2, the ligase and substrate are free to interact in such a way that the PY3 site is 
sometimes in contact with the Nedd4 in the same position as PY2 would be, allowing a 
small increase in ubiquitination (figure 3.1.8).  
The data in figure 3.1.3 indicates that the residues at positions one and three in the 
vPY motif can apparently be altered with little or no impact on ubiquitination. The major 
exception to this that we found was that altering Thr102 to a serine residue appears to 
significantly increase the capacity of PMEPA1 to be ubiquitinated, possibly due to 
increased phosphorylation at the site by non-specific bacterial kinases as has been 
previously observed with recombinant enzymes (Yang & Liu, 2004).  Phosphorylation of  
this serine would also explain the odd double banding pattern that is only seen in this 
mutant. It has been found that the protein Sprouty2 has two conserved serine residues in 
a non-canonical, non-PY, Nedd4-specific  interaction region which must be 
phosphorylated in order to facilitate Nedd4 binding and catalysis of ubiquitination 
(Edwin et al, 2010). However, threonine is also phosphorylated, often by the same 
kinases that modify serine, and substituting this residue for the glutamic acid which 
mimics the change in charge associated with phosphorylation did not have the same 
effect as the mutation to serine. In addition, as seen in figure 3.1.4, substituting a proline 
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Figure 3.1.8. Schematic of the posited relationship between multiple PY motifs in PMEPA1 and Nedd4, with the three PY motifs 
represented in blue and the four WW domains in red. Nedd4 in the cytosolic approaches PMEPA1, anchored in the Golgi membrane by 
the N-terminal transmembrane domain (A). The vPY motif (PY1) weakly & transiently interacts with a WW domain of Nedd4, 
represented by the dotted line, in this case speculated as being WW2 (B). This interaction is then replaced by a stronger interaction, 
represented by the solid line, between PY2 and Nedd4, alongside a slightly weaker interaction between PY3 and Nedd4, represented by 
the broken line (C). When PY3 is absent (D), the total ubiquitination on Nedd4 is only slightly reduced as the dominant PY2-mediated 
interaction can still occur. But when PY2 is absent (E), only the weaker PY3-mediated interaction can occur, although Nedd4 is still held 
in position by the PY1 interaction. When PY1 and PY2 are absent (F), the Nedd4 is free to adopt other orientations, including ones which 
may allow a stronger interaction between the remaining PY3 and Nedd4, represented again by an unbroken line.  
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did not result in any change in ubiquitination that might be expected if phosphorylation 
of this residue plays a key role in the function of the motif. The vPY motif identified 
previously, APSY in Bsd2p, also has a serine in the third position, and there is at least 
one example, a transcriptional regulator implicated in Charcot-Marie-Tooth disease 
called LITAF (Shi et al, 2010), of a canonical PY motif also having a serine as the 
variant residue. Several, including the canonical motif of Bsd2p and PY3 of PMEPA1 
have a threonine, also susceptible to phosphorylation, in this position. Lu et al (2009) 
reported that isolated Nedd4 WW domains bind to phosphoproteins, specifically those 
rich in phosphoserine and phosphothreonine. Interestingly, the paper identified proline, 
serine, glutamic acid and threonine (PEST) as creating an environment particularly well 
suited to these phosphoprotein-WW domain interactions and this may go some way 
towards explaining why altering the residues flanking the core vPY motif had an effect 
on ubiquitination. Clearly the threonine in the vPY of PMEPA1 plays some kind of role, 
as it is universally conserved across species from humans to zebrafish, even when the 
rest of the protein is only 65% conserved (figure 3.1.9). 
Altering the phenylalanine upstream of the vPY motif to an alanine resulted in a 
significant loss of ubiquitination not seen when a glutamic acid was substituted in the 
same position (figure 3.1.4). This is unlikely to be due to the phosphomimetic nature of 
the glutamic acid, as phenylalanine is not phosphosphorylated, so this result is most 
likely due to a steric effect; the presence of a bulky side chain at this position may 
increase, or indeed decrease, the availability of the site to interact with WW domains. By 
contrast, altering the downstream proline residue of the same motif results in a reduction 
in ubiquitination regardless of the nature of the substituted amino acid, but the effect of 
having a glutamic acid in this position is less pronounced than an alanine. Once again, 
proline has a bulky ring side chain, but it is unique in having its primary amine group  
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Species Homology with human Sequence of PY motifs 1-3 & surrounding residues 
Human 100% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Orang-utan 98% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Panda 94% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Dog 94% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Cow 94% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Chimpanzee 94% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Mouse 92% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Rat 92% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Cat 92% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Platypus 84% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Opossum 84% ---- FQPTYP ---- EPPPYQ ---- PPPTYN ---- 
Chicken 84% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Frog 77% ---- FQPTYP ---- EPPPYQ ---- PPPTYN ---- 
Zebrafish 65% ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
 
Figure 3.1.9. PY motif sequence homology in PMEPA1. Comparison of PY motifs 
and flanking residues in PMEPA1 from 13 mammalian species in addition to the 
human protein used in all experiments described. The core residues of all 3 PY motifs 
can be seen to be conserved even in zebrafish PMEPA1, with only 65% overall 
homology with the human protein. In addition, both flanking residues of PY1 and 
PY2, and the upstream proline of PY3, are 100% conserved in all 14 species, and the 
downstream residue of PY3 is a conserved serine in 12 out of 14 species. 
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involved in that side chain, which induces a ‘kink’ in the protein chain which cannot be 
recreated by substitution with any other residue. Therefore the glutamic acid side chain 
may partly compensate for the loss of the steric environment, but a significant loss of 
ubiquitination is seen in both mutants. The fact that mutating both residues 
simultaneously to a glutamic acid seems to compensate for this loss is, however, very 
curious. It may that having the two additional glutamic acid residues, which are acidic, in 
place of the proline and phenylalanine, which are both nonpolar, causes a sufficient 
change in the environment surrounding the motif that the availability of the motif to 
Nedd4 is increased despite the physical changes surrounding the motif. Alternatively, 
both residues may be contributing to the topology of the region and the loss of one may 
cause a specific alteration in the three dimensional structure which can be compensated 
for by the loss of both. This alteration may cause access to the site to be blocked, or 
possibly cause the vPY motif to be more exposed to the ligase in a way which results in 
preferential binding of the WW domain(s) to the weaker motif to the detriment of 
binding to the canonical motifs. Unfortunately, despite several attempts, the double 
alanine mutant F98A/P103A could not be successfully cloned; it is possible that this is 
due to a problem with the primers. This would be an informative experiment to see 
whether substituting both flanking residues for a small amino acid has any effect on 
Nedd4 ubiquitination.  
PMEPA1 has never been structurally resolved, but there are several examples in the 
literature of isolated PY-containing peptides bound to individual WW domains (Seo et 
al, 2006, Kanelis et al, 2001; Chong et al, 2006). The WW domain structure features a 
conserved, aromatic-rich “XP groove” which binds proline-rich regions, as well as a loop 
formation which recognises the tyrosine residue of PY motifs (Zarrinpar & Lim, 2000).  
The PY motif of the ENaC sodium transporter adopts a helical conformation, due to the 
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rigid structure of the prolines as mentioned above, that fits into the XP groove, 
supporting the theory that the proline upstream from PY1 in PMEPA1 plays an important 
structural role. However, there is also a C-terminal leucine residue in the ENaC which is 
essential for WW domain interaction, but not via the same groove that binds the PY 
motif (Kanelis et al, 2001). The N-terminal domain of the Epstein-Barr virus associated 
protein LMP2A has a region between the two PY motifs which NMR analyses showed to 
contribute to binding WW domains of Nedd4 ligases, although the reason for this is not 
clear (Seo et al, 2006), and Chong et al (2006) showed that 6 residues immediately 
downstream of a PY motif in the Smurf2 adapter Smad7 are also implicated in binding, 
to a variable area of the WW domain separate from the XP groove, and posited that this 
variability was the source of substrate specificity in Nedd4 family ligases. This all 
indicates an important role for the residues outside of the PY motifs, and it would be an 
interesting future experiment to expand the programme of mutagenesis to include 
residues further out from the vPY motif. 
Given the importance of the PMEPA1 vPY in vitro for ubiquitination by Nedd4 the 
role of the N-terminal TMD may need to be investigated, as the presence of this may 
alter the folding of the protein and therefore the environment of vPY, being the closest to 
the TMD in the primary sequence. The residues immediately flanking the identified vPY 
motifs in PMEPA1, Bsd2p (Sullivan et al, 2007) and Commissureless (Kanelis et al, 
2006) do not seem to be conserved, although taking the canonical PY motifs into account 
reveals that proline, serine and aspartic acid are present more than once in the immediate 
vicinity of a PY motif (see figure 3.1.10). This may be related to the charged nature of 
these residues (including serine when phosphorylated) or their contribution to the surface 
exposure of the motif. Clearly the function of the vPY motif is affected by the 
surrounding environment and not simply governed by the four core residues, and this  
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Figure 3.1.10 PY motifs and surrounding residues.  Comparison of PY motifs and 
flanking residues in human PMEPA1, Bsd2 from S. cerevisiae and Commissureless 
from D. melanogaster. Residues which are present more than once in the immediate 
vicinity of a motif are highlighted in bold; proline, aspartic acid and serine are all 
represented more than once. Of the other residues around the motifs, 6/8 are 
hydrophobic or nonpolar, and 7/8 are uncharged.  
  
Protein Sequence around PY motifs 
PMEPA1 ---- FQPTYP ---- EPPPYQ ---- PPPTYS ---- 
Bsd2 ---- IPPTYD ---- MAPSYY---- 
Commissureless ---- SPPCYT ---- GLPSYD ---- 
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may relate to the specificity of binding to different members of the Nedd4 family, or 
different WW domains within the ligases. 
Nedd4-family ligases have a strong tendency to autoubiquitinate in appropriate 
conditions in vitro, which has been put forward as a regulatory event to limit stability and 
catalytic activity of the ligase (Bruce et al, 2008). This autoubiquitination event is 
thought to be linked to a PY motif located close to the catalytic cysteine in the HECT 
domain (Kasanov et al, 2001). When the ligase has the opportunity to bind with higher 
affinity to a substrate PY motif, perhaps due to the more canonical sequence, it is 
presumed that this displaces the intramolecular interaction and the ligase preferentially 
ubiquitinates the substrate (Bruce et al, 2008). If a lower affinity vPY motif is present on 
the substrate e.g. PMEPA1, this could result in binding to a single WW domain without 
breaking the interaction between the HECT PY motif and a different WW domain, 
bringing the substrate and enzyme into a very specific alignment before the 
intramolecular interaction is interrupted. 
Finally, the observation that the variant SUMO interaction motif (SIM) ΨxKE 
identified in Nedd4 appears to be a legitimate modification site indicates that this may be 
an area in which the accepted canonical recognition site for ubiquitin-like protein 
modification is more flexible than previously thought. While canonical SIMs interact 
with the ‘groove’ on SUMO created by the α helix and ȕ sheet folding common to 
SUMO and other ubiquitin-like proteins (Song et al, 2006; Hecker et al, 2006), a novel 
motif has been identified which bind specifically to the SUMO1 isoform via several 
residues in the ȕ sheet and connecting loop (Pilla et al, β01β). While this interaction was 
shown to be mediated by a valine/isoleucine-rich region on the dipeptidyl peptidase 
DPP9, it serves as an example of an alternate SUMO interaction, of which this may be 
another example. The relative loss of SUMOylation in the K598R mutant is small, but 
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there are no canonical SUMO modification sites in Nedd4, and this is reflected in low 
levels of SUMOylation, with only two higher molecular weight bands and a small 
amount of smear being observed in the wild type protein. This small effect, and the fact 
that the K598R mutant has similar autoubiquitination activity as the wild type, supports 
the observation as a true consequence of the loss of the variant SUMO site and not of a 
loss of catalytic activity of Nedd4. It would be extremely interesting to investigate this 
effect in vivo to see whether SUMOylation of Nedd4 has a regulatory effect on 
ubiquitination activity as demonstrated in Rsp5p, especially as the target SUMOylation 
lysine is so close to the catalytic cysteine of Nedd4, and subsequently on the regulation 
of AR.   
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3.2 In vivo localization of PMEPA1 and AR 
 
3.2.1 Introduction 
  
3.2.1.1 PMEPA1 localization 
 
Prostate membrane protein androgen induced 1 (PMEPA1) is a 252 kDa protein with 
a sequence that is mostly predictive of a soluble structure, with the notable exception of a 
type Ib transmembrane domain at the N-terminus (Xu et al, 2000). It is described in the 
literature as being targeted to the secretory pathway, however co-localisation with a cis-
Golgi marker is not perfect, with ‘spots’ of PMEPA1 being observed around the main 
area of overlap (Xu et al, 2003). 
While there have been publications on PMEPA1 since the initial papers by Xu et al, 
they have mostly focussed on its potential role in tumorigenesis and TGF-ȕ signalling 
(Nakano et al, 2010; Watanabe et al, 2010). However, Brunschwig et al (2003) identified 
PMEPA1 as a transcriptional target of TGF-ȕ in its capacity as a tumour suppressor in 
colon cancer. This paper reported an alternative splice variant lacking the N-terminal 
transmembrane domain; the RNA of both splice alternatives were directly shown to be 
present, although the full-length transcript was predominant, and in some cell lines, 
including the human LNCaP line, the truncated version was absent. The localisation of 
both splice alternatives were described as ‘cytoplasmic’ by Brunschwig et al, although 
the full length protein appeared much more diffuse, in contrast to the concentrated Golgi-
like appearance reported by Xu et al. (2003). The truncated variant, lacking the 
hydrophobic domain, has a much more perinuclear appearance that the authors described 
as “punctuate clusters”, with ‘spots’ of fluorescence becoming less densely packed 
further away from the nucleus; this is actually more similar in appearance to the Golgi 
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colocalisation reported previously. The authors make no comment on the potential 
reasons for the difference in localisation between the two proteins, but it is not 
immediately clear why the results do not agree with the previous observations of Xu et 
al, nor why a variant with the hydrophobic N-terminus removed might show a less 
diffuse, perinuclear clustering.  
 
3.2.1.2 Androgen receptor localisation  
 
 There was initially some uncertainty over the subcellular localisation of AR until it 
was established that it can vary by cell line (Jenster et al, 1993). The same paper 
connected several associated ideas about AR localisation, and showed that the addition 
of testosterone as a ligand induced relocation from the cytoplasm, or a diffuse spread 
over the cytoplasm and nucleus, into the nucleus exclusively in all cell lines. The same 
publication used mutation studies to show that blocking ligand binding prevented the 
movement of AR into the nucleus, and that mutating a bipartite basic region in the DNA 
binding domain, with similarity to a nuclear targeting domain in the histone-binding 
protein nucleoplasmin (Robbins et al, 1991), diminished or abolished the movement of 
AR into the nucleus on ligand binding. Conversely, deletion of a region of the C-
terminus resulted in a constitutively active, nuclear-localised AR (Jenster et al, 1991), 
and non-activational ligands including anti-androgens and oestrogens were able to induce 
nuclear localisation but not transcription, showing that the two processes are separate 
(Jenster et al, 1993). The report concluded that a novel nucleoplasmin-like nuclear 
localisation signal functions in tandem with a previously postulated signal (Simental et 
al, 1991) to mediate shuttling of the AR from the cytoplasm into the nucleus in an ATP-
dependent manner. 
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Later research revealed that the glucocorticoid receptor, a nuclear hormone receptor in 
the same family as AR, is trafficked into the nucleus in an importin α-dependent process 
(Savory et al, 1999) that is mediated by a nuclear localisation signal of basic residues, 
conserved in AR, with the sequence RKxxxxxxxxxxRKLKK. Importin α was then 
shown to co-immunoprecipitate with AR both in the presence and absence of a ligand, 
and the structure of the bound complex revealed the hinge region between the N and C 
termini to be crucial for this (Cutress et al, 2008). The loss of this region resulted in a 
loss of binding to importin and subsequent inability of AR to move into the nucleus as a 
response to ligand stimulation, however this report reiterated that nuclear import is 
necessary but not sufficient for transcriptional activation. The reverse process, the export 
of AR from the nucleus back into the cytoplasm, is triggered by ligand withdrawal and it 
has been suggested that ligand binding suppresses a nuclear export signal on the ligand-
binding domain and causes accumulation of nuclear protein (Saporita et al, 2003). It was 
also confirmed that cytosolic AR was trafficked out of the nucleus rather than 
synthesised de novo, that the nuclear export signal is in the ligand-binding domain 
between residues 743 and 814, and that it is partially conserved in the oestrogen and 
mineralocortocoid nuclear receptors (Saporita et al, 2003). The regulation of AR 
transactivation is complex and still being unravelled, but the postulated feedback loop 
between PMEPA1 and AR, described in detail in section 1.4.4, relies on a physical 
interaction between the two proteins. This does not tie with their published localisations, 
but no evidence has been presented to date regarding whether, when expressed together 
under different conditions, there is any alteration in those localisations which may 
support this theory. 
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3.2.2 Results 
 
3.2.2.1 In silico predictions of PMEPA1 localization  
 
 While the presence of a transmembrane domain in PMEPA1 is indicative of 
membrane targeting, to date there has been no published localisation prediction of 
PMEPA1, based on anything other than its transmembrane domain. This was addressed 
by using five independent online prediction programmes to calculate the probability of 
wild type PMEPA1, a variant with the N-terminal transmembrane domain removed, and 
another with the three PY motifs rendered inactive, localising to different subcellular 
compartments. The results of these programmes is summarised in figure 3.2.1. Pprowler 
(Boden & Hawkins, 2005) predicted a secretory pathway targeting for the wild type 
protein, based entirely on the region between residues 1 and 32 i.e. the transmembrane 
domain, as did TargetP (Emmuelsson et al, 2000), with a reliability class of 1, the highest 
denomination. MultiLoc2 (Hoeglund et al, 2006) returned a more specific prediction of 
endoplasmic reticular localisation with 87% certainty, despite an absence of specific ER 
retention motif. CELLO (Yu et al, 2006) returned a completely different result, 
predicting a nuclear localisation, although with some composition elements returning a 
low-probability of targeting to the plasma membrane, and WoLF PSORT concurred, 
predicting with 69.6% certainty nuclear localisation based on comparison with 23 
‘nearest neighbours’ sequence homologues despite the identification of a transmembrane 
domain with the C-terminus facing inwards and the lack of any nuclear localisation 
signal. 
 The localisation of the wild type proteins were not altered in the absence of the three 
PY motifs described in section 3.1, confirming that any effects on localization seen 
experimentally would be likely to be due to the resultant loss of Nedd4-interactions. 
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 PProwler CELLO MultiLoc TargetP WoLF 
PSORT 
Consensus 
PMEPA1 WT Secretory 
pathway 
Nucleus ER Secretory 
pathway 
Nucleus Secretory 
pathway 
PMEPA1 ∆NT Mitochondria Nucleus Cytosol Mitochondria Mitochondria Mitochondria 
 
PMEPA1 ∆PY Secretory 
pathway 
Nucleus ER Secretory 
pathway 
Nucleus Secretory 
pathway 
 
Figure 3.2.1. Predicted subcellular localisation of wild type (WT), ΔNT (with residues 1-βγ of the wild type sequence removed) and ΔPY 
(Y102A /Y126A/Y197A) PMEPA1 according to five online prediction programs. While removing the PY motifs, and therefore preventing 
interaction of PMEPA1 with Nedd4, has no effect on the predicted localisation, removing the N-terminal transmembrane domain appears 
to expose a mitochondrial targeting sequence.  
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Similarly, running the full sequence of PMEPA1 with a C-terminal fluorescent protein 
tag had no impact on the resultant sequence predictions. In contrast, repeating the 
process with an N-terminal truncated form of PMEPA1 yielded very different results. 
The N-terminal mutant sequence lacked the initial N-terminal 23 residues containing the 
transmembrane domain, and was the soluble protein used in the in vitro assays detailed 
in section 3.1. This construct was predicted to be targeted to the mitochondria, through a 
region corresponding to residues 24-59 in the full length protein, by PProwler, and this 
was corroborated with 56.5% certainty by WoLF PSORT and with the second-highest 
reliability class by TargetP. CELLO predicted nuclear localisation by every measured 
parameter, while MultiLoc2 returned a cytoplasmic prediction with 85%, despite the 
identification of a mitochondrial targeting peptide.  
 
3.2.2.2. Comparison of PMEPA1 localization with and without the transmembrane  
domain 
 
In order to try and establish which localisation of the wild type PMEPA1 was 
observable in our experimental system, as well as to clarify the effects of removing the 
transmembrane domain on PMEPA1, green (GFP) and red (RFP) C-terminal fluorescent-
tagged mammalian expression constructs of both versions of PMEPA1 (see figure 3.2.3) 
were cloned and transiently transfected into HeLa cells both individually and together. 
Having established that the tag used is likely to have no effect on PMEPA1 localisation 
and could therefore be discounted as a contributing factor (figure 3.2.3 G-I), it then 
became clear that the wild type (WT) protein shows a diffuse distribution throughout the 
cytoplasm, with apparent exclusion from the nucleus when expressed in both HeLa and 
LNCaP cells (figures 3.2.2B & D), but in contrast to the evenly distributed appearance 
displayed by GFP, unconnected specks and spots of concentrated protein were observed.  
In vivo localization of PMEPA1 and AR 
 
Page 134 of 229 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.2. Confocal microscope images of fixed HeLa cells transiently transfected 
with free GFP (A) compared to GFP-tagged wild-type (WT) PMEPA1 (B) PMEPA1 
lacking the N-terminal transmembrane domain (NT) (C) all expressed in HeLa cells, and 
LNCaP cells transfected with GFP-tagged WT (D). These are all representative images 
of three fields of view, each containing an average of 19 expressing cells. Cells were 
fixed using paraformaldehyde 48 hours post-transfection, mounted and a representative 
cell cluster was imaged using excitation at 488 nm to produce an emission spectrum 
across 500-570 nm. Images were desaturated and reversed to produce black-on-white 
images for easy comparison.  
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Figure 3.2.3. Confocal microscope images of fixed HeLa cells transiently cotransfected 
with RFP-tagged WT (A) and GFP-tagged ∆NT (B) PMEPA1, and an overlay of the two 
channels showing almost overlap (C). RFP-tagged WT (D) and GFP-tagged ∆PY (E) are 
also shown overlaid in (F). For comparison, WT-PMEPA1 tagged with GFP (D) and 
RFP (E) are shown separately and overlaid (F). These are all representative images of 
three fields of view, each containing an average of 4 doubly expressing cells. Cells were 
fixed using paraformaldehyde 48 hours post-transfection, mounted and a representative 
cell cluster was imaged. Red channel (A) was excited at 633nm to produce an emission 
spectrum across 660-750 nm, green channel (B) was excited at 488 nm to produce an 
emission spectrum across 500-570 nm. Images were desaturated and reversed to produce 
black-on-white images for easy comparison.  
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The protein showed a similar appearance in both HeLa (figure 3.2.2B) and LNCaP 
(figure 3.2.2D), although overall fluorescence was generally lower in LNCaP. This is the 
opposite effect to that predicted based on the activated status of AR in the LNCaP line, 
which might be expected to increase PMEPA1 production, but this effect may be lost 
because the transfected PMEPA1 expression levels are higher than the endogenous 
protein. The N-terminal truncated protein (∆NT) appears to show the same distribution 
despite lacking the transmembrane domain region (figure 3.2.2C), and this was 
corroborated by double transfections showing almost complete overlap between RFP-
tagged WT and GFP-tagged ∆NT (figure γ.β.γ).  
 
3.2.2.3 Coexpression of PMEPA1 and subcellular markers 
 
 To see if the observed punctate distribution of PMEPA1 could be identified as 
representing any specific subcellular compartment, both WT and ∆NT PMEPA1, as well 
as a triple PY mutant Y10βA/Y1β6A/Y197A (∆PY), were transfected into HeLa cells 
and immunofluorescence was used to visualise markers of the secretory system, nucleus 
and mitochondria. The results of these experiments are shown in figures 3.2.4 and 3.2.5. 
Again the characteristic shattered appearance of PMEPA1 is seen throughout the 
cytoplasm, both with and without the N-terminal transmembrane domain, and this does 
not seem to be dependent on the PY motifs being intact (see also section 3.3.2). The 
signal partly overlaps with that of GM130, a cis-Golgi marker protein (Nakamura et al, 
1995), particularly in a region towards the centre of the PMEPA1 distribution close to 
the nucleus, but there is a large amount of PMEPA1 further out in the cytosol which does 
not correspond to a Golgi location, as well as areas of Golgi which are free of PMEPA1. 
Similarly, there is a smaller degree of overlap with the ER-Golgi intermediate 
compartment, as shown by the marker ERGIC-53 (Schweizer et al, 1988), particularly  
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Figure 3.2.4. Confocal microscope images of fixed HeLa cells showing the degree of 
overlap between wild-type GFP-tagged PMEPA1 and various subcellular compartment 
markers. The immunolocaization of the cis-Golgi using anti GM130 antibodies (A), the 
nucleus as imaged by DAPI staining (B) and the ERGIC as imaged using anti ERGIC53 
(C) is shown in untransfected cells. The localization of wild-type PMEPA1-GFP (WT-
GFP) is shown in cells counterstained using anti-GM130 (D, E) and anti-ERGIC-53(G, 
H) and the two channels are merged in (F) and (I). In both cases a degree of overlap can 
be seen, appearing yellow and highlighted using the white arrows, but with distinct areas 
where the two do not colocalize, highlighted using red arrows. These are all 
representative images of three fields of view, each containing an average of 24 
immunostained cells, plus an average of 12 expressing cells if transfected with labelled 
protein. Cells were fixed using paraformaldehyde 48 hours after transfection, then 
permeabilised and stained for immunofluorescence using an appropriate primary 
antibody followed by AlexaFluor-594. A representative cell cluster was imaged; red 
channel (A, C, E, H) was excited at 633nm to produce an emission spectrum across 660-
750 nm, green channel (D, G) was excited at 488 nm to produce an emission spectrum 
across 500-570 nm. DAPI was excited at 356 nm to produce an emission spectrum across 
the range 400-475 nm. Single channel images were desaturated and reversed to produce 
black-on-white images for easy comparison, merged images were produced using Leica 
LAS AF software.   
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Figure 3.2.5. Confocal microscope images of fixed HeLa cells showing the degree of 
overlap between PMEPA1 ∆PY and ∆NT mutants and various subcellular compartment 
markers. ∆PY PMEPA1-GFP is shown in cells counterstained using anti-GM130 (A, B) 
and the two channels are merged in (C). ∆NT PMEPA1-GFP is shown in cells 
counterstained using anti-GM130 (D, E) and Mitotracker Red (G, H), and the merged 
images are presented in (F) and (I).  In both cases a degree of overlap can be seen, 
appearing yellow and highlighted using the white arrows, but ∆PY appears to overlap 
slightly better with the cis-Golgi than ∆NT. These are all representative images of three 
fields of view, each containing an average of 24 immunostained cells, plus an average of 
8 expressing cells if transfected with labelled protein. Cells were fixed using 
paraformaldehyde 48 hours after transfection, then permeabilised and stained for 
immunofluorescence using an appropriate primary antibody followed by AlexaFluor-
594. A representative cell cluster was imaged; red channel (B, E, H) was excited at 
633nm to produce an emission spectrum across 660-750 nm, green channel (A, D, G) 
was excited at 488 nm to produce an emission spectrum across 500-570 nm. Mitotracker 
Red was added to cell growth medium at a concentration of 200nm for 45 minutes prior 
to fixation. Images were desaturated and reversed to produce black-on-white images for 
easy comparison, merged images were produced using Leica LAS AF software. 
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around the edges of the cluster formed by the marker, but there are still large regions of 
PMEPA1 expression which don’t overlap with this marker. As predicted the absence of 
all 3 PY motifs made no difference to the co-localization with GM130 (figure 3.2.5 A-
C). By this point it seemed clear that the ∆NT PMEPA1 was not, as predicted by the 
online software, localised differently to the wild-type protein or to the mitochondria, but 
this was tested by staining HeLa cells transfected with GFP-tagged ∆NT with 
Mitotracker red (Minamikawa et al, 1999). The mitochondrial signal was diffuse and 
evenly distributed throughout the cytosol, but the ∆NT construct retained the completely 
different spotty, concentrated appearance seen previously, with some areas of slight 
overlap apparently caused by the fact that the red signal was present throughout the cell 
(figure 3.2.5). This supports the WT/∆NT overlap data shown in figure γ.β.β suggesting 
that the ∆NT mutant is in fact retained in the same compartment as the wild type protein. 
For completion, transfections of ∆PY and ∆NT mutants with α-GM130 staining are also 
presented in figure 3.2.5, showing a similar pattern to the wild type; some overlap with 
the cis-Golgi marker, especially in the perinuclear region, but the majority scattered 
throughout the cytosol and not overlapping with the GM130 signal. 
 
3.2.2.4 Nuclear vs. cytoplasmic localization of AR in the presence and absence of ligand 
 
 While it is well-established that AR can localise either to the cytosol or the nucleus, 
the exact distribution between the two compartments varies between cell lines. To try 
and establish precisely what percentage of AR is present in each compartment under 
different conditions, and to re-examine the AR localisation with a view to identifying 
possible areas of interaction with PMEPA1, we used GFP-tagged constructs (see 
appendix 5.2.4) to transiently transfect HeLa and LNCaP cell lines. The constructs used 
were wild type (WT) AR and a mutant containing a single point mutation at position 877  
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in the ligand-binding domain, T877A. This mutation is found in the endogenous AR of 
LNCaP line cells (Veldscholte et al, 1990) and affects the ligand-binding pocket, 
resulting in a decreased ligand binding specificity and greater transactivational activity 
(Sack et al, 2001). Examination of these tagged proteins expressed in cells showed that 
the addition of DHT to cells expressing wild type AR induced a large-scale shift, from 
either an exclusive cytosolic or diffuse cytosolic and nuclear pattern, to an almost 
exclusively nuclear pattern which also seemed to show higher levels of expression. This 
shift was recreated in cells transfected with tagged T877A-AR, and the presence or 
absence of ligand had no effect on the targeting of this mutant (figure 3.2.6). Figures 
3.2.7 and 3.2.8 show examples of each of these distributions as well as the results of a 
statistical analysis involving ANOVA testing, to assess whether the number of cells 
showing each pattern differed between conditions, and pairwise post-hoc Tukey’s tests to 
establish which of the conditions differed significantly from each other. In both Hela and 
LNCaP, there was a statistically significant difference in localisation between wild type 
protein in the absence of ligand, and wild type protein in the presence of ligand. There 
was also a significant difference between wild type protein in the absence of ligand and 
T877A in the absence of ligand, however there was no significant difference in 
localisation between wild type protein in the presence of DHT and T877A in the absence 
of DHT. In HeLa cells, 73.9% of cells transfected with WT-AR in the absence of DHT 
showed a nuclear and cytosolic distribution, 23.3% showed an exclusively cytosolic 
localisation and only 2.8% showed an exclusively nuclear localisation (n=180). When 
DHT was added to the culture medium for 24 hours, 65.1% of cells showed an 
exclusively nuclear localisation, 33.0% showed a nuclear-cytosolic distribution and only 
1.9% showed an exclusively cystosolic distribution (n=106). When AR-T877A was 
expressed in the absence of ligand, 46.9% of cells showed an exclusively nuclear 
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Figure 3.2.6. Confocal microscope images of GFP-AR transiently expressed in HeLa (A-D) and LNCaP (E-H) human cell lines. These are 
all representative images of five fields of view, each containing an average of 25 expressing cells. Cells were grown for 24 hours following 
transfection, then either 100 nM DHT or an ethanol control was added and the cells left for a further 24 hours prior to fixation. Cells were 
fixed using paraformaldehyde 48 hours after transfection and a representative cell cluster was imaged; GFP was excited at 488 nm to 
produce an emission spectrum across 500-570 nm. Images were desaturated and reversed to produce black-on-white images for easy 
comparison. For each cell line, WT-AR in the absence (A, E) and presence (B, F) of DHT is shown alongside AR-T877A (CaP) under the 
same conditions(C, D, G, H). AR-T877A, shows the same nuclear distribution as the activated wild type protein even in the absence of 
DHT or other ligands, as distinct from the cytosolic appearance of WT-AR when not activated by ligand binding.  
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Figure 3.2.7. Panel (A) shows representative confocal microscope images of the three 
observed localisations of AR in HeLa cells - exclusively cytosolic, exclusively nuclear 
and nuclear/cytosolic.  Cells were grown for 24 hours following transfection, then either 
100 nM DHT or an ethanol control were added for a further 24 hours prior to fixation. 
Cells were fixed using paraformaldehyde 48 hours after transfection and a representative 
cell cluster was imaged; GFP was excited at 488 nm to produce an emission spectrum 
across 500-570 nm. Images were desaturated and reversed to produce black-on-white 
images for easy comparison. The histogram (B) shows the number of cells in each 
treatment category – WT-AR with only an ethanol control, WT-AR + DHT and AR-CaP 
(T877A) – showing each of these localisations. Panel (C) shows the results of Tukey’s 
post-hoc testing showing pairwise comparisons of means of each group; the degree of 
difference is represented by the horizontal axis and each line spans 95% confidence 
when comparing two groups, as shown on the vertical axis. A statistically significant 
(p<0.05) difference between a given two groups is represented by asterisks on the right 
hand side.  
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Figure 3.2.8. Panel (A) shows representative confocal microscope images of the three 
observed localisations of AR in LNCaP cells - exclusively cytosolic, exclusively nuclear 
and nuclear/cytosolic. . Cells were grown for 24 hours following transfection, then either 
100 nM DHT or an ethanol control were added for a further 24 hours prior to fixation. 
Cells were fixed using paraformaldehyde 48 hours after transfection and a representative 
cell cluster was imaged; GFP was excited at 488 nm to produce an emission spectrum 
across 500-570 nm. Images were desaturated and reversed to produce black-on-white 
images for easy comparison. The histogram (B) shows the number of cells in each 
treatment category – WT-AR with only an ethanol control, WT-AR + DHT and AR-CaP 
(T877A) – showing each of these localisations. Panel (C) shows the results of Tukey’s 
post-hoc testing showing pairwise comparisons of means of each group; the degree of 
difference is represented by the horizontal axis and each line spans 95% confidence 
when comparing two groups, as shown on the vertical axis. A statistically significant 
(p<0.05) difference between a given two groups is represented by asterisks on the right 
hand side.  
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distribution and 53.1% showed a nuclear/cytosolic distribution, but none were observed 
at all showing an exclusively cytosolic distribution (n=81). In LNCaP cells, the 
differences were slightly less stark but were still shown to be significant (see figure 
3.2.5); 75.7 % of WT-AR in the absence of ligand was exclusively cytosolic, 23.2 % was 
nuclear-cytosolic, and only 1.1 % was nuclear (n=177), compared to 26.7 % cytosolic, 
48.5 % nuclear-cytosolic and 26.9 % nuclear in the presence of DHT (n=130). 24.7 % of 
cells expressing AR-T877A showed cytosolic distribution, 36.6 % showed nuclear-
cytosolic and 36.7 % showed exclusively nuclear (n=131).   
 
3.2.3 Discussion 
 
 The initial observation that WT-PMEPA1 localises in a pattern that resembles part of 
the Golgi-ER pathway, but does not completely correspond to either the Golgi or the 
ERGIC, is consistent with the 2003 observation of Xu et al, which reported a cis-Golgi 
localisation. However on closer examination of the figures presented by Xu et al (2003) 
it is clear that  PMEPA1 partially but by no means completely overlaps with the cis-
Golgi marker. This is in contrast with other proteins reported as Golgi-localised, such as 
COH1 (Seifert et al, 2011), which overlaps almost completely with immunostained 
GM130. The fact that there is a slight overlap with the ERGIC may indicate that 
PMEPA1 is rapidly trafficked through the cell and is consequently only transiently 
present in specific compartments in a particular moment, but the high levels of protein, 
especially in transiently transfected cells, would be expected to compensate for that 
resulting in a signal which overlapped each of the compartments rather than none. 
Another possibility is that the spotted distribution observed actually corresponds to a 
different part of the secretory pathway, or another cellular compartment altogether, or 
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that the transmembrane domain of PMEPA1 in fact targets to several different membrane 
bound organelles, such as the perinuclear membrane and the lysosomal network. If 
PMEPA1 does localise to the secretory pathway, high levels of protein in transfected 
cells might cause a disruption to the Golgi morphology, such as that seen when the 
GTPase acceptor PRA1 is mutated and overexpressed (Gougeon et al, 2002). This is 
something that would certainly merit further investigation, possibly using alternative 
markers, along with the expression of mutants in the LNCaP line as well as HeLa. Figure 
3.2.2 shows that wild type PMEPA1 expression in LNCaP is similar to that seen in 
HeLa, with weak, diffuse cytosolic signal and small, irregular areas of stronger signal in 
the same punctuate arrangement. 
 A very interesting observation is that that the removal of the transmembrane domain, 
which was predicted across four of the five localisation prediction programmes to 
completely alter the targeting of PMEPA1, has absolutely no impact on the protein’s 
appearance within the cell. This construct was used extensively in vitro for the assays 
reported in chapter 3.1, because it was found to be much more soluble than the full 
length protein, which resisted recombinant purification. There is a possibility that the 
transiently transfected soluble PMEPA1 is associating with endogenous full-length 
protein at membranes, however there no evidence of dimerization in the literature. This 
would have been the subject of future experimentation if time permitted, and would be a 
priority for future experimentation. Alternatively, there may be a non-canonical means 
by which PMEPA1 is localising to its correct compartment, possibly mediated by other 
proteins; the RNA helicase RIG-1 translocates from the cytosol to the mitochondrial 
membrane in a process that relies on the chaperones TRIM25 (also a RING type E3 
ligase) and 14-3-γε, and is also ubiquitination-mediated (Liu et al, 2012). Another 
relevant example is the bacterial secretin PulD, which is targeted to the outer membrane 
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by binding to a dedicated chaperone called PulS (Nickerson et al, 2011). This binding 
causes a shift from mostly disordered secondary structure in PulD to a slightly more 
ordered, α-helical structure which is then targeted to the outer membrane; PMEPA1 is 
also predicted to have a mostly unstructured nature, so something similar may be 
occurring. Eliminating the three Nedd4-binding PY motifs has no effect on PMEPA1 
localisation (see section 3.3) but the targeting process may be mediated by other, yet to 
be identified proteins.  
 The location studies on AR presented here are the first to show that the subcellular 
targeting of AR-T877A mimics that of the ligand-bound wild type protein, even in the 
absence of any activating molecules. This is in contrast to several previous findings; a 
2002 paper on endogenous AR in LNCaP cells, which carries the T877A mutation, 
reported that the mutant protein accumulated in the nucleus following activation by 
oestrogens (Maggiolini et al, 2002), and that this was associated with upregulation of the 
AR target gene PSA. However, the immunostaining detection used in this study did not 
detect any AR in cells prior to the addition of ligand, in contrast to our studies and others 
which show that AR-T877A is constitutively expressed in LNCaP cells at relatively high 
levels regardless of the presence or absence of steroids (Nakauchi et al, 2007). Another 
paper, published around the same time and focussing on the xenoandrogenic properties 
of bisphenol A, reported only 20-40% of endogenous AR-T877A in LNCaP cells as 
showing nuclear distribution under androgen-depleted conditions, rising to 90-95% after 
the addition of DHT (Wetherill et al, 2002). While my statistical data supports the initial 
observation, finding that 36.7 % of transfected AR-T877A showed a nuclear distribution, 
my qualitative data (figure 3.2.6) does not indicate the same significant shift towards an 
exclusively nuclear arrangement. The similarity in the behaviour of both the wild type 
and mutant receptors in LNCaP cells compared to HeLa is interesting; Nakauchi et al 
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(2007) found significant differences in the distribution of transiently transfected wild 
type and T877A mutant AR between prostate and non-prostate cancer cell lines. This 
group reported that COS-1 cells showed a predominantly cytoplasmic distribution of 
AR-T877A in the absence and low concentrations of ligand, although their representative 
figures show some fluorescence in the nucleus at T-0 after the addition of DHT, while 
LNCaP cells showed a diffuse nuclear-cytosolic distribution that showed a rapid, 
complete shift to nuclear on addition of even a very low concentration (0.1 nM) of DHT. 
The authors conclude that the T877A mutation alone is not sufficient for the androgen 
hypersensitivity associated with LNCaP, but rather must be influenced by other 
intracellular factors, such as differently active cofactors or chaperone proteins; this is 
contradictory both to the findings presented here, and to functional analyses of the effects 
of the mutation on PSA expression in LNCaP and other cell lines (Magiollini et al, 2002; 
Wetherill et al, 2002). The differences in microscopy results may be put down to the use 
of living cells in the 2007 paper, while our experiments are based upon fixed, preserved 
cells, but this does not account for the inconsistency with the gene product analyses. 
Finally, a 2009 paper showed that endogenous AR-T877A in LNCaP cells showed a 
diffuse nuclear-cytosolic (with a large proportion of the protein shown in the nucleus) 
distribution when grown in the absence of steroids, but showed absolute nuclear 
translocation upon exposure to the synthetic androgen R1881 (Stan & Singh, 2009).  
However, these authors present only single cell images, and no statistical data to indicate 
that these observations are consistent; indeed, the focus of the paper is more on in vivo 
immunohistochemical data. Unfortunately, I did not carry out statistical analysis on AR-
T877A in the presence of ligand, as the primary purpose of these experiments was to 
show that the mutant receptor behaves in a quantifiably similar way to the activated wild 
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type receptor, but this would certainly shed more light on which of these prior 
observations this data can be said to support. 
The increased promiscuity of AR-T877A, a result of the single residue mutation 
making the ligand-binding pocket larger and more accessible to ligands other than 
testosterone and DHT (Sack et al, 2001), may account for the behaviour of the mutant if 
the receptor is constantly binding to and being activated by other components of the 
growth media, although the charcoal-stripped serum used should contain only trace 
amounts of steroid, if any. Alternatively, the mutation may interfere with the N/C 
regulation of AR, the intracellular association of the ligand-binding domain and with the 
DNA-binding domain, which stabilises the bound ligand and potentiates the receptor 
activity (see section 1.4.3) and is usually terminated on translocation to the nucleus, 
resulting in potentiated activation even in the absence of ligand binding. However, this is 
not such a clear-cut conclusion; while AR-T877A is apparently localised in the same 
way as the ligand-bound wild type, it is not necessarily the case that the transcriptional 
activation capacity is constitutively raised, as follows DHT-binding to the wild type. AR-
T877A, as the only endogenous AR present in the LNCaP line, has been shown to 
mediate increased cell proliferation in the presence of DHT compared to controls, and to 
have increased levels of expression induced by the addition of androgens (Yeap et al, 
1999). A more recent study found a high level of transcriptional activity of AR-T877A in 
the absence of ligand (Sun et al, 2006), but there is no evidence in this paper that the 
experiments performed in the ‘absence’ of steroid were performed using stripped media 
of any kind. However, the fact that the T877A mutation is prevalent in advanced 
metastatic prostate cancers (Gaddipati et al, 1994), and that the LNCaP cell line is 
sensitive to androgens (Horoszewitz et al, 1983), indicate that the steroid binding to the 
mutant protein must precipitate some function that the unbound mutant cannot fulfil. The 
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constitutive nuclear localisation and raised expression levels may in fact be indicative of 
low transcriptional activity, for example if the presence of more AR than would normally 
be expected in the nucleus resulted in increased exposure to co-repressors which inhibit 
its activity, resulting in a large amount of inactive, nuclear mutant protein. Regardless of 
transcriptional activation of the endogenous mutant in LNCaP cells, the mechanism 
behind the nuclear localisation does not induce the same pattern in the exogenous wild 
type protein, as evidenced by the fact that the majority of GFP-tagged wild type AR 
expressed in LNCaP in the absence of steroid was cytosolic, with a shift to 
nuclear/cytosolic or nuclear distribution observed only on the addition of DHT. This is 
the same pattern observed in HeLa cells, without the activated endogenous AR, and 
indicates that the processes set in motion by the activation of AR, whether that is 
selective degradation, increases nuclear import or both, are not self-perpetuating and are 
dependent on the structural alterations that occur on AR following ligand binding. Future 
work to investigate the impact of inhibiting protein degradation and intracellular 
trafficking on the DHT-mediated localisation shift would help shed light on the 
intricacies of this process. 
 In conclusion, the data presented here represent a systematic study of the localisation 
PMEPA1 and AR, in various forms, for the first time. The role of the transmembrane 
domain of PMEPA1 seems more complex than was previously thought, as its absence 
does not preclude the trafficking of PMEPA1 to the secretory pathway and an as-yet 
unidentified compartment. The mutant T877A androgen receptor is shown to be located 
almost exclusively in the nucleus, and to mimic the distribution of ligand-bound wild 
type even in the absence of steroid, however further work on the transcriptional activity 
of both forms of AR is required to clarify if the ligand-precipitated functions are also 
mimicked by this mutant. An interesting side observation, seen particularly clearly in 
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figure 3.2.6B, is that occasionally AR appears to have a spotty distribution in the 
cytoplasm, either alone or alongside some protein in the nucleus, in contrast to the even 
appearance seen more commonly and shown in figures 3.2.6A, C and D
. 
This looks 
remarkably similar to the distribution of PMEPA1 shown in figures 3.2.2 & 3.2.3, and 
could shed some light on the physical interactions behind the proposed PMEPA1-AR 
feedback mechanism. This possibility is examined in more detail in the next chapter. 
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3.3 In vivo association between Nedd4, PMEPA1 and AR 
 
3.3.1 Introduction 
  
3.3.1.1 Physical interaction between Nedd4, PMEPA1 and AR 
 
 PMEPA1 has been shown to interact directly and non-transiently with Nedd4 through 
co-immunoprecipitation studies (Xu et al, 2003). Similarly, AR has been shown to co-
precipitate with PMEPA1 (Li et al, 2008). However, there is no direct evidence of a 
direct interaction between AR and Nedd4, and the basis for the hypothesised negative 
feedback loop, described in detail in section 1.4.4, between AR and PMEPA1 is that 
PMEPA1 acts as an adaptor to facilitate Nedd4-mediated ubiquitination of AR. 
Ubiquitination of AR has been widely reported, mediated by several RING-type ligases 
including Mdm2 (Lin et al, 2002), RNF6 (Xu et al, 2009) and Siah2 (Qi et al, 2013), 
however Nedd4 has never been directly shown to utilise AR as a substrate. The fact that 
the loss of the 2 canonical PY motifs in PMEPA1 appears to attenuate its ability to 
downregulate AR points to Nedd4 involvement, corroborated by a direct observation that 
Nedd4 levels are influenced by AR levels and vice versa (Li et al, 2012). However, there 
are some aspects of the theory that warrant further investigation in order to clarify the 
precise nature of the association between AR and Nedd4. AR is well-documented as 
localising to the nucleus or cytoplasm, or a combination of the two (Jenster et al, 1993) 
and this is corroborated by the results detailed in section 3.2 showing redistribution of 
AR into the nucleus on addition of a ligand. PMEPA1, however, shows a spotty 
distribution over the perinuclear and cytoplasmic region, and although PMEPA1 and AR 
were shown to co- immunoprecipitate in the LNCaP line (Li et al 2008), no consideration 
has been given to this apparent difference in localization. In addition, although there is 
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abundant in vitro evidence for PMEPA1 and Nedd4 interaction, it is not clear where in 
the cell this takes place, as Nedd4 adopts a cytosolic distribution similar to that of AR 
prior to ligand binding (Anan et al, 1998).   
 
 3.3.1.2 Testosterone activation of AR and the effects on PMEPA1 and Nedd4 
 
  AR binds specifically to the male hormone testosterone, with approximately half the 
affinity as to its potentiated metabolite dihydrotestosterone (DHT) (Grino et al, 1990). 
The conversion from testosterone to DHT is catalysed by the enzyme 5α-reductase, the 
cellular distribution of which varies by age and gender. When AR binds to a ligand, AR 
alters conformation from a relatively unfolded, loose structure to a more compact, tightly 
folded shape in which the N- and C-termini are closely associated; this is followed by 
movement of the receptor into the nucleus and rapid dimerization (Schaufele et al, 2005). 
The subsequent transcriptional activation of a variety of genes, including PMEPA1, is 
the basis of all testosterone-mediated cellular effects. PMEPA1 is a direct transcriptional 
target of AR, and is highly androgen-induced, with expression levels reported as 29 
times higher in the presence of the artificial AR ligand R1881 (Xu et al, 2000), and this 
is the theoretical basis for the negative feedback loop for regulation of AR. Up-regulation 
of PMEPA1 has also been noted in other endocrine cancers, such as breast cancer 
(Singha et al, 2010) but this does not appear to be induced by other hormones such as 
oestrogen or progestogen, indeed the tissues in which enhanced expression was found are 
receptor-negative tumours.  
  None of the Nedd4 family ligases, unlike PMEPA1, are known to be directly induced 
by androgens, however there is some evidence of an indirect association, indicated by the 
observation that AR up-regulates expression of Nedd4, although a full methodology is 
yet to be published (Li et al, 2012). In addition, the PMEPA1-mediated regulation of AR 
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described in detail previously is attenuated upon the loss of the two canonical PY motifs 
in PMEPA1, strongly implying a Nedd4-mediated mechanism. Nedd4-2 has previously 
been identified as binding to the aldosterone-induced kinase SGK-1 as part of the 
regulation of the sodium transporter ENaC (Wiemuth et al, 2010), a nuclear receptor 
response pathway with parallels to that induced by testosterone.  
 
 3.3.1.3 Potential role of the proteasome vs. ubiquitin-mediated trafficking 
 
  As well as its best-studied and widely-known role as a proteasome targeting signal, 
the modification of proteins by ubiquitination has several other functions. With regards 
to the role of ubiquitination in AR-mediated signalling, the RING E3 ligase RNF6 
catalyses the formation of K6- and, to a lesser extent, K27-linked chains on AR, however 
this is not associated with any decrease in stability (Xu et al, 2009). Recruitment of 
another RING ligase, Siah2, has been reported to decrease the half-life of AR by a factor 
of three (Qi et al, 2013), and this is consistent with the identified K48-linked chain 
topology, associated with proteasomal targeting (Finley et al, 2004). Conversely, MDM2 
is associated with increased turnover of AR in a process that is proteasome dependent 
and regulated by phosphorylation of AR (Chymokowitch et al, 2010), despite previous 
reports of MDM2 catalysing specifically the formation of K63-linked lysine chains 
(Sehat et al, 2008), which are generally a marker for non-proteasomal activity. Nedd4 
has previously been identified as catalysing the formation of predominantly K63-linked 
(Fan et al, 2013, Tofaris et al, 2011), as well as occasionally K11-linked chains (Platta et 
al, 2012), which would seem to indicate a non-proteasomal role in PMEPA1-mediated 
AR regulation, but that is not consistent with the negative feedback mechanism proposed 
by Li et al in 2008. 
 
In vivo association between Nedd4, PMEPA1 and AR 
 
Page 154 of 229 
 
 3.3.2 Results 
 
3.3.2.1 In vivo interaction between PMEPA1 and Nedd4  
 
 While we have been able to efficiently and consistently reproduce in vitro interactions 
between recombinant Nedd4 and PMEPA1, and shown these to be dependent on the two 
canonical and single variant PY motifs on PMEPA1 (see chapter 3.1), in vivo 
interactions are more difficult to quantify. Xu et al (2003) used immunoprecipitation to 
show binding between transiently transfected, tagged PMEPA1 and Nedd4 expressed in 
HEK293 cells, but there has not been any subsequent published investigation of this 
complex formation. To investigate the in vivo interaction between Nedd4, PMEPA1 and 
AR initial experiments involved overexpressing wild-type PMEPA1 and PY motif 
mutants, in order to assess the outcome of interfering with the ability of PMEPA1 to 
interact with Nedd4 a construct of full length PMEPA1, with a dual epitope tag of cMyc 
(MEQKLSEED) and the IgG-binding domain of protein A at the C-terminus (giving a 
predicted MW of 45.7 kDa) was expressed in HeLa cells (figure. 3.3.1A). In addition to 
the wild-type PMEPA1 sequence mutated versions each with a single PY motif 
inactivated through tyrosine-alanine substitution at the crucial fourth position (see 
section 3.1) were also transiently expressed in HeLa cells. The results of this transient 
expression are, shown in figure 3.3.1, where an expected band of approximately 45kDa 
was observed with wild-type PMEPA1 with both anti-myc (figure 3.3.1A) and 
peroxidase-anti-peroxidase that binds the protein A domain (figure 3.3.1B). Very 
interestingly, a smaller epitope-positive fragment of approximately 25 kDa was also 
observed with wild-type and all of the PY motif mutants used except Yβ16A (ΔPYβ) 
where a single band of approximately 38 kDa was observed (figures 3.3.1A and B) with 
both epitopes. All constructs were sequenced prior to recombinant expression and known  
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Figure 3.3.1. Western blots showing Myc-IgG-tagged PMEPA1 transiently expressed 
in HeLa cells. Proteins were harvested using detergent lysis and visualised using SDS-
PAGE followed by Western blotting using anti-Myc primary and anti-mouse HRP-
conjugated secondary (A) or peroxidase anti-peroxidase (B). Mock lanes show lysate 
from cells transfected with empty vector under the same conditions. Bands 
corresponding to tagged PMEPA1 were observed at the expected size, ~45kDa, at 
indicated by the black arrow on the right hand side, as well as ~38kDa and ~25kDa, 
indicated by asterisks. The largest and smallest bands are observed in every PMEPA1 
construct with the exception of Y126A. The band corresponding to the 38 kDa size is 
observed in Y126A, but is absent or greatly reduced in the wild type protein, as well 
as the Y102A and Y197A single mutants.  
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to produce proteins of the same size, with only substitution mutations introduced as 
opposed to truncations or additional stop codons. Although not visible when using anti-
myc, when the more sensitive peroxidase-anti-peroxidase detection was used, the 38 kDa 
was visible with all constructs although was clearly more abundant with Y126A (figure 
3.3.1B). 
 Unfortunately, attempts to recreate the 2003 co-immunoprecipitation experiment 
failed due to difficulties in obtaining sufficiently high protein levels for accurate 
detection This could have been due to using a different cell line (HeLa instead of 
HEK293) or a different protein tag (PMEPA1-Myc instead of PMEPA1-V5), or simply 
due to the size of the culture vessels used. Attempts to use fluorescence resonance energy 
transfer (FRET) to elucidate if subcellular locations of Nedd4 and PMEPA1 are in close 
enough proximity (<10 nm) for photon transfer were partially successful (figure 3.3.2), 
showing some FRET signal in the perinuclear and cytoplasmic regions of some cells 
expressing both proteins. This signal also appears, although somewhat fainter, in cells 
co-expressing Nedd4 and a triple mutant Y10βA/Y1β6A/Y197A (∆PY) which is 
prevented from interacting with Nedd4; the triple PY mutant retained a small (< 10% 
compared to wild type) ability to be ubiquitinated by Nedd4 so it is possible that this 
signal is due to the same residual interaction. However, this is much less likely in a 
crowded cellular environment compared to in vitro, where protein levels are much 
higher, so difficult to be sure whether this is a true signal or due to some bleed-through 
from the overlapping emission spectra of the green and red fluorescent proteins. As 
reported in section γ.β, confocal microscope images of PMEPA1 WT and ∆PY co-
expressed with different fluorescent tags in HeLa have already been established as 
showing no difference in subcellular localisation or apparent expression levels  
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Figure 3.3.2. Confocal microscope images of fixed HeLa cells transiently 
cotransfected with PMEPA1-GFP, wild type (WT) or Y10βA/Y1β6A/Y197A (∆PY), 
and Nedd4-RFP. Cells were fixed using paraformaldehyde 48 hours post-transfection, 
mounted and a representative cell cluster was imaged. Red channel (A and D) was 
excited at 633nm to produce an emission spectrum across 660-750nm, green channel 
(B and E) was excited at 488nm to produce an emission spectrum across 500-570nm. 
To produce FRET images (C and F), the green fluorescence was excited at 488nm, 
but the emission spectrum was collected across 660-750nm, to ensure only RFP-
spectrum excitation was detected. Images were desaturated and reversed to produce 
black-on-white images for easy comparison. There appears to be some FRET signal 
produced by interaction with both WT and to a lesser extent ∆PY, indicated by the 
black arrows. 
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 (figure 3.2.2) when the Nedd4-interacting motifs are removed. 
 
3.3.2.2 Effect of testosterone on Nedd4 levels and implications for Nedd4-AR interaction 
 
 I used a succession of experiments to infer a role for AR in Nedd4 regulation, or vice 
versa, by altering the levels of ligand, and therefore AR transcriptional activity. The 
hypothesis being tested was that induction of AR activity is the signal for up-regulation 
of PMEPA1, which in turn seems to regulate AR in a process which recruits Nedd4; 
therefore any alteration in Nedd4 levels or localisation associated with increased cellular 
DHT would be linked to the activation of AR. There was sufficient quantity of lysate 
from these experiments to run an α-Nedd4 blot concurrently with the α-AR blot, which 
also offered the opportunity to examine any potential effect on Nedd4 levels as a result 
of AR activation, in light of the increasing literature evidence of a two-way interplay 
between the two proteins (Li et al, 2012). Initial observations were undertaken to assess 
endogenous Nedd4 and AR levels in the presence and absence of DHT and in cell lines 
with (LNCaP) and without (HeLa) AR expression. The results are shown in figure 3.3.3; 
while the western blots are of poor quality due to the relative lack of control over signal 
intensity afforded by the ECL method, it can be seen that there is a no apparent variation 
in Nedd4 abundance on addition of DHT within both cell lines. However, this cannot be 
quantified in the absence of a loading control; provisional indications are that Nedd4 is 
neither up-regulated nor degraded when AR is activated. Higher levels of AR are seen in 
response to DHT treatment in the LNCaP cell line, consistent with previous findings; as 
expected, there is no AR present in the HeLa cell line. 
 Figure 3.3.4 shows the results of the addition of the Eukaryotic protein synthesis 
inhibitor cycloheximide to both HeLa and LNCaP cell lines on endogenous Nedd4  
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Figure 3.3.3. Western blots showing endogenous Nedd4 (A) and AR (B) from 
untransfected cells harvested by detergent lysis. The cell line is indicated by H (HeLa) 
or L (LNCaP). Cells were grown in charcoal-stripped MEM for 48 hours following 
passage, then either 100 nM DHT or an ethanol control was added to the medium for 
a further 24 hours. Lysates were run on SDS-PAGE followed by western blotting 
using anti-Nedd4 primary and anti-rabbit HRP-conjugated secondary or anti-AR 
primary and anti-mouse HRP-coupled secondary The main band for Nedd4 is 
~120kDa in size compared to ~110kDa for AR. Both proteins seem to show higher 
levels of the main band of protein, as well as lower molecular weight degradation 
products, in HeLa compared to LNCaP. Nedd4 undergoes no change in cellular levels 
on the addition of DHT while AR levels are increased in LNCaP. 
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Figure 3.3.4. Western blots showing endogenous Nedd4 from untransfected cells following the addition of 50µg/ml cycloheximide to the 
growth medium and harvested by detergent lysis. Panels (A) and (B) show the products of HeLa cell lysates in the absence and presence 
of DHT, while panels (C) and (D) show the products of LNCaP cell lyastes. Cells were grown in charcoal-stripped MEM for 48 hours 
following passage, then either 100 nM DHT or an ethanol control was added to the medium for a further 24 hours. Control samples had 
water added in place of cycloheximide and were harvested after 240 minutes. Lysates were run on SDS-PAGE followed by western 
blotting using anti-Nedd4 primary and anti-rabbit HRP-conjugated secondary. The membranes were then stripped by incubating in a 
solution of 0.1M glycine and 1% w/v SDS (pH 2.2) and reincubated in anti-actin primary and anti-rabbit HRP-conjugated secondary. The 
Nedd4 band at 120 kDa shows declining levels over four hours, while the actin loading control (40 kDa band) shows that overall protein 
levels in the LNCaP cell line are lower than in HeLa, despite the Nedd4 signal being stronger.   
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levels. This experiment was to attempt to determine the half-life of Nedd4 and AR in the 
presence and absence of DHT since if the activation of AR results in Nedd4 and/or 
PMEPA1 recruitment that might be associated with a decrease in Nedd4 stability when 
activated by the ligand. Unfortunately the anti-AR blots produced no signal at all over 
several attempts, even in a control lane with no cycloheximide present, so I was not able 
to infer anything about the stability of endogenous AR in different activation states.  
However, I was able to detect Nedd4 in the lysates; the role of Nedd4 in the PMEPA1 
feedback mechanism is still unclear, but following addition of cycloheximide in the 
absence of DHT an apparent decrease in Nedd4 levels can be seen in both HeLa and 
LNCaP cells over the course of 4 hours, particularly between 60 and 120 minutes 
(figures 3.3.4A and 3.3.4C). In HeLa, addition of DHT appears to slightly stabilise 
Nedd4 with some protein being observed 120 minutes following the addition of 
cycloheximide following DHT treatment (figure 3.3.4B). However in LNCaP, the 
opposite appears to be true in that addition of DHT results in lower Nedd4 abundance at 
120 min although the actin signal suggests that the overall protein level in that particular 
sample may also lower. It should also be noted that in relative to the actin loading 
controls the levels of endogenous Nedd4 appear to be higher in extracts from LNCaP 
cells as compared to HeLa (figures 3.3.4A and 3.3.4C) supporting the hypothesis that 
DHT (or a mutation that mimics AR binding to DHT) stabilizes Nedd4. However, signal 
from the loading controls is relatively low and inconsistent, meaning that the Nedd4 
signal unfortunately cannot be accurately quantified; these are speculations rather than 
conclusions. 
 
 
 
In vivo association between Nedd4, PMEPA1 and AR 
 
Page 162 of 229 
 
3.3.2.3 Effect of testosterone on Nedd4 and AR localisation 
 
 The question of where in the cell any interaction between Nedd4 and AR might occur 
was still unanswered, given that the trigger for such an interaction appears to be 
activation of AR and movement into the nucleus, when Nedd4 is a soluble, cytosolic 
protein. While the effect of DHT on AR has been shown to induce nuclear localisation 
(see section 3.2), the potential effect on Nedd4 has not been assessed. To see whether 
there was any co-localisation between Nedd4 and AR upon ligand binding, which might 
point to a direct interaction, confocal microscopy was used to visualise the response of 
Nedd4 to DHT on a subcellular level. Figure 3.3.5 shows the result of the addition of 
DHT which, as seen previously, causes a distinctive large-scale shift from a diffuse 
cellular expression pattern to an exclusively nuclear localisation for AR (Fig. 3.3.5D). In 
contrast, in these cells RFP-Nedd4 remains cytoplasmic regardless of the presence of 
DHT (Fig. 3.3.5E). There is, however, an apparent change in the Nedd4 distribution from 
diffuse signal in the absence of DHT to a more punctate appearance in the presence of 
DHT. While this does not coincide with any increased association with AR, in fact the 
opposite is true as AR is almost entirely excluded from any compartment except the 
nucleus under these conditions, it intriguingly does resemble the localisation pattern of 
PMEPA1 (as shown in figure 3.2.1) 
 
3.3.2.4 Investigating the postulated feedback loop between AR and PMEPA1 
 
 In order to further elucidate the potential mechanism of the observed interplay 
between PMEPA1 and AR, LNCaP cells were transiently transfected with FLAG-
histidine-tagged ubiquitin (figure 6.2.5; derived from that used in Novoselova et al 2013) 
alongside PMEPA1 and/or Nedd4. The cells were lysed in a guanidine-based denaturing 
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Figure 3.3.5. Confocal microscope images of HeLa cells transiently co-transfected with RFP-Nedd4 and GFP-AR. Cells were fixed 
using paraformaldehyde 48 hours post-transfection, mounted and a representative cell cluster was imaged. Green channel (A & D) was 
excited at 488nm to produce an emission spectrum across 500-570nm. Red channel (B & E) was excited at 633nm to produce an 
emission spectrum across 660-750nm, The single channel images were desaturated and reversed to produce black-on-white images for 
easy comparison, and the overlaid channels are shown in sections C & F. Nedd4 can be clearly seen to be expressed in the cytoplasm at 
variable levels, and this does not appear to be altered by the addition of DHT, although its appearance in panel E resembles the Golgi-
like distribution of PMEPA1. In contrast AR can be seen to switch from a nuclear-cytosolic, diffuse expression pattern throughout the 
cell to an exclusively nuclear localisation on the addition of DHT, and this eliminates any areas of overlap in the merged images. 
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buffer, and HisSelect nickel resin (Sigma Aldrich) was used to capture the His-tagged 
ubiquitin, along with any covalently attached proteins. A western blot was performed on 
the samples using anti-AR antibody in order to determine whether directly ubiquitinated 
endogenous AR could be detected, and whether the level of protein and extent of 
ubiquitination was affected by increased levels of PMEPA1 and/or Nedd4. The result is 
presented in figure 3.3.6; a higher molecular weight AR band is clearly seen in the 
presence of PMEPA1 and ubiquitin but this modification appears to be lost on the 
addition of Nedd4. However, levels of Nedd4 were not high enough to be detected in the 
same sample, although ubiquitin was highly expressed, making interpretation of the 
result difficult. AR does appear to be modified, but whether this is mediated by Nedd4 or 
a result of previously reported in vivo interactions is unclear, and the fact that these 
experiments were not able to be repeated means that any conclusions are at best 
preliminary. 
Having assessed the modification status of AR, the next step was to try to establish 
whether the PMEPA1-mediated regulatory effect previously reported was ubiquitin-
proteasome mediated, or dependent on a non-proteasomal function of ubiquitination. The 
original experiment (Li et al, 2008), expressing AR in the presence and absence of 
PMEPA1 and assessing the effect of adding the proteasomal inhibitor lactacystin, did not 
factor in the potential effect of depletion of the free ubiquitin pool on cellular processes. 
In order to assess whether compensating for this depletion, by overexpressing transiently 
transfected ubiquitin, eliminates the observed PMEPA1 down-regulation of AR, the 
experiment was repeated with ubiquitin co-expressed in each well. The results are shown 
in figure 3.3.7; the significant drop in AR levels reported by Li et al in 2008 in response 
to co-expressing PMEPA1 in the absence of ubiquitin is not seen when ubiquitin levels 
are increased in this way, and adding lactacystin in this case does not seem to result in 
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Figure 3.3.6. Results of a denaturing immunoprecipitation of a histidine-FLAG tagged ubiquitin construct, expressed alongside 
PMEPA1 and in the presence and absence of GFP-tagged Nedd4, in HeLa cells 48 hours post-transfection. Ubiquitin was precipitated via 
the histidine tag using HisSelect nickel resin in denaturing conditions. Panels (A) and (B) shows the same input samples detected using 
anti-FLAG primary (A) and anti-Nedd4 primary (B); ubiquitin is clearly expressed in both positive samples and is absent from the 
controls as expected. A greater proportion of the exogenous ubiquitin appears to be incorporated into conjugates in the presence of 
Nedd4, as indicated by the absence of an ~8 kDa band representing free ubiquitin. Unfortunately Nedd4 itself is only visible in one of the 
two lanes it was transfected in, and that is the control lane. Panel (C) shows total lysate (input) and pulldown samples with endogenous 
AR detected by western blots using anti-AR primary and anti-mouse HRP-conjugated secondary. A smeared band corresponding to the 
expected size of unmodified AR (~110 kDa) is visible but only in the negative contol lane of the input sample without Nedd4, indicated 
by the asterisk on the right hand side. A higher molecular weight product, indicating post-translational modification, is visible in three of 
the four input lanes and in the pull-down samples without Nedd4, indicated by the black arrow on the right hand side. 
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Figure 3.3.7. Levels of transiently transfected wild type AR, in the presence and absence of PMEPA1, in HeLa cells coexpressing 
exogenous ubiquitin.  Both panels (A) and (B) show cell lysates harvested by detergent lysis and detected using SDS-PAGE following by 
western blotting with α-AR primary and α-mouse HRP-conjugated secondary antibodies. Panel (A) shows, for comparison, the effect of 
the non-proteasomal protease inhibitor E-64 (E) compared to lactacystin (L) and controls, in the presence and absence of wild type 
PMEPA1 (W) and the triple PY mutant Y102A/Y126A/Y197A (P). Panel (B) shows a repeat of the experiment using only WT PMEPA1 
and lactacystin. Cells were grown in charcoal stripped media for 24 hours following transfection, then either 100µM E-64 or an ethanol 
control was added to the medium. Cells were then grown for a further 18 hours, then either 10µM lactacystin or a DMSO control was 
added for the final 6 hours. The addition of ubiquitin appears to eliminate the previously observed loss of AR on the addition of 
PMEPA1, and the addition of lactacystin has no effect on the levels of unmodified AR, in contrast to the previous findings.  
  
In vivo association between Nedd4, PMEPA1 and AR 
 
Page 167 of 229 
 
any increase in AR levels, although in one experimental replicate (figure 3.3.7B) there 
was an accumulation of higher molecular weight products which is presumably 
ubiquitinated protein as a result of the proteasomal machinery being rendered non-
functional.  
Figure 3.3.8 shows the results of overexpressing the constitutively active form of AR, 
the mutant T877A, which has already been shown in section 3.2 to behave in a manner 
similar to the wild type protein bound to testosterone, with and without PMEPA1, similar 
to the experiment conducted originally on the wild type protein, but with the addition of 
ubiquitin to assess whether this has any effect on the mutant AR as it did on the wild 
type. In the HeLa cell line, the addition of PMEPA1 results in an apparent decrease in 
AR T877A, consistent with the previously published wild type result, but the addition of 
ubiquitin as a co-transfected plasmid appears to reverse this effect to some extent. 
However the levels of AR in the absence of PMEPA1 seem to be lower in the presence 
of ubiquitin, and a stain for total protein (figure 3.3.8 C) shows that this is not due to 
higher DNA levels arising from multiple co-transfections leading to increased toxicity 
and lower overall protein; it, could be the case that turnover of AR-T877A is more rapid 
than that of the wild type, for example if its constitutively active state triggers 
upregulation and recruitment of ubiquitin-proteasome machinery. In this scenario, having 
more free ubiquitin in the cell may allow that process to occur more readily, resulting in 
the lower cellular levels of mutant AR observed. Alternatively this may be an artefact 
due to cell number or variability in transfection efficiency, but the fact that the same 
pattern is seen in the LNCaP cell line seems to indicate that is not the case. 
 The final experiment to assess where in the cell any direct interaction between 
PMEPA1 and AR could take place was to image PMEPA1 in the presence and absence 
of DHT i.e. when AR is active and the proposed negative feedback mechanism between  
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Figure 3.3.8. HeLa (A) and LNCaP lysates (B), harvested by detergent lysis and 
detected using SDS-PAGE following by western blotting with α-AR primary and α-
mouse HRP-conjugated secondary antibodies, of cells overexpressing mutant AR-
T877A in the presence of ubiquitin with and without PMEPA1, alongside negative 
controls. The ~110 kDa band, corresponding to the expected size of the mutant AR, 
and a higher molecular weight ~130 kDa band seen in the HeLa cell lysates are 
indicated by black arrows to the left of the blot. Levels of unmodified AR-T877A 
were much lower or absent when coexpressed with PMEPA1, an effect that was 
partially reversed when ubiquitin was also coexpressed. The 130 kDa band seen in 
panel (A) may be modification but its presence in the negative control lanes indicates 
a possible nonspecific cross reaction with bacterial protein. Also shown is a 
Coomassie stained 7.5% SDS-PAGE gel showing total protein levels in the same cell 
lysates as those used in lanes 2, 4 and 6 of panel (A), along with repeats of the same 
experiments carried out with the addition of empty vectors to bring the total amount 
of DNA used up to the same level in each transfection (C). The additional DNA 
actually appears to reduce the total level of protein compared to the same experiments 
performed without their addition.  
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AR and PMEPA1 would be ongoing. Figure 3.3.9 shows the localization of GFP-tagged 
PMEPA1 wild type and Y10βA/Y1β6A/Y197A (∆PY) in HeLa cells in the presence and 
absence of DHT. PMEPA1 localisation is never seen to cross the nuclear membrane 
regardless of the presence of steroid, either in the wild type or in the mutant which 
cannot interact with Nedd4.  
 
3.3.3 Discussion 
 
 The observation of lower molecular weight forms of PMEPA1 suggests that more 
than one cleavage event is occurring, at least one of which appears to be dependent on 
the canonical PY2 (Fig. 3.3.1). The predicted size of PMEPA1 with the Myc-IgG-
binding-domain tag on is 45 kDa, the size of the largest observed band. As the tag being 
detected is on the C-terminus of the protein, the reduction in size must be caused by 
truncation from the N-terminus. A reduction in weight from 45 kDa to 38 kDa, the only 
band of PMEPA1 Y126A observed, reflects a reduction in size of full length PMEPA1-
IgG of approximately 64 residues, encompassing approximately 25% of the PMEPA1 
protein, including the hydrophobic transmembrane domain, but leaving all three PY 
motifs intact. Similarly, truncation to 25 kDa would reflect truncation at approximately 
residue 182, encompassing approximately 72% of the PMEPA1 part of the protein; this 
leaves only one PY motif, PY3 (PPTY197) intact, removing both the variant PY1 and the 
canonical PY2. The apparent disruption to this process caused by a mutation in PY2, but 
not either of the other PY motifs, suggests that this process is Nedd4-mediated, and also 
fits with the idea put forward in section 3.1.3 that the PY2 motif on PMEPA1 plays the 
most significant role in interaction with Nedd4 and subsequent modification. 
Interestingly in these assays no modified, i.e. higher molecular weight, forms of  
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Figure 3.3.9. Confocal microscope images of fixed HeLa cells transiently transfected 
with wild-type (A & B) and ∆PY (C & D) PMEPA1-GFP. Cells were grown in 
charcoal-stripped medium for 24 hours post-transfection then either 100 nm DHT or 
an ethanol control was added for a further 24 hours. Cells were fixed using 
paraformaldehyde, mounted and a representative cell cluster was imaged. GFP was 
excited at 488nm to produce an emission spectrum across 500-570nm. The images 
were desaturated and reversed to produce black-on-white images for easy comparison. 
Regardless of the presence or absence of PY motifs and DHT, AR concentrates in the 
nucleus following ligand binding, but PMEPA1 is never seen to cross the nuclear 
membrane. 
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PMEPA1 were observed in any lane. The purpose of the partial digestion in vivo is 
unclear, as the loss of all PY motifs has no effect on the localisation of PMEPA1 
compared to wild type, even in the presence of DHT, when it might be expected to 
inhibit some form of nuclear transfer to represent an interaction with activated AR 
(figures 3.3.2 & 3.3.9).  
 Levels of Nedd4 don’t seem to differ significantly in the presence or absence of 
steroid (figure 3.3.3), but the Nedd4 turnover rate (figure 3.3.4) does seem to be affected 
by ligand-activation of AR in LNCaP, however the lack of quantification in the 
cycloheximide chases make it impossible to draw any definite conclusions in that regard.  
There is no change in Nedd4 localisation (figure 3.3.5), again in spite of ligand-
induced activation of AR and significant change in AR localisation upon DHT binding. 
This indicates that the role of Nedd4 in AR regulation is confined to an indirect effect, 
possibly mediated by an adaptor – a role PMEPA1 may fill. It is plausible that the role of 
Nedd4, which is implied by the role of PY motifs in the paper that first described the AR 
regulatory cycle, and later confirmed directly by the same group (Li et al, 2008; Li et al, 
2012) is to catalyse a ubiquitin-mediated partial proteolysis of PMEPA1, producing the 
observed fragments, and that this fragment in turn plays a role in regulation of AR. There 
are parallel examples of such a process in the literature, for example, the activation of 
two yeast transcription factors, Spt23p and Mga2p, which is mediated by Rsp5p and 
regulates production of unsaturated fatty acids by transcriptional control of the 
desaturase enzyme Ole1p (Hoppe et al, 2000; Shcherbik et al, 2003). Like PMEPA1, the 
homologues Spt23p and Mga2p are membrane-associated with a ~20 residue 
transmembrane domain, contain a PY motif LPKY and localise to the secretory pathway 
(ER). Rsp5p-mediated ubiquitination triggers the processing of the 120 residue precursor 
protein to a 90 residue active form, with subsequent passage into the nucleus where they 
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function as transcription factors. However, the question remains why PMEPA1 is never 
seen in the nucleus, as this is where AR is confined to once activated and therefore where 
any negative regulatory effect would be expected to occur (see figures 3.3.5 and 3.3.9). It 
would be interesting to detect endogenous proteins, rather than, as shown here, using 
transfected, tagged proteins; the transfection process itself subjects the cells to significant 
stress, which may mean that the expressed constructs do not localise as they would under 
normal growth conditions. In addition, the highly variable expression levels of 
transiently expressed protein can both interfere with normal cellular function and cause 
misleadingly high levels of fluorescence that may be difficult to pinpoint accurately. Use 
of immunofluorescence would not preclude co-detection of two proteins if appropriate 
antibodies were used, and would bypass these potential problems, but would rely heavily 
on consistently detectable levels of endogenous protein which, as demonstrated by the 
difficulty in obtaining Western blot and immunoprecipitation results, may present a 
problem in this instance. 
 The results in figure 3.3.7B, showing that wild type, transiently transfected AR 
expressed in HeLa cells does not disappear when PMEPA1 is co-expressed in the 
presence of an artificially expanded ubiquitin pool, seems to indicate that the drop in AR 
levels in the presence of PMEPA1 observed by Li et al (2008) were artifactual; certainly 
their result is valid in showing a PMEPA1-mediated event, but the assumption that this is 
necessarily proteasome mediated is incorrect. Repeating this experiment with the use of a 
loading control such as co-detection of actin would provide more concrete evidence of 
this, but the fact that the addition of lactacystin and similar proteasome inhibitors, in the 
initial paper, rescues the PMEPA1-associated loss of AR is fundamentally not reason 
enough to conclude a proteasomal involvement, because there is a finite pool of free 
ubiquitin available in the cell. Ordinarily this pool is turned over continuously because 
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the proteins are deubiquitinated upon entry to the proteasome, but inhibiting the 
degradation mechanism causes a build-up of polyubiquitinated proteins, resulting in a 
loss of the ubiquitin reserves as they cannot be replenished. Therefore a point is reached 
where non-proteasomal ubiquitin-mediated processes also cannot occur, as the cellular 
free ubiquitin is no longer available; the therapeutic proteasome inhibitor bortezomib has 
been shown to precipitate such an event, with processes such as histone regulation and 
the IκBα pathway also being affected (Xu et al, 2004). Evidence for this can be seen in 
figure 3.3.8; the addition of PMEPA1 apparently precipitates an increase in AR 
ubiquitination, and a smear of high molecular weight protein is seen in that lane which is 
absent in the equivalent experiment without the inhibitor as the modified protein 
accumulates in the cell. While these experiments were carried out on HeLa cells, rather 
than the LNCaP prostate cancer model used in the 2008 paper, the results in figure 3.3.9, 
showing a similar pattern in the CaP mutant AR (T877A) to that reported in the wild 
type, indicate the model is valid. The drop or complete loss of AR in the presence of 
PMEPA1 is apparently rescued by the addition of supplementary ubiquitin even in the 
absence of proteasome inhibitors; this is an odd result, and may be due to total DNA 
levels in the transfections being higher and leading to less efficient transfection. 
However, analysis of the total protein in the samples by SDS-PAGE and Coomassie 
staining (see figure 3.3.9C) shows that there is actually more protein present in cell 
lysates transfected with less DNA, although this does not distinguish between 
endogenous and transfected proteins. Repeating the proteasome inhibitor experiments in 
LNCaP would be a future extension of the experiment.  
AR is a 110 kDa protein, while the cutoff for passive diffusion across the nuclear 
envelope is around 60 kDa (Alberts et al, 2002); nuclear localisation of AR occurs 
through a combination of importin-dependent (i.e. active transport through nuclear pores) 
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and importin-independent processes (Kaku et al, 2008). One alternative pathway for 
nuclear translocation would be through the Golgi apparatus/endosomal pathway, which 
would afford opportunity for AR to interact with PMEPA1. The observation (figure 
3.3.6) that some Nedd4 appears to localise in a Golgi-like pattern in the presence of DHT 
may indicate that the activation of AR by ligand binding precipitates the recruitment of 
Nedd4 to the endosomal trafficking pathway, with could in turn facilitate association of 
Nedd4 with AR and regulation through its interception between the cytosol and nucleus. 
However, this would presumably be a transient event that could only result in a small 
proportion of the total cellular AR being targeted, whereas the almost total loss of 
cellular AR seen in response to PMEPA1 up-regulation, both in the 2008 paper and our 
own data (figure 3.3.9) implies this is not the case. 
There were a lot of difficulties encountered while undertaking co-
immunoprecipitation experiments, and no Nedd4 or AR signal was detectable even in 
input samples. While no definite conclusions can be drawn from this, overexpression of 
Nedd4 would certainly be expected to destabilise AR if indeed the Nedd4/PMEPA1 
complex is responsible for the negative feedback previously observed; the lack of Nedd4 
signal means that the lack of AR signal could also be due to poor detection or low overall 
protein, although this is countered by the observation of a strong FLAG-ubiquitin signal 
in the same experiment.  
It is possible that, despite the discrepancy in observed localisations of the three 
proteins, a direct interaction is occurring. In Arabidopsis, the RING ligase KEG localises 
to the early endosome, while the transcription factor AB15 is seen exclusively in the 
nucleus, yet the two interact directly in the cytoplasm (Liu & Stone, 2013) and when this 
process is blocked, AB15 accumulates in the cytoplasm. AB15 contains both nuclear 
import and nuclear export signals, and is transported both ways across the nuclear 
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envelope, but the cytoplasmic levels are kept low by this compartment-selective 
degradation. It is therefore feasible that the truncated PMEPA1 products seen, the release 
of which is dependent on Nedd4-mediated ubiquitination, enter the cytoplasm as soluble 
fragments where they recruit the ubiquitin-proteasome pathway to precipitate the 
degradation of AR in the cytosol only. 
The use of controls to assess whether the high molecular weight band is still observed 
in lysates which are not overexpressing PMEPA1 would be a logical extension of this 
experiment, and I would also like to see a direct interaction between PMEPA1 and AR, 
as seen in the 2008 paper; multiple attempts to detect this interaction using tagged 
PMEPA1 or bound α-AR were not successful.  
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4. EXPERIMENTAL WORK NOT INCLUDED DUE TO LACK OF CONCLUSIVE FINDINGS 
 
4.1. Attempted structural analyses on PMEPA1 and Nedd4 
 
 A significant portion of my time between November 2009 and November 2010 was 
spent preparing large quantities of highly pure protein with the intention of undertaking 
X-ray crystallography studies. This involved repeated culture of large quantities (4-8 L) 
of E. coli expressing recombinant 6xHis-PMEPA1 lacking the transmembrane domain, 
followed by affinity column purification. Further steps were necessary to obtain the 95 % 
purity required for successful structural analysis, and this was achieved using FPLC. The 
difficulties arose due to the low solubility of PMEPA1, even with the transmembrane 
domain removed; a typical prep yielded 2.5 ml protein at a concentration of around 0.5 
µL, with a large proportion of the cellular protein lost in the insoluble fraction. While it 
was possible, using concentrating columns, to obtain a reduced volume at higher 
concentration, attempting to obtain concentrations higher than 2 mg/ml resulted in 
PMEPA1 precipitating out of the aqueous solution and the prep being rendered unusable. 
I attempted various solutions, including the use of detergents and stabilising agents such 
as glycerol in the lysis buffers, but when these were subsequently removed by buffer 
exchange during the FPLC process, any stabilising effect was lost. In addition, PMEPA1 
degrades rapidly; initial samples that were stored at 4 oC overnight were completely 
unusable after 24 hours. These factors all combined to make obtaining sufficient protein 
at sufficient concentration for crystallography – approximately 1 mL at 1.5 mg/ml – an 
extremely long and arduous process. When I did succeed in obtaining samples of this 
quality, I laid down Hampton I and II crystal screens on two occasions and waited the 
required 2 weeks for any crystals to form, the result was only unusable precipitate.  
Experimental work not included elsewhere due to lack of conclusive findings 
 
Page 177 of 229 
 
 Alternative structural analysis was attempted during July-September 2012, in the form 
of circular dichroism spectroscopy to try and quantify any structural alterations that arise 
upon PMEPA1 binding to Nedd4, and whether this was affected by the loss of any of the 
PY motifs. Again, this required extremely pure protein at a concentration of 1.5-2 mg/ml, 
but in smaller quantities, so I was able to obtain sufficient quantity of samples and pass 
these on to a collaborator. Unfortunately, the GST tag on Nedd4 interfered with the CD 
spectra, and attempts to remove the tag using PreScission protease (GE Healthcare) were 
unsuccessful due to the stability of Nedd4 in the required buffer; a construct of Nedd4 
with a 6xHis tag in place of GST was successfully cloned near the end of the project. 
 
4.2. Developing stable cell lines and use of inducible expression vectors 
 
 The initial idea, when planning the mammalian cell culture aspect of the project, was 
to use a tetracycline-inducible vector to express both PMEPA1 and AR simultaneously 
from a controlled time point, a similar technique to that used by Li et al (2007). This 
required multiple steps; following purchase of the vector system in March 2011, I 
undertook multiple cloning procedures in order to obtain both AR and PMEPA1, with 
appropriate affinity tags that could be simultaneously detected, and with restriction sites 
that would allow those fragments to be introduced into the inducible vector downstream 
of the two promoters already present in the plasmid. This alone took several months 
(alongside other experiments). Between September 2011 and July 2012, a significant 
proportion of my time was spent repeatedly attempting to clone both proteins into a 
single vector, optimising doxycycline concentration to induce expression of these 
proteins in vivo, and using linear selection markers to try to establish stable cell lines, an 
extremely time consuming process which required multiple dilutions to try and establish 
Experimental work not included elsewhere due to lack of conclusive findings 
 
Page 178 of 229 
 
monoclonal cultures in what is necessarily a stress-inducing selective media. 
Unfortunately, these attempts were not successful and, due mostly to time constaints, I 
instead used simultaneous transient transfections as described in this thesis. 
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5. DISCUSSION 
 
 
5.1 The in vitro interaction between PMEPA1 and Nedd4 
 
 
 The identification of the novel variant PY motif in PMEPA1 is very interesting, as it 
is only the third WW domain-interacting PY motifs with a non-canonical xPxY 
sequence, and the first confirmed in a human protein. The fact that inactivating the vPY 
and each of the canonical PY motifs has a different level of impact on the level of 
Nedd4-mediated ubiquitination on PMEPA1 indicates that they are not equivalent, and 
their roles differ. In theory, if the role of a PY motif is purely to bind WW domains as 
strongly as possible to facilitate ubiquitination on as many sites as possible, then 
changing the nature of the vPY motif to mimic the two stronger sites would have been 
expected to increase the ability of Nedd4 to ubiquitinate PMEPA1, however the data 
presented in section 3.1 appear to show that this is not the case.  
The motif now labelled PY2 appears to play the most significant role in PMEPA1 
ubiquitination, as the removal of this motif has the largest impact on the extent of 
modification by Nedd4 in vitro. This seems to be due to more than simply the sequence 
of this motif (PPPY), as altering the gluatamic acid and threonine PY1 (QPTY) to mimic 
this sequence does not ‘rescue’ ubiquitination in a Y126A mutant (figure 3.1.5). A 
possible explanation for this is (as outlined as figure 3.1.8) is that the vPY motif interacts 
only transiently with Nedd4 in order to align the enzyme with PMEPA1, allowing the 
two canonical PY motifs to interact with specific WW domains. The spacing and 
sequence of the three PY motifs is perfectly conserved across many different species, and 
selective binding of PY motifs to specific WW domains of the Nedd4 family has been 
previously observed (Ingham et al, 2005). In addition, the paper that identified the vPY 
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Bsd2p in yeast posited a similar theory, based additionally on the observation that Bsd2 
interacts specifically with WW3 in Rsp5p (Sullivan et al, 2007). The next stage of in 
vitro experimentation on the PMEPA1/Nedd4 interaction would involve the use of 
individual WW domain mutants in ubiquitination assays to pinpoint the specificity of 
each PY motif on PMEPA1. This would be a relatively simple way to test whether the 
theory that the vPY motif has an orientation effect is correct, as it assumes that both PY2 
and PY3 interact predominantly with a single WW domain and that this reaction is so 
specific that the vPY needs to be conserved in order to allow the Nedd4 to align correctly 
with PMEPA1. Further experimental work with the microscale thermophoresis 
technique, or alternatives such as SPR, may also be useful in this regard, as a way of 
quantifying the precise binding affinity of wild type and mutant PMEPA1 to Nedd4 and 
therefore clarifying whether the vPY motif does indeed bind with lower affinity to the 
enzyme. The data presented in figure 3.1.7 show a clear binding curve between WT 
PMEPA1 and Nedd4, as well as a much weaker binding event between Nedd4 and a 
triple mutant ∆PY 1,2,3 PMEPA1, but the data for the ∆PY 2,3 PMEPA1 mutant does 
not show any clear binding event corresponding to either interaction. This is due to the 
first six data points appearing displaced from one another; it is not clear whether points 
1-3 or points 4-6 are the anomalies which make drawing a binding curve impossible. 
Since August 2013, we have been in contact with Nanotemper Technologies and have 
repeated these experiments, with PMEPA1 ∆PY β,γ as well as the original wild type, 
triple mutant and the mutant ∆PY 1. Unfortunately, this data had to be gathered off-site 
due to technical limitations, and despite being stored on dry ice during transport, 
PMEPA1 became highly aggregated and usable results could not be obtained. 
Further in vitro assays that might shed more light on the nature of the interaction 
would be to use a wild type construct as the base for further mutations; all the mutations 
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detailed in section 3.1 were made in PMEPA1 with the PY2 motif inactivated by the 
Y126A mutation, as early on in the project, initial results of the experiment shown in 
figure 3.1.2 seemed to indicate that the reduction in ubiquitination observed in a double 
∆PY1/2 mutant, compared to ∆PY2 alone, was greater than the reduction observed in a 
∆PY1 mutant compared to wild type. As the experiment was repeated and statistical data 
accumulated, this turned out to be a false assumption (see figure 3.1.2), and repeating the 
experiments with both PY motifs intact may allow differences which were not 
statistically significant, such as those resulting from the vPY motif being altered to 
mimic the canonical motifs, to be amplified. 
 The mutagenesis experiments on the residues either side of the four core PY motif 
amino acids (see figure 3.1.4) show that those residues immediately flanking the PY  
motif are also important for PMEPA1 ubiquitination. This raises the possibility that the 
PY motif should be considered to extend beyond those four residues; while such motifs 
are usually referred to as PPxY or LPxY, it has already been discussed in detail here that 
a motif that does not adhere to this convention is still recognised by WW domain-
containing proteins and has a role in modification by those proteins. It is absolutely 
reasonable that their functionality is not restricted to those residues alone. There are 
already examples of extended recognition motifs, such as the PY motif of ENaC being 
considered as PPPxY (Furuhasi et al, 2005) and six residues downstream from the PY 
motif of Smad7 being essential for recognition by Smurf2 (Chong et al, 2006). However, 
further research through mutagenesis studies on the residues surrounding the vPY motif, 
as well as the canonical motifs, of PMEPA1 would be very informative as to what 
exactly their role is. The nature of the upstream residues are almost universally 
conserved in PMEPA1 (the only exception being an S198N substitution of the residue 
immediately downstream of PY3 in two species) possibly indicating a functional role. In 
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addition, the particular substitution of the phenylalanine upstream of PY1 has profound 
effects on ubiquitination in vitro, clearly demonstrating its importance. However, at 
present the precise role of these flanking residues is not yet clear and it would be useful 
to shed some light their specific molecular significance.  
 The potential impact of other post-translational modifications on the PMEPA1-Nedd4 
interaction is another intriguing area for future study. The interesting observation that the 
substitution of the threonine of the vPY motif for a serine results in an increase in 
ubiquitination, combined with the fact that phosphorylated residues have been shown to 
provide a favourable environment for Nedd4 WW domain binding (Lu et al, 2009) 
implies that substrate phosphorylation plays a regulatory role in ubiquitination by these 
enzymes. In addition, phosphorylation of the Rsp5p adaptors, Bul1p and Bul2p has 
recently been implicated as a regulatory mechanism in the ubiquitination of the amino 
acid permease Gap1p; in a low-nitrogen environment, the adaptors are phosphorylated by 
the kinase Npr1, preventing their ubiquitination by Rsp5p and subsequent ubiquitination 
and degradation of Gap1. However, when cellular amino acid levels increase, the Bul 
proteins are dephosphorylated and released from binding to chaperones, releasing them 
to interact with Rsp5p and Gap1p (Merhi and André, 2012). Therefore it might be useful 
to use a technique such as assessing kinase activity, both in vitro in E. coli as a model 
system, and in vivo in mammalian cultures, to see whether there is significant 
phosphorylation of PMEPA1 occurring that may have a regulatory effect. 
 As well as PMEPA1, there is evidence that the ubiquitin ligase activity of Nedd4 may 
be regulated by alternative modification events; a recent paper has identified conserved 
threonine residues in each of the WW domains of Rsp5p, at least one of which is 
constitutively phosphorylated (Sasaki & Takagi, 2013). Mutation of the conserved 
threonine in the WW2 domain causes the Gap1p permease to be downregulated by 
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targeting to the vacuole instead of the plasma membrane. In combination with the data 
presented in figure 3.1.6, showing that the non-canonical SUMO modification site in the 
HECT domain of Nedd4 has a role in autoSUMOylation, and a recently-discovered 
modification of Nedd4 by the UBL protein ISG15 that inhibits its ability to bind E2 
enzymes (Malakhova & Zhang, 2008), suggests that this might be a focus for future work 
on the effects of non-ubiquitin modifications on the Nedd4 ligases themselves. Finally, 
autoubiquitination of Nedd4 may warrant investigation; autoubiquitination assays (figure 
3.1.6) show that Nedd4 is extensively self-modified, and the original paper which 
identified the PY motif in the HECT domain postulated that this is a regulatory 
phenomenon, acting to control Nedd4-2 activity levels when the substrate ENaC is not 
bound (Bruce et al, 2008). It should be relatively easy to simultaneously assess PMEPA1 
and Nedd4 ubiquitination using antibodies for both and western blotting with Odyssey 
detection, to see whether the degree of autoubiquitination is altered when Nedd4 is 
modifying wild type and ∆PY PMEPA1. 
 
5.2 In vivo and structural analyses on PMEPA1 and Nedd4 
 
 The most important observation from the in vivo experiments detailed in section 3.2 is 
that the N-terminal transmembrane region of PMEPA1 challenges both the in silico 
prediction and current published thinking, as it does not appear to play any significant 
role in subcellular targeting of PMEPA1. An important next phase of experimentation to 
define this phenomenon would be to establish in exactly what compartment PMEPA1 is 
found. As seen in figure 3.2.4, there is some overlap between fluorescent tagged 
PMEPA1 and markers for both the cis-Golgi and the ER-Golgi intermediate 
compartment, but neither is a perfect match. Ubiquitination itself has been identified as a 
targeting signal for Golgi proteins to be transported to the yeast vacuole (Scheuring et al, 
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2012), and this may have a counterpart in mammalian cells involving trafficking to the 
lysosome. If PMEPA1 is being constantly turned over and trafficked between the Golgi 
and lysosome, this might explain the Golgi-like appearance and partial overlap with 
markers for different parts of the secretory pathway. If ubiquitination rather than the 
TMD is the trigger for PMEPA1 localization, this might explain why the removal of the 
N-terminus does not affect it. An alternative explanation, mentioned briefly in section 
3.2.3, is that the transfected PMEPA1 is dimerising with endogenous protein; there is no 
direct evidence for this, but it would explain why none of the PMEPA1 mutants showed 
any altered localization compared to wild type, and the fact that the PY mutant still 
showed some FRET signal (see figure 3.3.3) despite having no intact Nedd4 interaction 
motifs. The priority experiment to assess this possibility would be to use a gene silencing 
technique such as RNAi to knock down expression of the endogenous protein and see 
whether this makes any difference to the expression of transfected PMEPA1. An 
alternative method would be to use anti-PMEPA1 antibodies to detect endogenous 
protein via immunofluorescence, rather than using tagged protein; there are no published 
examples of endogenous localization studies in PMEPA1, but such antibodies have been 
used successfully in Western blotting and immunoprecipitation experiments (Li et al, 
2008). I did attempt, by using GFP-only controls, to ensure that the observed targeting is 
genuinely a product of the tagged protein, not the tag itself, but (as discussed in section 
3.3.2) it is possible that, by the nature of the transfection process itself, these 
localizations are not representative of what would be the case in vivo. 
 Structural information, both on PMEPA1 alone and the Nedd4/PMEPA1 complex, 
would be extremely useful in understanding the nature of PMEPA1 and its role as a 
substrate for Nedd4; during this project, we attempted both circular dichroism (CD) and 
crystallographic studies, but these were hindered by various factors (see section 4.1). X-
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ray crystallography would have provided atomic-level imaging of both proteins in 
solution; there is a possibility that this could be attempted again in the future, either using 
a different tag to increase the solubility of PMEPA1, such as MBP, or cleaving the 
existing tag after purification. As an alternative, CD is a useful technique for assessing 
changes in protein structure resulting from binding events; although it cannot give 
atomic-level resolution in the same way as other spectrographic techniques, circular 
dichroism (CD) uses the chiral nature of amino acids to predict secondary structure of 
proteins. The relative levels of random coil, helices, turns and ȕ-sheet can be broadly 
inferred, and the technique is most useful for assessing the degree of structural change 
that occurs under different conditions; in this case, in the presence and absence of Nedd4. 
During the project, an attempt was made by Dr. Robert Janes to assess the spectra of the 
same recombinant PMEPA1 constructs used in the microscale thermophoresis 
experiments (described in section 3.1), alone and in solution with Nedd4, using 
synchrotron radiation circular dichroism (SRCD). However, this was hindered by the 
same solubility problems with PMEPA1 restricting the concentration of solutions, and 
the fact that the GST tag on Nedd4 produced a UV-wavelength spectrum that interfered 
with the ability of the technique to detect the impact of the enzyme on PMEPA1 (see 
section 4.1).  
 
5.3 In vivo interactions between Nedd4, PMEPA1 and AR 
 
 While the experiments detailed here represent significant experimental work, drawing 
firm conclusions with regards to the multiple interactions between AR and 
Nedd4/PMEPA1 has proved difficult due to the high proportion of negative and 
inconclusive results. The priority for future experiments would be to successfully 
recreate the experiments of Li et al (2008) involving protease inhibitors (see figure 5.1).  
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Figure 5.1. Original image from Li, H. et al, J. Biol. Chem. 2008; 283 28988-28995 
showing cell lysates from LNCaP cells stably expressing PMEPA1-GFP in a Tet-Off 
vector, grown with or without tetracycline for 11 days then incubated in either a 
DMSO control, 50 µM MG132, 50 µM LLnL, 10 µM lactacystin or 50 µM E-64 for 
an additional 5 hours. Lysates were harvested by detergent lysis, run on a 4-12% 
SDS-PAGE gradient gel and detected by western blotting using α-AR, α-GFP or α-
actin as indicated.  
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During this project several attempts were made to repeat the experiment as described in 
the original paper, but AR levels in the resultant lysates were too low to be detected. This 
may be due to the fact that we were using transient transfections rather than stably 
expressing cell lines; in fact constructs based on the Clontech Tet-On system, expressing 
both PMEPA1 and AR in a plasmid containing a tetracycline-induced promoter, were 
created during this project and around 6 months was dedicated to attempting to cultivate 
stable, clonal cell lines using antibiotic selection (see section 4.2). However the rate of 
cell adherence and division in the antibiotic-containing media was very low, and even 
once a usable population had been established, no induction was observed upon addition 
of tetracycline. In theory AR should have been detectable in the transiently transfected 
cells, as we have on several occasions detected both endogenous (figure 3.3.3) and 
transiently transfected AR (figure 3.3.7) using the same detection method, and the fact 
that this was not the case may indicate a problem with the cells, possibly due to high 
passage number, which could be eliminated by repeated attempts. The use of multiple 
plasmids using the same pCMV  promoter may also need to be addressed; figure 3.3.8C 
appears to show that introducing empty vectors does not result in increased cell toxicity, 
which can be an adverse effect of increasing DNA in transient transfections, but is both a 
poor quality blot, and therefore possibly inaccurate, and does not take into account the 
possibility that introducing additional plasmids using the same promoter may result in 
competition for a limited pool of cellular transcription factors or that the higher negative 
charge may result in a lower transfection efficiency. This could be compensated for by 
using cloning vectors containing a CMV promoter but no gene to express. 
 The issue of potential low expression may also explain why the immunoprecipitation 
experiments, which were attempted on several occasions (figure 3.3.6), were 
unsuccessful. Variability in levels of expression between experiments is a factor which 
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cannot be controlled in transient transfections, and at the very least a loading control, 
such as simultaneous detection of an abundant protein such as actin, would be required 
upon repeat of these experiments. However, there is evidence that the reasons for the 
negative results are not as simple as this; especially in figure 3.3.6, the transfected 
FLAG-ubiquitin is detectable in the input samples, but Nedd4, which was cotransfected 
using the same amount of DNA, is not. Neither is the endogenous Nedd4, which is 
detectable using the same antibodies and detection method in figures 3.3.3 and 3.3.4, 
visible in these blots. This is an extremely odd result which implies that a fundamental 
change in the experimental protocol may be required; we used NEM as a protease 
inhibitor, to prevent proteolytic cleavage of ubiquitin modification prior to lysis, 
however there is no equivalent step in the protocol used by Li et al (2008), and there are 
published protocols describing detection of ubiquitinated proteins in vivo without using 
any such inhibitors (Choo & Zhang, 2009). In addition, we used a modified TCA 
precipitation protocol to ensure that proteins with low solubility were detectable, 
however Li et al (2008) used a much less aggressive detergent lysis method, which may 
be more effective in the case of mammalian pull-downs as opposed to yeast or bacteria, 
which produce much higher yields. Certainly in the future, refinement and repeats of the 
immunoprecipitation experiments would be very valuable in order to establish whether 
AR and Nedd4 are directly interacting. For example, if the reaction is transient or weak, 
in vivo crosslinking using NHS-ester reagents would be a relatively quick and simple 
technique that could be used to stabilise the bonds and enable detection using 
immunological techniques or mass spectrometry. 
 Alternative experiments which could shed light on the mechanism of the potential 
AR/Nedd4/PMEPA1 interaction include in vitro ubiquitination assays along the lines of 
those performed on PMEPA1 (see section 3.1). One thing that could be tentatively 
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concluded from figure 3.3.6 is that AR does co-precipitate with ubiquitin, indicating in 
vivo modification. AR contains what resembles a variant PY motif very close to the C 
terminus (KPIY855) and this may mediate direct interaction with Nedd4, or alternatively 
PMEPA1 may be acting as an adaptor in a similar way to  Bsd2p in yeast (Sullivan et al, 
2007). If PMEPA1 is essential for AR ubiquitination by Nedd4, in vitro assays in the 
presence and absence of PMEPA1 would be a quick and efficient way to establish this, 
and similarly mutation of the KPIY sequence will quickly show whether this has a 
significant role. In addition, the surface plasmon resonance (SPR) technique might be a 
good way to detect direct protein-protein interaction between AR and ubiquitin or AR 
and Nedd4, as this is a way to determine binding affinity between two proteins without 
the multi-step labelling process involved in microscale thermophoresis, and requires 
achievable analyte concentrations, as low as 100 nM. However, this technique requires 
specialised equipment and expensive consumables, and therefore was not a practical 
option for us during the course of this project.  
The CaP mutation (T877A) in AR appears, in the results presented here, to localize in 
the same way as wild type AR activated by DHT, even in the absence of ligand (figures 
3.2.7 & 3.2.8). This is not in agreement with previous published results (see section 
3.2.3), but does represent consistent observations subjected to rigorous statistical 
analysis. Interestingly, the experiments shown in figure 3.3.8 involving AR-CaP were 
repeated at the same time, under the same conditions, using the wild type protein, but 
these were not successful, producing only blank western blots with no protein, 
endogenous or transfected, detectable. In addition, the GFP signal from both the CaP-AR 
and wild type AR (in the presence of DHT), seen in the confocal microscopy images 
(figure 3.2.6) is much stronger than the wild type in the absence of DHT. It has 
previously been shown that when bound to a ligand in vivo, AR does show up-regulated 
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expression, but that this is due to increased transcription efficiency rather than stability of 
existing protein, as mRNA levels actually fall following androgen treatment (Krongrad et 
al, 1991). Therefore the apparent increase in detectable protein when using AR-CaP as 
opposed to wild type supports the evidence from the confocal microscopy studies that the 
mutant behaves in a way which mimics the wild type bound to DHT; this may provide a 
useful tool in the future to understand the metabolic behaviour of the LNCaP cell line, 
but it must first be qualified with studies on endogenous protein to compliment these 
transfection-based results (see section 3.3.3). 
 
5.4 Evidence for an altered model for the PMEPA1/AR feedback system 
 
The issue of where in the cell any potential interaction between PMEPA1 and AR 
may occur is still unresolved; logically, this would be expected to be the nucleus as this 
is where AR is concentrated in the presence of DHT i.e. in an activated state, but these 
results indicate (figure 3.3.9) that PMEPA1 is excluded from the nucleus regardless of 
whether there is a ligand present to activate AR. The same image also appears to show 
that wild type PMEPA1 has a more punctuate appearance in the presence of DHT, while 
the ∆PY triple mutant has a more diffuse appearance when AR is activated. However, 
these are representative images chosen from multiple repeats of the experiments, and this 
may not be consistent observation, rather it is more likely due to variation in imaging & 
signal intensity. While the consistent exclusion of PMEPA1 from the nucleus is in 
agreement with previous localisation studies on PMEPA1 (Xu et al, 2003), these studies 
are limited and, as mentioned earlier, focus on the use of fluorescent tagged proteins 
which may produce an artificial result. 
Other interesting observations are that Nedd4 appears more punctuate in appearance 
in the presence of DHT (figure 3.3.5) and that DHT may also increase the half-life of 
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Nedd4 (figure 3.3.4); both of these are supportive of a role for Nedd4 which involves 
both up-regulation and recruitment to a cellular compartment which resembles the Golgi, 
although this is an extremely provisional statement and would require further 
experimentation to confirm, including co-imaging with cellular markers to identify the 
precise position of Nedd4 in the presence and absence of DHT, and a repeat of the 
cycloheximide chase experiments, or an alternative such as radioactivity pulse-chase 
assay, to confirm the precise half-life of both Nedd4 and AR under different conditions. 
The result shown in figure 3.3.7, suggesting that the addition of supplementary 
ubiquitin to cells over-expressing PMEPA1 appears to compensate for the complete loss 
of AR reported by Li et al (2008), is important in our understanding the interaction 
between the two proteins, and it is disappointing that repeating the experiment produced 
such different results in terms of the apparent modification of AR under these conditions. 
An extremely useful future experiment would be to corroborate this result with repeats of 
this experiment, including loading controls and preferably using a time-controlled, 
inducible construct, to address the question of why the higher molecular weight AR is 
visible in one iteration of the experiment (figure 3.3.7B) but not the other (figure 
3.3.7A). Such a build up of modified protein could be considered an expected effect of 
inhibition of the proteasome by lactacystin, and this does not seem to have been 
accounted for at all in the original paper. Their published result is shown in figure 5.1 
and clearly shows that the increase in androgen receptor, interpreted as being due to the 
PMEPA1-mediated degradation being prevented, is actually an increase in the 
unmodified protein, running at the same position on a gel as that observed in the absence 
of any proteasome inhibitor. As previously mentioned, the fact that, in the same paper, an 
immunoprecipitation of AR bound to ubiquitin showed a smear of high molecular weight 
protein (figure 5.2), in contrast to the result shown here in figure 5.1, demonstrates that  
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Figure 5.2. Original image from Li, H. et al, J. Biol. Chem. 2008; 283 28988-28995 
showing immunoprecipitated AR HEK 293 cell lysates transiently expressing AR as 
well as HA-tagged ubiquitin and either PMEPA1 or an empty plasmid. After 24 hours 
growth, the cells were treated with both 10 nm R1881 and 5 µM MG132, then 
incubated further for 16 hours. Cell contents were harvested by detergent lysis and 
immune-precipitated with α AR and a western blot was performed using anti-HA 
antibody. 
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the proposed model is oversimplified even if we have not been able to confirm a viable 
alternative.  
Bearing in mind the inconsistencies and unanswered questions in the original paper, 
and the (albeit limited) data obtained throughout this project, I do not believe that the 
proposed simple feedback loop between AR and PMEPA1, in which PMEPA1 initiates 
ubiquitin-mediated proteasomal degradation of AR, is correct. Instead, PMEPA1, 
possibly in a truncated form as a result of partial proteolysis resulting from a precise 
Nedd4-mediated ubiquitination event, may be acting as an adaptor to mediate Nedd4 
interaction with AR to initiate selective degradation in the cytosol. This degradation may 
be occurring via the lysosomal pathway, or it may in fact be a trafficking event initiated 
by saturation of the primary importin-α pathway at high ligand concentrations.  Figure 
5.3 shows a simple schematic of such a model, postulating that the initial Nedd4-
PMEPA1 interaction occurs through a different WW domain (illustrated as WW3/4) to 
that involved in the modification of AR. The use of a specific inhibitor of the importin-α 
nuclear import pathway, such as ivermectin (Wagstaff et al, 2012), could be used to 
assess the impact of blocking this pathway on the cellular localisation of AR and clarify 
its role in the model.  
 
5.5   Concluding remarks 
 
In summary, the work presented here indicates that the N-terminal transmembrane 
domain of PMEPA1 is not, as was previously thought, responsible for targeting 
PMEPA1 to the Golgi apparatus, that the apparent localisation of both the wild type and 
∆NT mutant are in fact to the same compartment, and that this compartment does not 
align with the Golgi network. In addition, the variant PY motif in PMEPA1 has a  
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Figure 5.3. Potential alternative model of the interaction between androgen receptor, PMEPA1 and Nedd4. PMEPA1, anchored 
in the membrane by the TMD, is ubiquitinated by Nedd4 in an interaction that relies heavily on PY2. A partial proteolysis event 
follows (1) which results in a soluble fragment of PMEPA1 being released into the cytosol, where a second interaction involving 
both Nedd4 and AR occurs (2). PMEPA1 acts as an adaptor to facilitate Nedd4 ubiquitination of AR (3) and the ubiquitinated 
protein either triggers autophagosome formation and subsequent targeting to the lysosome (4a) or uptake into the Golgi network 
and subsequent delivery to the nucleus (4b).  
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functional role in interaction with Nedd4, and flanking residues, as well as the core four 
considered to be a minimal interaction motif, play a significant role in Nedd4-mediated 
ubiquitination in vitro. The variant residues within the newly identified PY1 motif are 
flexible at least in vitro, to some extent, but replacing the variant motif with a canonical 
motif counter-intuitively results in a decrease in ubiquitination; in this report, a 
hypothesis is put forward that relies on a weak interaction between the variant motif and 
WW domains to orientate PMEPA1 correctly for optimal ubiquitination.  
Using a combination of in vivo imaging and immunoassay techniques, the data 
presented here imply that the CaP mutation of AR, associated with the development of 
advanced prostatic cancer, behaves in the same way as ligand-bound wild type AR, both 
in terms of localisation and stability. Finally I have tried to show, though re-
interpretation of the results presented by Li et al (2008) and some additional 
experimentation, that the previously published model of AR/PMEPA1 interaction as a 
straightforward feedback cycle in which AR is targeted to the proteasome for 
degradation is oversimplified, and postulated an alternative model which relies on 
PMEPA1 acting as an adaptor between Nedd4 and AR, and a non-proteasomal role for 
ubiquitination of AR. Future work should build on this to test the hypotheses presented 
and elucidate the precise nature of the interaction between Nedd4 and PMEPA1 in the 
regulation of the androgen receptor, and possibly identify new therapeutic targets for the 
treatment of the fourth most deadly cancer in the UK. 
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6.   APPENDICES 
 
6.1   List of abbreviations 
 
AMPS   Ammonium persulphate 
AR   Androgen receptor 
ATP  Adenosine triphosphate 
Bsd2p  Bypass Sod1p defects protein 
CaP  Cancer of the prostate 
CBP  Calmodulin binding protein tag 
CMV  Cytomegalovirus 
DHT  5α-dihydrotestosterone 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DTT  Dithiothreitol 
E. coli  Escherichia coli 
EDTA  Ethylenediaminetetraacetic acid 
EGTA  Ethylene glycol tetraacetic acid 
FBS  Foetal bovine serum 
FLAG  Trademarked affinity peptide tag with sequence DYKDDDDK 
Gap1p  General amino acid permease 1 protein 
GFP  Green fluorescent protein 
GST  Glutathione S-transferase 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His  Histidine 
HRP  Horseradish peroxidase 
IgG  Immunoglobulin G 
IPTG  Isopropyl ȕ-D-1-thiogalactopyranoside 
kDa  KiloDalton 
kPa  KiloPascal 
MOPS  3-(N-morpholino)propanesulfonic acid 
Myc  Peptide affinity tag with sequence N-EQKLISEEDL-C 
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Nedd4 Neural precursor cell expressed developmentally down-regulated 
protein 4 
NEM  N-Ethylmaleimide 
ORF  Open reading frame 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PFA  Paraformaldehyde 
PMEPA1  Prostate transmembrane protein, androgen-induced 1 
PMSF  Phenylmethanesulfonylfluoride 
RNAse  Ribonuclease enzyme 
Rpm  Revolutions per minute 
Rsp5p  Reverses Spt-phenotype protein 
SDS  Sodium dodecyl sulfate 
S-tag  N-terminal region of ribonuclease S (KGTAAAKFERQHMDS) 
SUMO  Small ubiquitin-like modifier 
TAE  Tris-Acetic acid-EDTA buffer 
TAP  Tandem affinity purification tag 
TBS  Tris-buffered saline 
TCA  Trichloroacetic acid 
TEMED  Tetramethylethylenediamine 
Tris  Tris(hydroxymethyl)aminomethane 
Uba1  Ubiquitin activating enzyme 1 
Ubc1  Ubiquitin-conjugated enzyme E2K 
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6.2   Plasmid maps 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.1. Soluble PMEPA1 in pET30a. Map showing construct for bacterial 
expression of recombinant, soluble PMEPA1 subsequently used in in vitro assays. 
The bacterial T7 promoter, 6xHis and S-tags, PMEPA1 ORF and kanamycin 
resistance ORF are shown along with restriction sites used for cloning. This plasmid 
was also used to clone a 6xHis-tagged Nedd4 for recombinant expression. Note that 
the N-terminal 23-residue transmembrane domain is absent. Created using SnapGene 
Viewer version 1.5.2. 
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Figure 6.2.2. Nedd4 in pGEX6P2. Map showing construct for bacterial expression of 
recombinant GST-tagged human Nedd4 subsequently used in in vitro assays. The 
bacterial tac promoter, GST tag, Nedd4 ORF and ampicillin resistance ORF are 
shown along with restriction sites used for cloning. Created using SnapGene Viewer 
version 1.5.2. 
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Figure 6.2.3. PMEPA1 in pGRIP. Map showing construct for mammalian expression 
of full-length, mCherry-tagged PMEPA1 for use in microscopy and western blotting. 
The bacterial T7 promoter, mammalian CMV promoter, mCherry tag, PMEPA1 ORF 
and ampicillin resistance ORF are shown along with restriction sites used for cloning. 
Note that this plasmid, with the same restriction sites, was used to clone GFP and 
mCherry-tagged AR, Nedd4 and non-WT PMEPA1 for microscopy, as well as Myc-
IgG-tagged PMEPA1 for the western blotting experiments described in section 
3.3.2.Created using Snapgene viewer version 1.5.2. 
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Figure 6.2.4. AR in pGRIP. Map showing construct for mammalian expression of 
HA-tagged human AR for use in western blotting. The bacterial T7 promoter (not 
labelled), mammalian CMV promoter, HA tag, AR ORF and ampicillin resistance 
ORF are shown along with restriction sites used for cloning. Created using Snapgene 
Viewer version 1.5.2. 
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Figure 6.2.5. Ubiquitin in p3. Map showing construct for mammalian expression of 
ubiquitin with an N-terminal 8xHis-FLAG tag, for use in western blotting and 
pulldowns. The bacterial T7 promoter, mammalian CMV promoter, 8xHis tag, 
thrombin cleavage site and FLAG tag (not labelled), ubiquitin ORF, neomycin 
resistance ORF and ampicillin resistance ORF are shown along with restriction sites 
used for cloning. Created using Snapgene Viewer version 1.5.2. 
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6.3   Annotated PMEPA1 protein sequence 
 
 
MAELEFVQIIIIVVVMMVMVVVITCLLSHYKLSARSFISRHSQGRRREDALS
SEGCLWPSESTVSGNGIPEPQVYAPPRPTDRLAVPPFAQRERFHRFQPTYPYL
QHEIDLPPTISLSDGEEPPPYQGPCTLQLRDPEQQLELNRESVRAPPNRTIFDS
DLMDSARLGGPCPPSSNSGISATCYGSGGRMEGPPPTYSEVIGHYPGSSFQHQ
QSSGPPSLLEGTRLHHTHIAPLESAAIWSKEKDKQKGHPL 
 
 
The annotated 252-amino acid protein sequence of PMEPA1, shown above, includes 
the transmembrane domain, which encompasses the first 23 residues of the sequence 
and is removed in constructs encoding a soluble form of the recombinant protein, as 
well as in some mammalian expression constructs. The arrows indicate the locations 
of the five lysine residues (K31, K242, K244, K246, K248); note that apart from one, all 
are located at the far C-terminus of the protein. The three PY motifs are highlighted 
in bold and underlined.  
 
TMD  
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